AU2020272472A1 - Pesticidally active diazine-amide compounds - Google Patents

Pesticidally active diazine-amide compounds Download PDF

Info

Publication number
AU2020272472A1
AU2020272472A1 AU2020272472A AU2020272472A AU2020272472A1 AU 2020272472 A1 AU2020272472 A1 AU 2020272472A1 AU 2020272472 A AU2020272472 A AU 2020272472A AU 2020272472 A AU2020272472 A AU 2020272472A AU 2020272472 A1 AU2020272472 A1 AU 2020272472A1
Authority
AU
Australia
Prior art keywords
formula
spp
compounds
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020272472A
Inventor
Andrew Edmunds
Julien Daniel Henri GAGNEPAIN
Roger Graham Hall
André Jeanguenat
Amandine KOLLETH KRIEGER
Camille LE CHAPELAIN
Shrikant PALWE
Mangala Phadte
Thomas Pitterna
Sebastian RENDLER
Christopher Charles SCARBOROUGH
Jürgen Harry SCHAETZER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Crop Protection AG Switzerland
Original Assignee
SYNGENTA CROP PROT AG
Syngenta Crop Protection AG Switzerland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SYNGENTA CROP PROT AG, Syngenta Crop Protection AG Switzerland filed Critical SYNGENTA CROP PROT AG
Publication of AU2020272472A1 publication Critical patent/AU2020272472A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/24—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms
    • A01N43/26—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P5/00—Nematocides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P7/00—Arthropodicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.

Description

PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS
The present invention relates to pesticidally active, in particular insecticidally active diazine-amide compounds, to processes for their preparation, to compositions comprising those compounds, and to their use for controlling animal pests, including arthropods and in particular insects or representatives of the order Acarina.
WO2017192385 describes certain heteroaryl-1 ,2,4-triazole and heteroaryl-tetrazole compounds for use for controlling ectoparasites in animals (such as a mammal and a non-mammal animal).
There have now been found novel pesticidally active-diazine amide compounds.
The present invention accordingly relates, in a first aspect, to a compound of the formula I
wherein
Ri is H, Ci-C6alkyl, Ci-C6cyanoalkyl, aminocarbonylCi-Cealkyl, hydroxycarbonylCi-Cealkyl, Ci- Cenitroalkyl, trimethylsilaneCi-C6alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6haloalkeny, C2-C6alkynyl, C2-C6haloalkynyl, C3-C4cycloalkylCi-C2alkyl-, C3-C4cycloalkylCi-C2alkyl- wherein the C3-C4cycloalkyl group is substituted with 1 or 2 halogen atoms, oxetan-3-yl-CH2-, benzyl or benzyl substituted with halogen or Ci-C6haloalkyl;
R2 is selected from phenyl, pyridine, pyrimidine, pyrazine, pyridazine, and phenyl, pyridine, pyrimidine, pyrazine and pyridazine, each of which is substituted with one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon C=X is attached, and each substituent is independently selected from: Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3haloalkylthio, Ci-C3alkoxy, Ci- C3haloalkoxy, halogen, SFs, CN, CONH2, and C(S)NH2; R3 is Ci-C3alkyl or Ci-C3haloalkyl;
A2 is CR4b or N;
R4b is hydrogen, or halogen;
R4a is cyano, or Ci-C3haloalkoxy;
R5a and Rsb are, independently of each other, selected from hydrogen, halogen, CN, Ci-C3alkyl, Ci- C3haloalkyl, C3-C4cycloalkyl, Ci-C3alkoxy, and Ci-C3haloalkoxy; or agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of the compounds of formula I. Compounds of formula I which have at least one basic centre can form, for example, acid addition salts, for example with strong inorganic acids such as mineral acids, for example perchloric acid, sulfuric acid, nitric acid, nitrous acid, a phosphorus acid or a hydrohalic acid, with strong organic carboxylic acids, such as Ci-C4alkanecarboxylic acids which are unsubstituted or substituted, for example by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid or phthalic acid, such as hydroxycarboxylic acids, for example ascorbic acid, lactic acid, malic acid, tartaric acid or citric acid, or such as benzoic acid, or with organic sulfonic acids, such as Ci-C4alkane- or arylsulfonic acids which are unsubstituted or substituted, for example by halogen, for example methane- or p-toluenesulfonic acid. Compounds of formula I which have at least one acidic group can form, for example, salts with bases, for example mineral salts such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower-alkylamine, for example ethyl-, diethyl-, triethyl- or dimethylpropylamine, or a mono-, di- or trihydroxy-lower-alkylamine, for example mono-, di- or triethanolamine.
In each case, the compounds of formula I according to the invention are in free form, in oxidized form as a N-oxide or in salt form, e.g. an agronomically usable salt form.
N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book“Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.
The compounds of formula I according to the invention also include hydrates which may be formed during the salt formation.
The term "Ci-Cnalkyl” as used herein refers to a saturated straight-chain or branched hydrocarbon radical attached via any of the carbon atoms having 1 to n carbon atoms, for example, any one of the radicals methyl, ethyl, n-propyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2, 2-dimethylpropyl, 1- ethylpropyl, n-hexyl, n-pentyl, 1 ,1-dimethylpropyl, 1 , 2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1-dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1 ,1 ,2-trimethylpropyl,
1 ,2,2-trimethylpropyl, 1 -ethyl-1 -methylpropyl, or 1-ethyl-2-methylpropyl.
The term "Ci-Cnhaloalkyl" as used herein refers to a straight-chain or branched saturated alkyl radical attached via any of the carbon atoms having 1 to n carbon atoms (as mentioned above), where some or all of the hydrogen atoms in these radicals may be replaced by fluorine, chlorine, bromine and/or iodine, i.e. , for example, any one of ch loro methyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 2- fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2- fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 2-fluoropropyl, 3-fluoropropyl, 2,2-difluoropropyl, 2,3-difluoropropyl, 2-chloropropyl, 3-chloropropyl, 2,3-dichloropropyl, 2-bromopropyl, 3-bromopropyl, 3,3,3-trifluoropropyl, 3,3,3-trichloropropyl, 2, 2, 3,3,3- pentafluoropropyl, heptafluoropropyl, 1 -(fluoromethyl)-2-fluoroethyl, 1 -(chloromethyl)-2-chloroethyl, 1 - (bromomethyl)-2-bromoethyl, 4-fluorobutyl, 4-ch loro butyl, 4-bromobutyl or nonafluorobutyl. According a term "Ci-C2fluoroalkyl" would refer to a Ci-C2alkyl radical which carries 1 , 2, 3, 4, or 5 fluorine atoms, for example, any one of difluoromethyl, trifluoromethyl, 1 -fluoroethyl, 2-fluoroethyl, 2,2- difluoroethyl, 2,2,2-trifluoroethyl, 1 ,1 ,2,2-tetrafluoroethyl or pentafluoroethyl.
The term "Ci-Cnalkoxy" as used herein refers to a straight-chain or branched saturated alkyl radical having 1 to n carbon atoms (as mentioned above) which is attached via an oxygen atom, i.e., for example, any one of the radicals methoxy, ethoxy, n-propoxy, 1 -methylethoxy, n-butoxy, 1 - methylpropoxy, 2-methylpropoxy or 1 ,1 -dimethylethoxy. The term“haloCi-Cnalkoxy" as used herein refers to a Ci-Cnalkoxy radical where one or more hydrogen atoms on the alkyl radical is replaced by the same or different halogen atom(s) - examples include tnfluoromethoxy, 2-fiuoroetlioxy, 3- fluoropropoxy, 3,3,3-trifluoropropoxy, 4-chlorobutoxy.
The term“Ci-Cncyanoalkyl” as used herein refers to a straight chain or branched saturated Ci-Cnalkyl radical having 1 to n carbon atoms (as mentioned above), where one of the hydrogen atoms in these radicals is be replaced by a cyano group: for example, cyanomethyl, 2-cyanoethyl, 2-cyanopropyl, 3- cyanopropyl, 1 -(cyanomethyl)-2-ethyl, 1 -(methyl)-2-cyanoethyl, 4-cyanobutyl, and the like.
The term“C3-Cncycloalkyl” as used herein refers to 3-n membered cycloalkyl groups such as cyclopropane, cyclobutane, cyclopropane, cyclopentane and cyclohexane.
The term“C3-CncycloalkylCi-Cnalkyl“ as used herein refers to 3 to n membered cycloalkyl group with an alkyl radical, which alkyl radical is connected to the rest of the molecule. In the instance, the C3- CncycloalkylCi-C2alkyl- group is substituted, the substituent(s) can be on the cycloalkyl group or alkyl radical.
The term“aminocarbonylCi-Cnalkyl“ as used herein refers to an alkyl radical where one of the hydrogen atoms in the radical is replaced by CONH2 group.
The term“hydroxycarbonylCi-Cnalkyl“ as used herein refers to an alkyl radical where one of the hydrogen atoms in the radical is replaced by COOH group.
The term“Ci-Cnnitroalkyl“ as used herein refers to an alkyl radical where one of the hydrogen atoms in the radical is replaced by N02 group. The term“Ci-Cnalkylsulfanyl“ or“Ci-Cnhaloalkylthio“ as used herein refers to a Ci-Cnalkyl moiety linked through a sulfur atom. Similarly, the term“Ci-Cnhaloalkylsulfanyl“ as used herein refers to a Ci- Cnhaloalkyl moiety linked through a sulfur atom.
The term“Ci-Cnalkylsulfinyl“ as used herein refers to a Ci-Cnalkyl moiety linked through the sulfur atom of the S(=0) group. Similarly, the term“Ci-Cnhaloalkylsulfinyl“ as used herein refers to a Ci- Cnhaloalkyl moiety linked through the sulfur atom of the S(=0) group.
The term“Ci-Cnalkylsulfonyl“ as used herein refers to a Ci-Cnalkyl moiety linked through the sulfur atom of the S(=0)2 group. Similarly, the term“Ci-Cnhaloalkylsulfonyl“ as used herein refers to a Ci- Cnhaloalkyl moiety linked through the sulfur atom of the S(=0)2 group
The term“trimethylsilaneCi-Cnalkyl“ as used herein refers to an alkyl radical where one of the hydrogen atoms in the radical is replaced by a -Si(CH3)3 group.
The term“C2-Cnalkenyl” as used herein refers to a straight or branched alkenyl chain having form two to n carbon atoms and one or two double bonds, for example, ethenyl, prop-l -enyl, but-2-enyl.
The term“C2-Cnhaloalkenyl” as used herein refers to a C2-Cnalkenyl moiety substituted with one or more halogen atoms which may be the same or different.
The term“C2-Cnalkynyl” as used herein refers to a straight or branched alkynyl chain having from two to n carbon atoms and one triple bond, for example, ethynyl, prop-2-ynyl, but-3-ynyl,
The term“C2-Cnhaloalkynyl” as used herein refers to a C2-Cnalkynyl moiety substituted with one or more halogen atoms which may be the same or different.
Halogen is generally fluorine, chlorine, bromine or iodine. This also applies, correspondingly, to halogen in combination with other meanings, such as haloalkyl
The pyridine, pyrimidine, pyrazine and pyridazine groups (unsubstituted or substituted) for R2 and R4 are each connected via a carbon atom on the respective ring to the rest of the compound.
As used herein, the term "controlling" refers to reducing the number of pests, eliminating pests and/or preventing further pest damage such that damage to a plant or to a plant derived product is reduced.
The staggered line as used herein, for example, in M-1 and L-1 , represent the point of connection/ attachment to the rest of the compound. As used herein, the term "pest" refers to insects, acarines, nematodes and molluscs that are found in agriculture, horticulture, forestry, the storage of products of vegetable origin (such as fruit, grain and timber); and those pests associated with the damage of man-made structures. The term pest encompasses all stages in the life cycle of the pest.
As used herein, the term "effective amount" refers to the amount of the compound, or a salt thereof, which, upon single or multiple applications provides the desired effect. An effective amount is readily determined by the skilled person in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount a number of factors are considered including, but not limited to: the type of plant or derived product to be applied; the pest to be controlled & its lifecycle; the particular compound applied; the type of application; and other relevant circumstances.
As one of ordinary skill in the art will appreciate, compounds of formula I contain a stereogenic centre which is indicated with an asterisk in the structure below:
I*
where Ri , R2, R3, R4a, Rsa, Rsb, and Aå are as defined in the first aspect.
The present invention contemplates both racemates and individual enantiomers. Compounds having preferred stereochemistry are set out below. Particularly preferred compounds of the present invention are compounds of formula I’a:
where Ri , R2, R3, R4a, Rsa, Rsb, and Aå are as defined in the first aspect, and stereoisomers, enantiomers, tautomers and N-oxides of the compounds of formula (I’a), and agrochemically acceptable salts thereof.
The term“optionally substituted” as used herein means that the group referenced is either unsubstituted or is substituted by a designated substituent, for example,“C3-C4cycloalkyl is optionally substituted with 1 or 2 halogen atoms” means C3-C4cycloalkyl, C3-C4cycloalkyl substituted with 1 halogen atom and C3-C4cycloalkyl substituted with 2 halogen atoms.
Embodiments according to the invention are provided as set out below.
In an embodiment of each aspect of the invention, Ri is
A. hydrogen, methyl, ethyl, n-propyl, isobutyl, cyclopropylmethyl or HCHºCCH2-; or
B. hydrogen, methyl, or cyclopropylmethyl; or
C. hydrogen; or
D. methyl; or
E. cyclopropylmethyl.
In an embodiment of each aspect of the invention, R2 is
A. phenyl, pyridine, pyrimidine, pyrazine, pyridazine, or the phenyl, pyridine, pyrimidine, pyrazine and pyridazine, each of which is substituted with one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon C=X is attached, and each substituent is independently selected from: Ci-C3haloalkyl, Ci-C3haloalkylthio, Ci-C3alkoxy, Ci-C3haloalkoxy, and halogen; or
B. one of M-1 to M-13
C. one of M-3, M-4, M-5, M-6, M-8, M-9, M-1 1 M-12 or M-13; or
D. one of M-3, M-4, M-5, M-6, M-8, M-9, M-12 or M-13; or
E. one of M-3, M-4, M-6, M-8; M-9, M-12 or M-13; or
F. one of M-3, M-6, M-8, M-9, M-12 or M-13; or
G. one of M-3, M-8, M-12 or M-13; or
H. one of M-6, M-9 or M-12; or
I. one of M-3, M-8 or M-12; or
J. one of M-3, M-12 or M-13 or
K. M-12 or M-13.
In an embodiment of each aspect of the invention, R3 is A. Ci-C3alkyl or Ci-C3haloalkyl; or
B. methyl.
In an embodiment of each aspect of the invention, A2 is
A. N; or
B. C-F b, where R4b is hydrogen or halogen (such as Cl, F, Br and I); preferably R4b is hydrogen.
In an embodiment of each aspect of the invention, R4a is
A. cyano, or Ci-C3fluoroalkoxy; or
B. cyano, trifluoromethoxy, difluoromethoxy, 2,2,2-trifluoroethoxy, or 2,2-difluoroethoxy.
In an embodiment of each aspect of the invention, Rsa and Rst>, independent of each other, are
A. hydrogen, halogen, Ci-C3alkyl, or Ci-C3alkoxy; or
B. selected from hydrogen, bromo, chloro, methyl, and methoxy; or
C. hydrogen.
The present invention, accordingly, makes available a compound of formula I having the substituents Ri , R2a, Råb, R3, R4a, Rsa, Rsb, Ai and A2 as defined above in all combinations / each permutation. Accordingly, made available, for example, is a compound of formula I with Ri being embodiment B (i.e. hydrogen, methyl, cyclopropylmethyl); R2 being an embodiment C (i.e. one of M-3, M-4, M-5, M-6, M-8, M-9, M-1 1 M-12 or M-13); R3 being embodiment B (i.e. methyl); A2 being embodiment B (i.e. C- R4b, where R4b is hydrogen or halogen (such as Cl, F, Br and I); preferably R4b is hydrogen); R4a being embodiment A (i.e. cyano, or Ci-C3fluoroalkoxy); and Rsa being embodiment A (i.e selected from hydrogen, halogen, Ci-C3alkyl, and Ci-C3alkoxy); and Rsb being embodiment C (i.e hydrogen).
In an embodiment, the compound of formula I can be represented as
wherein Ri , R2, Rsa, and Rsb are as defined in the first aspect, and R4 is the cyclic group containing A2 and the substituent R4a as defined in the first aspect.
In an embodiment of each aspect of the invention, the R4 (the cyclic group containing A2 and the substituent R4a) is
A. selected from L-1 to L-9 L-6 L-7 L-8 L-9
B. selected from L-1 , L-2, L-3, L-4, L-5, L-6, L-7, L-8, and L-9; or
C. selected from L-1 , L-3, L-5, L-6, L-7, L-8 and L-9; or
D. selected from L-1 , L-2, L-7, L-8 and L-9; or
E. selected from L-3, L-4, L-7, L-8 and L-9; or
F. selected from L-1 , L-3, L5, L-7, L-8 and L-9; or
G. selected from L-1 , L-5, L-7, L-8 and L-9; or
H. L-7, L-8 or L-9; or
I. L-3, L-7 or L-9; or
J. L-8 or L-9; or
K. L-5 or L-9; or
L. L-7 or L-9; or
M. L-1 or L-9; or
N. L-9.
L-1 , L-5, L-7, L-8 and L-9
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, ethyl, n-propyl, isobutyl, cyclopropylmethyl or HCHºCCH2-; as R2 one of M-1 to M-13; as R3 methyl; as R4 one of L-1 to L-9; and as Rsa and Rsb, independently selected from hydrogen, halogen, Ci-C3alkyl, and Ci-C3alkoxy.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-1 to M-13; as R3 methyl; as R4 one of L-1 to L-9; and as Rsa and Rsb, independently selected from hydrogen, halogen, Ci-C3alkyl, and Ci-C3alkoxy. In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen; as R2 one of M-1 to M-13; as R3 methyl; as R4 one of L-1 to L-9; and as Rsa and Rsb, independently selected from hydrogen, halogen, Ci-C3alkyl, and Ci-C3alkoxy.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-4, M-5, M-6, M-8, M-9, M-1 1 M-12 or M-13; as R3 methyl; as R4 one of L-1 to L-9; and as Rsa and Rst>, independently selected from hydrogen, halogen, Ci-C3alkyl, and Ci-C3alkoxy.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-4, M-5, M-6, M-8, M-9, M-1 1 M-12 or M-13; as R3 methyl; as R4 one of L-1 , L-2, L-3, L-4, L-5, L-6, L-7, L-8, or L-9; and as Rsa and Rsb, independently selected from hydrogen, halogen, Ci-C3alkyl, and Ci-C3alkoxy.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-4, M-5, M-6, M-8, M-9, M-1 1 , M-12 or M-13; as R3 methyl; as R4 one of L-1 , L-2, L-3, L-4, L-5, L-6, L-7, L-8, or L-9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-6, M-8, M-9, M-12 or M-13; as R3 methyl; as R4 one of L-1 to L-9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-6, M-8, M-9, M-12 or M-13; as R3 methyl; as R4 one of L-1 , L-2, L-3, L-4, L-5, L-6, L-7, L-8, or L-9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-4, M-6, M-8, M-9, or M-12; as R3 methyl; as R4 one of L-1 , L-2, L-7, L-8 and L-9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-4, M-6, M-8, M-9, or M-12; as R3 methyl; as R4 one of L-3, L-4, L-7, L-8 and L-9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-8, M-12, or M-13; as R3 methyl; as R4 one of L1 to L9; and as Rsa and Rsb, each hydrogen. In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-8, M-12, or M-13; as R3 methyl; as R4 one of L-1 , L-2, L-7, L-8 and L-9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-8, M-12, or M-13; as R3 methyl; as R4 one of L-3, L-4, L-7, L-8 and L-9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-8, M-12, or M-13; as R3 methyl; as R4 one of L7,
L8 or L9; and as Rsa and Rsb, each hydrogen.
In an embodiment of each aspect of the invention, the compound of formula I has as Ri hydrogen, methyl, or cyclopropylmethyl; as R2 one of M-3, M-8, or M-12; as R3 methyl; as R4 L9; and as Rsa and Rsb, each hydrogen.
In a second aspect, the present invention makes available a composition comprising a compound of formula I as defined in the first aspect, one or more auxiliaries and diluent, and optionally one more other active ingredient.
In a third aspect, the present invention makes available a method of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound as defined in the first aspect or a composition as defined in the second aspect.
In a fourth aspect, the present invention makes available a method for the protection of plant propagation material from the attack by insects, acarines, nematodes or molluscs, which comprises treating the propagation material or the site, where the propagation material is planted, with an effective amount of a compound of formula I as defined in the first aspect or a composition as defined in the second aspect.
In a fifth aspect, the present invention makes available a plant propagation material, such as a seed, comprising, or treated with or adhered thereto, a compound of formula I as defined in the first aspect or a composition as defined in the second aspect.
The present invention in a further aspect provides a method of controlling parasites in or on an animal in need thereof comprising administering an effective amount of a compound of the first aspect. The present invention further provides a method of controlling ectoparasites on an animal in need thereof comprising administering an effective amount of a compound of formula I as defined om the first aspect. The present invention further provides a method for preventing and/or treating diseases transmitted by ectoparasites comprising administering an effective amount of a compound of formula I as defined in the first aspect, to an animal in need thereof. Compounds of formula I can be prepared by those skilled in the art following known methods. More specifically compounds of formulae I, and I’a, and intermediates therefor can be prepared as described below in the schemes and examples. Certain stereogenic centers have been left unspecified for the clarity and are not intended to limit the teaching of the schemes in any way. The process according to the invention for preparing compounds of formula I is carried out by methods known to those skilled in the art.
Compounds of formula I
can be prepared by reaction of an amine of formula II
wherein Ri , R3, A2, R4a, Rsa, and Rsb are as defined in formula I, with a carboxylic acid derivative of formula III
III
wherein F¾ is as defined in formula I. The chemistry is described in more detail in Scheme 1 . Scheme 1 :
In Scheme 1 compounds of formula III, wherein R2 is as defined in formula I, are activated to compounds of formula Ilia by methods known to those skilled in the art and described for example in Tetrahedron, 61 (46) , 10827-10852, 2005. For example, compounds where Xo is halogen are formed by treatment of compounds of formula III with for example, oxalyl chloride or thionyl chloride in the presence of catalytic quantities of DMF in inert solvents such as methylene dichloride or THF at temperatures between 20 °C to 100 °C., preferably 25 °C. Treatment of Ilia with compounds of formula II, wherein Ri , R3, A2, R4a, Rsa, and Rsb, are as defined in formula I, optionally in the presence of a base, e.g. triethylamine or pyridine leads to compounds of formula I. Alternatively, compounds of formula I can be prepared by treatment of compounds of formula III with dicyclohexyl carbodiimide (DCC) or 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC) to give the activated species Ilia, wherein Xo is X01 or Xo2, in an inert solvent, e.g. pyridine, or THF optionally in the presence of a base, e.g. triethylamine, at temperatures between 50-180 °C. In addition, an acid of the formula III can also be activated by reaction with a coupling reagent such as propanephosphonic acid anhydride (T3P®) or 0-(7-Aza-1 - benzotriazolyl)-N,N,N’,N’-tetramethyluronium-hexafluorophosphat (HATU) to provide compounds of formula Ilia wherein Xo is X03 and X04 as described for example in Synthesis 2013, 45, 1569 and Journal Prakt. Chemie 1998, 340, 581 . Subsequent reaction with an amine ofthe formula II provides compounds of formula I.
Intermediates of formula II, wherein Ri , R3, A2, R4a, Rsa and Rsb are as defined in formula I, can be prepared according to Scheme 2: Scheme 2:
IV VI
Xo5 = Cl, Br, I, OMs, OTs or OTf
In Scheme 2, compounds of formula II, wherein Ri , R3, A2, R4a, Rsa and Rsb are as defined in formula I, can be prepared by treatment of compounds of formula VI, wherein R3, A2, R4a, Rsa and Rsb are as defined in formula I, with compounds of formula VII (wherein Ri is as defined in formula I), e.g. in the presence of NaBH(OAc)3 or NaBHsCN, preferably with NaBHsCN as reductive reagent, in a suitable solvent, preferably in acetic acid at room temperature analog to W02002/088073, page 35.
Alternatively, another reagent system for the reductive amination uses a combination of Ti(i-OPr)4 and NaBH4 in the presence of an amine of formula VII can also provide compounds of formula II (see Synthesis 2003 (14), 2206).
Compounds of formula VI, wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I, can be prepared by a Stille reaction between compounds of formula IV, wherein X05 is a leaving group, such as chlorine, bromine, iodine, arysulfonate, alkylsulfonate or trifluoromethanesulfonate and R3, Rsa and Rsb are as defined in formula I, and tin compounds of formula V (wherein A2 and R4a are as defined in formula I), in the presence of a palladium catalyst, for example tetrakis(triphenylphosphine)palladium(0), or (1 ,1 'bis(diphenylphosphino)-ferrocene)dichloropalladium-dichloromethane (1 :1 complex), in an inert solvent, such as DMF, acetonitrile, or dioxane, optionally in the presence of an additive, such as potassium, cesium fluoride, or lithium chloride, and optionally in the presence of a further catalyst, for example copper(l)iodide. Such Stille coupling reactions are well known to those skilled in the art, and have been described in for example J. Org. Chem., 2005, 70, 8601 , J. Org. Chem., 2009, 74, 5599, Angew. Chem. Int. Ed., 2004, 43, 1132, Heterocycles 2010, 80, 1215 and J. Am. Chem. Soc. 2004, 126, 16433.
Alternatively, compounds of formula VI (wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I) can also be prepared by a Suzuki reaction (Scheme 3), which involves for example, reacting compounds of formula IV (wherein R3, Rsa, and Rsb are as defined in formula I and Xos is a leaving group like, for example, chlorine, bromine, iodine, arysulfonate, alkylsulfonate or trifluoromethanesulfonate) with compounds of formula VIII, wherein W ean be a boron-derived functional group, as for example B(OH)2 or a pinacol boronic ester. The reaction can be catalyzed by a palladium based catalyst, for example tetrakis(triphenylphosphine)-palladium or (1 ,1 'bis(diphenylphosphino)-ferrocene)dichloropalladium- dichloromethane (1 :1 complex), in presence of a base, like sodium carbonate or cesium fluoride, in a solvent or a solvent mixture, like, for example a mixture of 1 ,2-dimethoxyethane and water, dioxane and water, or DMF and water preferably under inert atmosphere. The reaction temperature can preferentially range from room temperature to the boiling point of the reaction mixture. Such Suzuki reactions are well known to those skilled in the art and have been reported, for example in J. Organomet. Chem. 576, 1999, 147-168, Science of Synthesis 2010, 45b, 547, Eur. J. Org. Chem. 2012, (31), 6248 and Synthesis 2017, 49, 4372. Scheme 3:
Compounds of formula IV are generally commercially available.
Alternatively compounds of formula VI, wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I, is outlined in Scheme 4.
Scheme 4:
For example, compounds of formula VI, wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I, may be prepared by allyl sulfone coupling reaction of compounds of formula IVa (wherein R3, Rsa, and Rsb are as defined in formula I), with compounds of formula XI, wherein A2 and R4a are defined in formula I, in suitable solvents, preferable dioxane or DMF, in the presence of a Pd-catalyst, preferable palladium acetate, a ligand, e.g. ditert-butyl(methyl)phosphane, and a base, e.g. CS2CO3 usually upon heating at temperatures between 120 to 130 °C. Such processes have been described, for example, in J. Am. Chem. Soc. 2018, 140, 15916.
The required intermediates of formula XI can be obtained from compounds of formula IX (wherein A2 and R4a are defined as for formula I and X06 is halogen or methyl sulfone) through nucleophilic substitution with prop-2-ene-1 -thiol and subsequent oxidation with mCPBA. Such transformation are well known and reported, for instance, in J. Am. Chem. Soc. 2018, 140, 15916.
Alternatively compounds of formula VI, wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I, is outlined in Scheme 5.
Compounds of formula VI (wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I) may be prepared by treatment of compounds of formula XIV with a Grignard reagent RsMgBr, e.g. MeMgBr at lower temperatures, preferable at 0 to 25 °C in a suitable solvent such as THF or diethyl ether.
Weinreb amides of formula XIV (wherein A2, R4a, Rsa, and Rsb are as defined in formula I) can be prepared in three steps from compounds of formula XIII, wherein A2, R4a, Rsa, and Rsb are as defined in formula I and Z is Ci-C6alkyl. Compounds of formula XIII are converted to carboxylic acids by methods known in the art (see e.g. WO201 1/143365, page 138) and activation (see Scheme 1) of the subsequent carboxylic acids followed by treatment with N-methoxy-N-methylamine (according to Weinreb et al. Tet. Lett. 1981 , 39, 3815) lead to compound of formula XIV.
Compounds of formula XIII, wherein A2, R4a, Rsa, and Rsb are as defined in formula I and Z is Ci-C6alkyl, can be prepared by reaction of compounds of formula XII (wherein Rsa, and Rsb are as defined in formula I, Z is Ci-C6alkyl, and X07 is a leaving group like, for example, chlorine, bromine, iodine) with compounds of formula V (Stille reaction) or compounds of formula VIII (Suzuki-Miyaura reaction) in the presence of a palladium catalyst as described in detail in Schemes 2 and 3.
Scheme 5: In an alternative process (Scheme 6), compounds of formula II, wherein Ri , R3, A2, R4a, Rsa, and Rsb are defined as in formula I, may be prepared by nucleophilic substitution reaction of compound of formula XVI, wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I and Xos is Cl, Br, OMs, OTs or OTf, with amines of formula VII, in suitable solvents that may include, for example, acetonitrile or DMF, in the presence of a suitable base, such as sodium, potassium or caesium carbonate, usually upon heating at temperatures between room temperature and 200°C, preferably between 40°C to the boiling point of the reaction mixture, optionally under microwave heating conditions. Compounds of formula XVI, wherein R3, A2, R4a, Rsa, Rsb are defined as in formula I and Xos is Cl, Br, OMs, OTs or OTf, may be prepared by activation of the alcohols of formula XV, wherein R3, A2, R4a, Rsa and Rsb are defined as in formula I, with compounds of formula XIII, wherein Y is CH3, CF3 or p-CFh- C6H4, in an inert solvent, preferably in methylene dichloride and in the presence of a base, e.g. triethyl amine. Alcohols of formula XV may be also be activated to alkyl halides XVI (wherein Xos is Cl or Br) by treatment with phosphorous compounds, e.g. P(Xo)3, wherein Xo is chlorine or bromine by methods known to those skilled in the art. Such general functional group transformations are described for example in Organische Chemie. 4. Auflage, Wiley-VCH Verlag, Weinheim 2005, p. 393 ff and Chem Commun. 2014, 50, 5756. Compounds of formula XV, wherein R3, A2, R4a, Rsa and Rsb are defined as in formula I, may be prepared by reduction of ketones VI (wherein R3, A2, R4a, Rsa, and Rsb are as defined in formula I) for example with NaBhU in the usual manner (see e.g. WO2012/082997, page 141), preferably in MeOH as solvent.
Scheme 6:
solvent e.g.
DMF or acetonitrile
base, e.g. K2C03
nucleophilic
substitution
Xog = OMs OTf
OTs, Cl, Br
Yet another methodology to prepare compounds of general formula of lla is outlined in Scheme 7.
Scheme 7: Thus, nucleophilic substitution reaction of compound of formula XVI with amines of formula VII furnishes compounds of formula II (wherein Ri , R3, A2, R4a, Rsa, and Rsb are defined as in formula I) as already described in detail in Scheme 6. Compounds of formula II suited with a protecting group, e.g. Ri is benzyl, can be hydrogenated with hydrogen in the presence of palladium (on charcoal) in a solvent, e.g. MeOH or EtOH, to give compounds of formula I la wherein R3, A2, R4a, Rsa, and Rsb is defined as in formula I (see e.g. Synlett, 2010, (18), page 2708). Compounds of formula II wherein Ri is allyl, and R3, A2, R4a, Rsa, and Rsb are as defined in formula I can also be converted to compounds of formula lla by reaction with N’N’dimethylbarbituric acid in the presence of a Pd-catalyst, preferable tetrakis(triphenylphosphine)palladium(0), in a suitable solvent, for example CH2CI2 to provide compounds of formula lla according to J. Org. Chem. 1993, 58, 6109.
Formation of compounds of formula V, wherein A2 and R4a are as defined in formula I, is outlined in Scheme 8.
Compounds of formula V, wherein A2 and R4a are as defined in formula I, may be prepared by treatment of compounds of formula IX with a palladium source such as for example Pd(Pti3)4 and bis(tributyltin) in a suitable solvent such as DMF usually upon heating at temperatures between 100 to 130 °C. Such processes have been described, for example, in Molecular Pharmacology, 90(3), 177-187; 2016. Alternatively compounds of formula V can also be prepared by treatment of compounds of formula IX with n-Butyllithium and tributyltin chloride in a suitable solvent such as THF, usually at lower temperature such as -78°C to 0°C. Such processes have been described, for example, in US20180273562.
Scheme 8: Pd source e.g Pd(Ph3)4,
(Bu)3Sn-Sn(Bu)3 , solvent
or
BuLi, Bu3SnCI, solvent
SnBu 3
V
XQ6 = Cl, Br
Compounds of formula IXa and IXaa, wherein A2 is as defined in formula I, X06 is a leaving group such as Cl, Br and Q is Ci-C3haloalkyl, are either commercially available or can be prepared according to well-known methods as shown in Scheme 9.
Scheme 9:
IXaa
Thus compounds of formula IXa, wherein A2 is as defined in formula I, X06 is a leaving group such as Cl or Br, and Q is Ci-C3haloalkyl, can be obtained by alkylation of compounds XVII with a compound of formula XVIII, wherein Q is Ci-C3haloalkyl and X09 is a leaving group, such as Cl, Br, F, I, OSO2CF3, or OSO2CH3, in the presence of a suitable base, for example cesium or potassium carbonate, in a solvent such as acetonitrile or DMF at temperatures between 20-80 °C. Such reactions are well known to those skilled in the art and have been reported for example in see e.g. Med. Chem. Letts., 2017, 8(5), p543- 548 and Bio. Med. Chem. Letts., 2017, 27(1 1), 2420-2423.
Compounds of formula IXaa, wherein A2 isas defined in formula I, X06 is a leaving group such as Cl or Br, can be prepared from compounds of formula XVII by treatment with a difluorocarbene source e.g. CICF2CC>2Na or CF2SO2OCHF2 in the presence of a base such as KOH, potassium carbonate and the like, in an inert solvent at temperatures between 20-80 °C. Such procedures have been described for example in J. Fluor. Chem. 2017, 203, 155, and US2013/0225552, page 128, and Org. Process Res. Dev., 201 1 , 15, 721 .
Compounds of formula XVII are commercially available.
Alternatively, compounds of formula I may be prepared from compounds of formula XX, wherein Ri , R2, R3, Rsa, and Rsb are defined in formula I and X07 is defined in Scheme 5, following the synthesis outlined in Scheme 10.
Scheme 10:
Compounds of formula I can be prepared by reaction of compounds of to compounds of formula XX with compounds of formula V (Stille reaction) or compounds of formula VIII (Suzuki Miyaura reaction) in the presence of a palladium catalyst as described in detail in Schemes 2 and 3. Compounds of formula XX can be synthesized by reaction of an activated compound of formula Ilia with an amine of formula XIX, wherein Ri , R3, Rsa, and Rsb are defined in formula I and X07 is defined in Scheme 5, following the conditions detailed in Scheme 1 .
Compounds of formula III are known, for example 3-(difluoromethyl)-5-(trifluoromethyl)benzoic acid CAS: [2248290-21 -1 ], 3-bromo-5-(trifluoromethyl)benzoic acid CAS: [328-67-6], 3-iodo-5-
(trifluoromethyl)benzoic acid CAS: [28186-62-1 ] are commercially available, or can be prepared by those skilled in the art. For example see also WO 2013/171712, WO 2012/1 17000, WO2017/192385. Some compounds of formula lllb and lllc are novel and have been especially prepared to enable preparation of compounds of formula I. Synthesis of such compounds is shown in scheme 1 1 :
Scheme 1 1
As shown in scheme 1 1 , compounds of formula XXI, wherein X10 is halogen, preferably bromine or iodine, Ai is nitrogen or methane, and Ra is Ci-C4alkyl, can be treated with a bipyridine copper reagent (bpy)CuSCF3, wherein bpy is bipyridyl, in an inert solvent such as acetonitrile or DMF, at temperatures between room temperature and 120°C, optionally under microwave heating, to give compounds of formula XXII, wherein Ai , and Ra are as defined for formula XXI. Such chemistry is known and has been described in the literature, for example, in Angew. Chem. Int. Ed. 2013, 52, 1548-1552. A preferred reagent for this transformation is (bpy)CuSCF3 (CAS [1413732-47-4]).
Compounds of formula XXII are converted to compounds of lllb by ester hydrolysis, for example reaction with a base e.g. Lithium, potassium, or sodium hydroxide, in water optionally in the presence of a water miscible solvent such a THF, acetone, dioxane and the like. Such reactions are well known to those skilled in the art.
Compounds of formula XXIV, wherein R6 is Ci-C3alkyl, or Ci-C3haloalkyl, and Ra is Ci-C4alkyl, can be prepared by reaction of a compound of formula XXIII with a compound of formula XXV, wherein Xn is Cl, Br, F, I, OSO2CF3, or OSO2CH3, in the presence of a base, such as sodium hydride, K2CO3, or CS2CO3, in an inert solvent such as THF, DMF, or acetonitrile, to give compounds of formula XXIV. Compounds of formula XXIV, wherein R6 is CHF2, are prepared by treatment with in situ generated difluorocarbene analogous to the procedures described for preparation of IXaa in scheme 9. Hydrolysis of compounds of formula XXIV give compounds of formula lllc is as described vide supra.
Compounds of formula I’a wherein Ri , R3, A2, R4a, Rsa, and Rsb are as described in formula I, with a carboxylic acid derivative of formula III wherein R2 is described as above under formula I.
Ill
The chemistry is described in in more detail in Scheme 12.
Scheme 12:
Ilia
I Compounds of formula Ilia, wherein R2 is described in formula I and X0 is described in Scheme 1 , can be treated with compounds of formula lib, wherein Ri , R3, A2, R4a, Rsa, and Rsb are described in formula I, under the conditions described in detail in Scheme 1 . The formation of compounds of formula Ilia from compounds of formula III is described in Scheme 1 .
The formation of compounds of formula lib is outlined in Scheme 13. Compounds of formula lib can be prepared by treatment of compounds of formula lie, wherein wherein A2, R3, R4a, Rsa, and Rsb are described in formula I, with compounds of formula XXVI (wherein Ri is as defined in formula I), e.g. in the presence of NaBH(OAc)3 or NaBhhCN, in a suitable solvent, preferably in acetic acid at room temperature analog to W02002/088073, page 35. Alternatively, another reagent system for the reductive amination uses a combination of Ti(i-OiPr)4 and NaBhU (see Synthesis 2003 (14), 2206). Compounds of formula XXVI are generally commercially available.
Amines of formula lie may be obtained by biocatalyzed deracemization of amines of formula I la. This may be done for instance using a lipase, e.g. Candida Antarctica lipase B or Pseudomonas fluorescens lipase, eventually in immobilized form (e.g. Novozym® 435) in presence of an acyl donor, e.g. ethyl methoxyacetate or vinyl acetate, in a suitable solvent such as acetonitrile or methyl tert-butyl ether at temperatures between 20 °C to 100 °C. Such processes are described for instance in J. Org. Chem. 2007, 72, 6918-6923 or Adv. Synth. Catal. 2007, 349, 1481 -1488. The expected stereochemical outcome of such enzymatic deracemization is known of those skilled in the art and is documented in the literature, for instance in J. Org. Chem. 1991 , 56, 2656-2665 or J. Am. Chem. Soc. 2015, 137, 3996-4009.
Scheme 13:
In an alternative process, compounds of formula lie can be obtained from XVa, herein A2, R3, R4a, Rsa, and Rsb are as described in formula I, following the synthesis described in Scheme 14.
Scheme 14: Amines of formula lie may be obtained from intermediates of formula XXVII, wherein A2, R3, R4a, Rsa, and Rsb are described in formula I and Z3 is NPhth or NB0C2. Such intermediates can be obtained from alcohols of formula XVa by a Mitsunobu reaction, which involves treating alcohols of formula XVa by diisopropyl azodicarboxylate in the presence of a phosphine such as triphenylphosphine or tributylphosphine and of an amine such as phthalimide or bis(fe/?-butoxycarbonyl)amine. Mitsunobu reactions are known by those skilled in the art to proceed with inversion of the stereocenter, as described for instance in Chem. Rev. 2009, 109, 2551 -2651 . Amines of formula XXVII can then be transformed into amines of formula lie by treatment with hydrazine if Z3 = NPhth or with TFA if Z3 = NB0C2.
Alternatively, amines of formula lie may be obtained by reduction of azides of formula XXVIII, wherein A2, R3, R4a, R5a, and Rsb are described in formula I, by treatment with triphenylphosphine and water (Staudinger reaction) or by hydrogenation for example using a palladium catalyst in the presence of hydrogen. Azides of formula XXVIII may be obtained by treatment of alcohols of formula XVa with an azidation reagent such as diphenyl phosphoryl azide in a solvent such as toluene or THF in presence of a base such as DBU. Such processes are known by those skilled in the art to proceed with inversion of the stereocenter and are described in the literature for instance in Adv. Synth. Catal. 2018, 360, 2157- 2165.
Alcohols of formula XVa may be obtained by enantioselective reduction of ketones of formula VI, wherein A2, R3, R4a, Rsa, and Rsb are as described in formula I. Such reductions can be done using a catalyst, for instance a ruthenium or a rhodium catalyst with a chiral ligand such as RuCI[(R,R)- TsDPEN](mesitylene) or RuBF4[(R,R)-TsDPEN](p-cymene) in the presence of a hydrogen donor system such as for example HCOOH/Et3N or HCO2NH4. Such processes are described in the literature for instance in J. Org. Chem. 2017, 82, 5607.
Alternatively, compounds of formula lie may also be prepared as outlined in Scheme 15. Scheme 15:
Amines of formula lie can be prepared by deprotection of amines of formula XXXVII, wherein A2, R3, R4a, R5a and Rsb are described in formula I, for instance using an acid such as trifluoroacetic acid or hydrochloric acid. Compounds of formula XXXVII may be synthesized from compounds of formula XXXVI, wherein A2, R3 and R4a are described in formula I and Zsa and Zsb are, independently of each other, selected from Rsa, Rsb, halogen, NH2 or OH. Such functional group interconversions are known to those skilled in the art and examples of such transformations have been described in the literature, for instance in Eur. J. Org. Chem. 2005, 19, 4141 -4153 or in J. Org. Chem. 2008, 73, 7481 -7485. Compounds of formula XXXVI can be obtained from compounds of formula XXXV by alkylation, for instance using a base and an electrophile, e.g. chlorodifluoroacetic acid. Compounds of formula XXXV may be prepared by hydroxylation of compounds of formula XXXIV, wherein A2 and R3 are described in formula I, Z4a is selected from R4a, halogen or NH2, and Zsa and Zsb are, independently of each other, selected from Rsa, Rsb, halogen, NH2 or OH. Conversion of XXXIV to XXXV can be done following methods referenced in the literature, for instance in Org. Lett. 2016, 18, 2244-2247 or Tetrahedron 2009, 65, 757-764. Amines of formula XXXIV can be obtained by condensation of diamines of formula XXXIII, wherein Zsa and Zsb are, independently of each other, selected from Rsa, Rsb, halogen, NH2 or OH, on diketones of formula XXXII, wherein A2 and R3 are described in formula I and å4a is selected from R4a, halogen or NH2. This condensation can take place in the presence of a suitable solvent such as ethanol or isopropanol in presence of an oxidant such as air or DDQ. Diketones of formula XXXII may be formed by oxidation of hydroxyketones of formula XXXI, A2 and R3 are described in formula I and å4a is selected from R4a, halogen or NH2. This oxidation can involve for instance S03-pyridine in presence of DMSO and a base, for instance triethylamine or also sodium hypochlorite in presence of a catalyst such as TEMPO/BU4NHSO4. Examples of such oxidations can be found in the literature, for instance in Synlett, 2014, 25, 596 or J. Am. Chem. Soc. 1990, 112, 5290-5313. Hydroxyketones of formula XXXI may be synthesized by cross-benzoin condensation between aldehydes of formula XXIX, wherein A2 is described in formula I and å4a is selected from R4a, halogen or NH2, and aldehydes of formula XXX, wherein R3 is as described in formula I. Aldehydes of formula XXX are commercially available in chiral form, like for instance Boc-L-alaninal (CAS 79069-50-4) or tert-butyl N-[(1 S)-1 -(cyclopropylmethyl)-2- oxo-ethyl]carbamate (CAS 881902-36-9). Cross-benzoin condensations are done in the usual way by employing an organocatalyst such as a triazolium salt or a thiazolium salt in the presence of a base such as potassium tert-butoxide or isopropyldiethylamine in a suitable solvent such as dichloromethane or tetrahydrofuran at a temperature between -20 °C and the boiling point of the solvent. Examples of catalysts for such transformations have been described in the literature for instance in J. Am. Chem. Soc. 2014, 136, 7539-7542 or in Org. Lett. 2016, 18, 4518-4521 .
Compounds of formula XXXVI may also be obtained directly from compounds of formula XXXIV, for instance using transition metal catalysis or diazonium chemistry. Such functional group interconversions are known to those skilled in the art and examples can be found in the literature, for instance in J. Am. Chem. Soc. 2019, 141, 19257-19262, Angew. Chem. !nt. Ed. 2015, 54, 5736-5739 or Heterocycles, 2004, 63, 2735-2746.
Compounds of formula XXXVII may be obtained from compounds of formula XXXIX, wherein A2, R3, R5a and Rsb are described in formula I, by alkylation for instance using a base and an electrophile, e.g. chlorodifluoroacetic acid. Compounds of formula XXXIX may be synthesized from compounds of formula XXXVIII (wherein A2, R3, Rsa and Rsb are described in formula I and å4a is selected from R4a, halogen or NH2)by hydroxylation reaction, following methods referenced in the literature, for instance in Org. Lett. 2016, 18, 2244-2247 or Tetrahedron 2009, 65, 757-764. Alternatively, compounds of formula XXXVII may be obtained from compounds of formula XXXVIII. Such functional group interconversions are known to those skilled in the art and examples can be found in the literature, for instance in J. Am. Chem. Soc. 2019, 141, 19257-19262, Angew. Chem. Int. Ed. 2015, 54, 5736-5739 or Heterocycles, 2004, 63, 2735-2746.
As shown in Scheme 16, compounds of formula I’a can be alternatively prepared by reaction of compounds of formula XXa (wherein Ri , R3, Rsa, and Rsb are defined in formula I, and X07 is a leaving group like, for example, chlorine, bromine, iodine) with compounds of formula V (Stille reaction) or compounds of formula VIII (Suzuki-Miyaura reaction) in the presence of a palladium catalyst as described in detail in Schemes 2 and 3.
Scheme 16:
>¾7 = CI, Br, I, OMs, OTs or qp
Compounds of formula I’a can be prepared by reaction of compounds of formula XXa with compounds of formula V (Stille reaction) or compounds of formula VIII (Suzuki-Miyaura reaction) in the presence of a palladium catalyst as described in detail in Schemes 2 and 3.
Compounds of formula XXa can be prepared by coupling of amines of formula XlXb (wherein Ri, R3, R5a, and Rsb are defined in formula I, and X07 is a leaving group like, for example, chlorine, bromine, iodine) and compounds of formula Ilia, wherein R2 is described in formula I and Xo is described in Scheme 1 , under the conditions described in detail in Scheme 1 . Under the same conditions, if Ri = H, compounds of formula XXa may be obtained directly from compounds of formula XlXa (wherein R3, Rsa, and Rsb are defined in formula I, and X07 is a leaving group like, for example, chlorine, bromine, iodine).
Compounds of formula XlXb can be prepared by treatment of compounds of formula XlXa, with compounds of formula XXVI (wherein Ri is defined in formula I), e.g. in the presence of NaBH(OAc)3 or NaBhhCN, in a suitable solvent, preferably in acetic acid at room temperature analog to W02002/088073, page 35. Alternatively, another reagent system for the reductive amination uses a combination of Ti(OiPr)4 and NaBhU (see Synthesis 2003 (14), 2206). Amines of formula XlXa can be prepared by deracemization procedure method, which involves for example, a selective acylation of one enantiomer. Such an example is described more in details in Scheme 17. Scheme 17:
x„7
Amines of formula XlXa may be obtained by biocatalyzed deracemization of amines of formula XIX, wherein R3, Rsa, and Rsb are described in formula I and X07 is a leaving group such as bromine, chlorine, iodine, mesylate, tosylate or triflate. This may be done for instance using a lipase, e.g. Candida Antarctica lipase B or Pseudomonas fluorescens lipase, eventually in immobilized form (e.g. Novozym® 435) in presence of an acyl donor, e.g. ethyl methoxyacetate or vinyl acetate, in a suitable solvent such as acetonitrile or methyl tert-butyl ether at temperatures between 20 °C to 100 °C. Such processes are described for instance in J. Org. Chem. 2007, 72, 6918-6923 or Adv. Synth. Catal. 2007, 349, 1481 - 1488. The expected stereochemical outcome of such enzymatic deracemization are known of those skilled in the art and are documented in the literature, for instance in J. Org. Chem. 1991 , 56, 2656-2665 or J. Am. Chem. Soc. 2015, 137, 3996-4009.
Alternatively, resolution of amines of formula XlXa may be achieved using a chiral auxiliary, as described in Scheme 18.
Scheme 18
Amines of formula XlXa can be prepared for intermediates of formula XLI, wherein R3, Rsa, and Rsb are described in formula I, X07 is a leaving group such as bromine, chlorine or iodine and X12* is a chiral auxiliary, by treatment with acids such as HCI or bases such as NaOH. Amines of formula XLI can be formed by coupling of a chiral compound of formula XL, wherein Xo is described in Scheme 1 and X12* is a chiral moiety of known chirality, with amines of formula XIX following the conditions detailed in Scheme 1 . Chiral auxiliaries of formula XL are for instance derived from mandelic acid or (1 R)- menthylchloroformate. Examples of such deracemization processes are reported in the literature, for instance in J. Org. Chem. 2007, 72, 485-493.
Alternatively, amines of formula XLVIIId (wherein R3, Rsa, and Rsb are defined in formula I, and X07 is a leaving group like, for example, chlorine, bromine, iodine), can be formed as described in Scheme 19.
Scheme 19:
Amines of formula XlXa may be obtained from intermediates of formula XLII, wherein R3, Rsa, and Rsb are as described in formula I, X07 is a leaving group as described in Scheme 5 and Z3 is NPhth or NB0C2. Such intermediates can be obtained from alcohols of formula XLIII, wherein R3, Rsa, and Rsb are described in formula I and X07 is a leaving group as described in Scheme 5, by a Mitsunobu reaction, which involves treating alcohols of formula XLIII by diisopropyl azodicarboxylate in the presence of a phosphine such as triphenylphosphine or tributylphosphine and of an amine such as phthalimide or bis(fe/f-butoxycarbonyl)amine. Mitsunobu reactions are known by those skilled in the art to proceed with inversion of the stereocenter, as described for instance in Chem. Rev. 2009, 109, 2551 -2651 . Amines of formula XLII can then be transformed into amines of formula XlXa by treatment with hydrazine if Z3 = NPhth or with TFA if Z3 = NBoc2.
Alternatively, amines of formula XlXa may be obtained by reduction of azides of formula XLV, wherein R3, R5a, and Rsb are as described in formula I and X07 is a leaving group as described in Scheme 5, by treatment with triphenylphosphine and water (Staudinger reaction) or by hydrogenation for example using a palladium catalyst in the presence of hydrogen. Azides of formula XLV may be obtained by treatment of alcohols of formula XLIII with an azidation reagent such as diphenyl phosphoryl azide in a solvent such as toluene or THF in presence of a base such as DBU. Such processes are known by those skilled in the art to proceed with inversion of the stereocenter and are described in the literature for instance in Adv. Synth. Catal. 2018, 360, 2157-2165.
Alcohols of formula XLIII may be obtained by enantioselective reduction of ketones of formula XLIV, wherein R3, Rsa, and Rsb are as described in formula I and X07 is a leaving group as described in Scheme 5. Such reductions can be done using catalysts, for instance a ruthenium or a rhodium catalyst with a chiral ligand such as RuCI[(R,R)-TsDPEN](mesitylene) or RuBF4[(R,R)-TsDPEN](p-cymene) in the presence of a hydrogen donor system such as for example HCOOH/Et3N or HCO2NH4. Such processes are described in the literature for instance in J. Org. Chem. 2017, 82, 5607.
Depending on the procedure or the reaction conditions, the reactants can be reacted in the presence of a base. Examples of suitable bases are alkali metal or alkaline earth metal hydroxides, alkali metal or alkaline earth metal hydrides, alkali metal or alkaline earth metal amides, alkali metal or alkaline earth metal alkoxides, alkali metal or alkaline earth metal acetates, alkali metal or alkaline earth metal carbonates, alkali metal or alkaline earth metal dialkylamides or alkali metal or alkaline earth metal alkylsilylamides, alkylamines, alkylenediamines, free or N-alkylated saturated or unsaturated cycloalkylamines, basic heterocycles, ammonium hydroxides and carbocyclic amines. Examples which may be mentioned are sodium hydroxide, sodium hydride, sodium amide, sodium methoxide, sodium acetate, sodium carbonate, potassium tert-butoxide, potassium hydroxide, potassium carbonate, potassium hydride, lithium diisopropylamide, potassium bis(trimethylsilyl)amide, calcium hydride, triethylamine, diisopropylethylamine, triethylenediamine, cyclohexylamine, N-cyclohexyl-N,N- dimethylamine, N,N-diethylaniline, pyridine, 4-(N,N-dimethylamino)pyridine, quinuclidine, N- methylmorpholine, benzyltrimethylammonium hydroxide and 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
The reactants can be reacted with each other as such, i.e. without adding a solvent or diluent. In most cases, however, it is advantageous to add an inert solvent or diluent or a mixture of these. If the reaction is carried out in the presence of a base, bases which are employed in excess, such as triethylamine, pyridine, N-methylmorpholine or N,N-diethylaniline, may also act as solvents or diluents.
The reactions are advantageously carried out in a temperature range from approximately -80°C to approximately +140°C, preferably from approximately -30°C to approximately +100°C, in many cases in the range between ambient temperature and approximately +80°C.
Depending on the choice of the reaction conditions and starting materials which are suitable in each case, it is possible, for example, in one reaction step only to replace one substituent by another substituent according to the invention, or a plurality of substituents can be replaced by other substituents according to the invention in the same reaction step. Salts of compounds of formula I can be prepared in a manner known per se. Thus, for example, acid addition salts of compounds of formula I are obtained by treatment with a suitable acid or a suitable ion exchanger reagent and salts with bases are obtained by treatment with a suitable base or with a suitable ion exchanger reagent.
Salts of compounds of formula I can be converted in the customary manner into the free compounds I, acid addition salts, for example, by treatment with a suitable basic compound or with a suitable ion exchanger reagent and salts with bases, for example, by treatment with a suitable acid or with a suitable ion exchanger reagent.
Salts of compounds of formula I can be converted in a manner known per se into other salts of compounds of formula I, acid addition salts, for example, into other acid addition salts, for example by treatment of a salt of inorganic acid such as hydrochloride with a suitable metal salt such as a sodium, barium or silver salt, of an acid, for example with silver acetate, in a suitable solvent in which an inorganic salt which forms, for example silver chloride, is insoluble and thus precipitates from the reaction mixture.
Depending on the procedure or the reaction conditions, the compounds of formula I, which have saltforming properties can be obtained in free form or in the form of salts.
The compounds of formula I and, where appropriate, the tautomers thereof, in each case in free form or in salt form, can be present in the form of one of the isomers which are possible or as a mixture of these, for example in the form of pure isomers, such as antipodes and/or diastereomers, or as isomer mixtures, such as enantiomer mixtures, for example racemates, diastereomer mixtures or racemate mixtures, depending on the number, absolute and relative configuration of asymmetric carbon atoms which occur in the molecule and/or depending on the configuration of non-aromatic double bonds which occur in the molecule; the invention relates to the pure isomers and also to all isomer mixtures which are possible and is to be understood in each case in this sense hereinabove and hereinbelow, even when stereochemical details are not mentioned specifically in each case.
Diastereomer mixtures or racemate mixtures of compounds of formula I, in free form or in salt form, which can be obtained depending on which starting materials and procedures have been chosen can be separated in a known manner into the pure diasteromers or racemates on the basis of the physicochemical differences of the components, for example by fractional crystallization, distillation and/or chromatography.
Enantiomer mixtures, such as racemates, which can be obtained in a similar manner can be resolved into the optical antipodes by known methods, for example by recrystallization from an optically active solvent, by chromatography on chiral adsorbents, for example high-performance liquid chromatography (HPLC) on acetyl celulose, with the aid of suitable microorganisms, by cleavage with specific, immobilized enzymes, via the formation of inclusion compounds, for example using chiral crown ethers, where only one enantiomer is complexed, or by conversion into diastereomeric salts, for example by reacting a basic end-product racemate with an optically active acid, such as a carboxylic acid, for example camphor, tartaric or malic acid, or sulfonic acid, for example camphorsulfonic acid, and separating the diastereomer mixture which can be obtained in this manner, for example by fractional crystallization based on their differing solubilities, to give the diastereomers, from which the desired enantiomer can be set free by the action of suitable agents, for example basic agents.
Pure diastereomers or enantiomers can be obtained according to the invention not only by separating suitable isomer mixtures, but also by generally known methods of diastereoselective or enantioselective synthesis, for example by carrying out the process according to the invention with starting materials of a suitable stereochemistry.
N-oxides can be prepared by reacting a compound of the formula I with a suitable oxidizing agent, for example the FhC^/urea adduct in the presence of an acid anhydride, e.g. trifluoroacetic anhydride. Such oxidations are known from the literature, for example from J. Med. Chem., 32 (12), 2561 -73, 1989 or WO 2000/15615.
It is advantageous to isolate or synthesize in each case the biologically more effective isomer, for example enantiomer or diastereomer, or isomer mixture, for example enantiomer mixture or diastereomer mixture, if the individual components have a different biological activity.
The compounds of formula I and, where appropriate, the tautomers thereof, in each case in free form or in salt form, can, if appropriate, also be obtained in the form of hydrates and/or include other solvents, for example those which may have been used for the crystallization of compounds which are present in solid form.
The compounds of formula I according to the following Tables A-1 to A-27 can be prepared according to the methods described above. The examples which follow are intended to illustrate the invention and show preferred compounds of formula I, in the form of a compound of formula J-1 .
J-1
Table A-1 provides 13 compounds A-1.001 to A-1.013 of formula J-1 wherein Ri is H, R4 is [5-(trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z. For example, A-1.002 is Table Z: Substituent definitions of Rå:
Table A-2 provides 13 compounds A-2.001 to A-2.013 of formula J-1 wherein Ri is H, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-3 provides 13 compounds A-3.001 to A-3.013 of formula J-1 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-4 provides 13 compounds A-4.001 to A-4.013 of formula J-1 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-5 provides 13 compounds A-5.001 to A-5.013 of formula J-1 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z. Table A-6 provides 13 compounds A-6.001 to A-6.013 of formula J-1 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-7 provides 13 compounds A-7.001 to A-7.013 of formula J-1 wherein Ri is H, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-8 provides 13 compounds A-8.001 to A-8.013 of formula J-1 wherein Ri is H, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-9 provides 13 compounds A-9.001 to A-9.013 of formula J-1 wherein Ri is H, R4 is (5-cyano- 2-pyridyl) and R2 is as defined in table Z.
Table A-10 provides 13 compounds A-10.001 to A-10.013 of formula J-1 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-1 1 provides 13 compounds A-1 1 .001 to A-1 1 .013 of formula J-1 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-12 provides 13 compounds A-12.001 to A-12.013 of formula J-1 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-13 provides 13 compounds A-13.001 to A-13.013 of formula J-1 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-14 provides 13 compounds A-14.001 to A-14.013 of formula J-1 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-15 provides 13 compounds A-15.001 to A-15.013 of formula J-1 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-16 provides 13 compounds A-16.001 to A-16.013 of formula J-1 wherein Ri is Chh, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-17 provides 13 compounds A-17.001 to A-17.013 of formula J-1 wherein Ri is Chh, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-18 provides 13 compounds A-18.001 to A-18.013 of formula J-1 wherein Ri is Chh, R4 is (5- cyano-2-pyridyl) and R2 is as defined in table Z.
Table A-19 provides 13 compounds A-19.001 to A-19.013 of formula J-1 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-20 provides 13 compounds A-20.001 to A-20.013 of formula J-1 wherein Ri is CH2Cyp, R4 is [5-(trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-21 provides 13 compounds A-21 .001 to A-21 .013 of formula J-1 wherein Ri is ChhCyp, R4 is [5-(2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-22 provides 13 compounds A-22.001 to A-22.013 of formula J-1 wherein Ri is ChhCyp, R4 is [5-(2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-23 provides 13 compounds A-23.001 to A-23.013 of formula J-1 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-24 provides 13 compounds A-24.001 to A-24.013 of formula J-1 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z. Table A-25 provides 13 compounds A-25.001 to A-25.013 of formula J-1 wherein Ri is CH2Cyp, R4 is [5-(difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table A-26 provides 13 compounds A-26.001 to A-26.013 of formula J-1 wherein Ri is CH2Cyp, R4 is [5-(difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table A-27 provides 13 compounds A-27.001 to A-27.013 of formula J-1 wherein Ri is CH2Cyp, R4 is (5-cyano-2-pyridyl) and R2 is as defined in table Z.
The compounds of formula I according to the following Tables B-1 to B-27 can be prepared according to the methods described above. The examples which follow are intended to illustrate the invention and show preferred compounds of formula I, in the form of a compound of formula J-2.
Table B-1 provides 13 compounds B-1 .001 to B-1.013 of formula J-2 wherein Ri is H, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-2 provides 13 compounds B-2.001 to B-2.013 of formula J-2 wherein Ri is H, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-3 provides 13 compounds B-3.001 to B-3.013 of formula J-2 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-4 provides 13 compounds B-4.001 to B-4.013 of formula J-2 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-5 provides 13 compounds B-5.001 to B-5.013 of formula J-2 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-6 provides 13 compounds B-6.001 to B-6.013 of formula J-2 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-7 provides 13 compounds B-7.001 to B-7.013 of formula J-2 wherein Ri is H, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-8 provides 13 compounds B-8.001 to B-8.013 of formula J-2 wherein Ri is H, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-9 provides 13 compounds B-9.001 to B-9.013 of formula J-2 wherein Ri is H, R4 is (5-cyano- 2-pyridyl) and R2 is as defined in table Z.
Table B-10 provides 13 compounds B-10.001 to B-10.013 of formula J-2 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-1 1 provides 13 compounds B-1 1 .001 to B-1 1 .013 of formula J-2 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z. Table B-12 provides 13 compounds B-12.001 to B-12.013 of formula J-2 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-13 provides 13 compounds B-13.001 to B-13.013 of formula J-2 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-14 provides 13 compounds B-14.001 to B-14.013 of formula J-2 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-15 provides 13 compounds B-15.001 to B-15.013 of formula J-2 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-16 provides 13 compounds B-16.001 to B-16.013 of formula J-2 wherein Ri is Chh, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-17 provides 13 compounds B-17.001 to B-17.013 of formula J-2 wherein Ri is Chh, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-18 provides 13 compounds B-18.001 to B-18.013 of formula J-2 wherein Ri is Chh, R4 is (5- cyano-2-pyridyl) and R2 is as defined in table Z.
Table B-19 provides 13 compounds B-19.001 to B-19.013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-20 provides 13 compounds B-20.001 to B-20.013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-21 provides 13 compounds B-21 .001 to B-21 .013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-22 provides 13 compounds B-22.001 to B-22.013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-23 provides 13 compounds B-23.001 to B-23.013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-24 provides 13 compounds B-24.001 to B-24.013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-25 provides 13 compounds B-25.001 to B-25.013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table B-26 provides 13 compounds B-26.001 to B-26.013 of formula J-2 wherein Ri is ChhCyp, R4 is [5-(difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table B-27 provides 13 compounds B-27.001 to B-27.013 of formula J-2 wherein Ri is ChhCyp, R4 is (5-cyano-2-pyridyl) and R2 is as defined in table Z.
The compounds of formula I according to the following Tables C-1 to C-27 can be prepared according to the methods described above. The examples which follow are intended to illustrate the invention and show preferred compounds of formula I, in the form of a compound of formula J-3.
Table C-1 provides 13 compounds C-1 .001 to C-1 .013 of formula J-3 wherein Ri is H, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-2 provides 13 compounds C-2.001 to C-2.013 of formula J-3 wherein Ri is H, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-3 provides 13 compounds C-3.001 to C-3.013 of formula J-3 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-4 provides 13 compounds C-4.001 to C-4.013 of formula J-3 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-5 provides 13 compounds C-5.001 to C-5.013 of formula J-3 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-6 provides 13 compounds C-6.001 to C-6.013 of formula J-3 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-7 provides 13 compounds C-7.001 to C-7.013 of formula J-3 wherein Ri is H, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-8 provides 13 compounds C-8.001 to C-8.013 of formula J-3 wherein Ri is H, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-9 provides 13 compounds C-9.001 to C-9.013 of formula J-3 wherein Ri is H, R4 is (5-cyano- 2-pyridyl) and R2 is as defined in table Z.
Table C-10 provides 13 compounds C-10.001 to C-10.013 of formula J-3 wherein Ri is CH3, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-1 1 provides 13 compounds C-1 1 .001 to C-1 1 .013 of formula J-3 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-12 provides 13 compounds C-12.001 to C-12.013 of formula J-3 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-13 provides 13 compounds C-13.001 to C-13.013 of formula J-3 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-14 provides 13 compounds C-14.001 to C-14.013 of formula J-3 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-15 provides 13 compounds C-15.001 to C-15.013 of formula J-3 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-16 provides 13 compounds C-16.001 to C-16.013 of formula J-3 wherein Ri is Chh, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z. Table C-17 provides 13 compounds C-17.001 to C-17.013 of formula J-3 wherein Ri is Chh, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-18 provides 13 compounds C-18.001 to C-18.013 of formula J-3 wherein Ri is Chh, R4 is (5- cyano-2-pyridyl) and R2 is as defined in table Z.
Table C-19 provides 13 compounds C-19.001 to C-19.013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-20 provides 13 compounds C-20.001 to C-20.013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-21 provides 13 compounds C-21 .001 to C-21 .013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-22 provides 13 compounds C-22.001 to C-22.013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-23 provides 13 compounds C-23.001 to C-23.013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-24 provides 13 compounds C-24.001 to C-24.013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-25 provides 13 compounds C-25.001 to C-25.013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table C-26 provides 13 compounds C-26.001 to C-26.013 of formula J-3 wherein Ri is ChhCyp, R4 is [5-(difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table C-27 provides 13 compounds C-27.001 to C-27.013 of formula J-3 wherein Ri is ChhCyp, R4 is (5-cyano-2-pyridyl) and R2 is as defined in table Z.
The compounds of formula I according to the following Tables D-1 to D-27 can be prepared according to the methods described above. The examples which follow are intended to illustrate the invention and show preferred compounds of formula I, in the form of a compound of formula J-4.
Table D-1 provides 13 compounds D-1 .001 to D-1 .013 of formula J-4 wherein Ri is H, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-2 provides 13 compounds D-2.001 to D-2.013 of formula J-4 wherein Ri is H, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-3 provides 13 compounds D-3.001 to D-3.013 of formula J-4 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z. Table D-4 provides 13 compounds D-4.001 to D-4.013 of formula J-4 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-5 provides 13 compounds D-5.001 to D-5.013 of formula J-4 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-6 provides 13 compounds D-6.001 to D-6.013 of formula J-4 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-7 provides 13 compounds D-7.001 to D-7.013 of formula J-4 wherein Ri is H, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-8 provides 13 compounds D-8.001 to D-8.013 of formula J-4 wherein Ri is H, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-9 provides 13 compounds D-9.001 to D-9.013 of formula J-4 wherein Ri is H, R4 is (5-cyano- 2-pyridyl) and R2 is as defined in table Z.
Table D-10 provides 13 compounds D-10.001 to D-10.013 of formula J-4 wherein Ri is CH3, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-1 1 provides 13 compounds D-1 1 .001 to D-1 1 .013 of formula J-4 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-12 provides 13 compounds D-12.001 to D-12.013 of formula J-4 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-13 provides 13 compounds D-13.001 to D-13.013 of formula J-4 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-14 provides 13 compounds D-14.001 to D-14.013 of formula J-4 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-15 provides 13 compounds D-15.001 to D-15.013 of formula J-4 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-16 provides 13 compounds D-16.001 to D-16.013 of formula J-4 wherein Ri is Chh, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-17 provides 13 compounds D-17.001 to D-17.013 of formula J-4 wherein Ri is Chh, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-18 provides 13 compounds D-18.001 to D-18.013 of formula J-4 wherein Ri is Chh, R4 is (5- cyano-2-pyridyl) and R2 is as defined in table Z.
Table D-19 provides 13 compounds D-19.001 to D-19.013 of formula J-4 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-20 provides 13 compounds D-20.001 to D-20.013 of formula J-4 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-21 provides 13 compounds D-21 .001 to D-21 .013 of formula J-4 wherein Ri is CH2Cyp, R4 is [5-(2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-22 provides 13 compounds D-22.001 to D-22.013 of formula J-4 wherein Ri is CH2Cyp, R4 is [5-(2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z. Table D-23 provides 13 compounds D-23.001 to D-23.013 of formula J-4 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-24 provides 13 compounds D-24.001 to D-24.013 of formula J-4 wherein Ri is ChhCyp, R4 is [5-(2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-25 provides 13 compounds D-25.001 to D-25.013 of formula J-4 wherein Ri is ChhCyp, R4 is [5-(difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table D-26 provides 13 compounds D-26.001 to D-26.013 of formula J-4 wherein Ri is ChhCyp, R4 is [5-(difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table D-27 provides 13 compounds D-27.001 to D-27.013 of formula J-4 wherein Ri is ChhCyp, R4 is (5-cyano-2-pyridyl) and R2 is as defined in table Z.
The compounds of formula I according to the following Tables E-1 to E-27 can be prepared according to the methods described above. The examples which follow are intended to illustrate the invention and show preferred compounds of formula I, in the form of a compound of formula J-5.
Table E-1 provides 13 compounds E-1 .001 to E-1.013 of formula J-5 wherein Ri is H, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-2 provides 13 compounds E-2.001 to E-2.013 of formula J-5 wherein Ri is H, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-3 provides 13 compounds E-3.001 to E-3.013 of formula J-5 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-4 provides 13 compounds E-4.001 to E-4.013 of formula J-5 wherein Ri is H, R4 is [5-(2,2- difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-5 provides 13 compounds E-5.001 to E-5.013 of formula J-5 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-6 provides 13 compounds E-6.001 to E-6.013 of formula J-5 wherein Ri is H, R4 is [5-(2,2,2- trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-7 provides 13 compounds E-7.001 to E-7.013 of formula J-5 wherein Ri is H, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-8 provides 13 compounds E-8.001 to E-8.013 of formula J-5 wherein Ri is H, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-9 provides 13 compounds E-9.001 to E-9.013 of formula J-5 wherein Ri is H, R4 is (5-cyano- 2-pyridyl) and R2 is as defined in table Z. Table E-10 provides 13 compounds E-10.001 to E-10.013 of formula J-5 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-1 1 provides 13 compounds E-1 1 .001 to E-1 1 .013 of formula J-5 wherein Ri is Chh, R4 is [5- (trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-12 provides 13 compounds E-12.001 to E-12.013 of formula J-5 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-13 provides 13 compounds E-13.001 to E-13.013 of formula J-5 wherein Ri is Chh, R4 is [5- (2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-14 provides 13 compounds E-14.001 to E-14.013 of formula J-5 wherein Ri is CH3, R4 is [5- (2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-15 provides 13 compounds E-15.001 to E-15.013 of formula J-5 wherein Ri is Chh, R4 is [5- (2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-16 provides 13 compounds E-16.001 to E-16.013 of formula J-5 wherein Ri is Chh, R4 is [5- (difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-17 provides 13 compounds E-17.001 to E-17.013 of formula J-5 wherein Ri is Chh, R4 is [5- (difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-18 provides 13 compounds E-18.001 to E-18.013 of formula J-5 wherein Ri is Chh, R4 is (5- cyano-2-pyridyl) and R2 is as defined in table Z.
Table E-19 provides 13 compounds E-19.001 to E-19.013 of formula J-5 wherein Ri is ChhCyp, R4 is [5-(trifluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-20 provides 13 compounds E-20.001 to E-20.013 of formula J-5 wherein Ri is CH2Cyp, R4 is [5-(trifluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-21 provides 13 compounds E-21 .001 to E-21 .013 of formula J-5 wherein Ri is CH2Cyp, R4 is [5-(2,2-difluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-22 provides 13 compounds E-22.001 to E-22.013 of formula J-5 wherein Ri is CH2Cyp, R4 is [5-(2,2-difluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-23 provides 13 compounds E-23.001 to E-23.013 of formula J-5 wherein Ri is CH2Cyp, R4 is [5-(2,2,2-trifluoroethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-24 provides 13 compounds E-24.001 to E-24.013 of formula J-5 wherein Ri is CH2Cyp, R4 is [5-(2,2,2-trifluoroethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-25 provides 13 compounds E-25.001 to E-25.013 of formula J-5 wherein Ri is CH2Cyp, R4 is [5-(difluoromethoxy)pyrimidin-2-yl] and R2 is as defined in table Z.
Table E-26 provides 13 compounds E-26.001 to E-26.013 of formula J-5 wherein Ri is CH2Cyp, R4 is [5-(difluoromethoxy)-2-pyridyl] and R2 is as defined in table Z.
Table E-27 provides 13 compounds E-27.001 to E-27.013 of formula J-5 wherein Ri is CH2Cyp, R4 is (5-cyano-2-pyridyl) and R2 is as defined in table Z. Also made available are certain intermediate compounds of the amine of formulae llaa to Mae, some of which are novel.
llad Cl Mae
Specfic examples of compounds of formula llaa to Mae are where Ri and R4 are as defined for a compound in Tables A-1 to A-27.
Further made available are certain intermediate compounds of the acid of formulae III, some of which are novel. Specific examples of compounds of formula III are where R2 is as defined in table Z.
Also made available are compounds of formulae VI, XV, XVa, XLII, XLV, XXXI, XXXII, XXXIV, XXV, XXX, XXXVIII, XXXIX, XlXa, XlXb, XXa, XLII, XLIII, and XLV, wherein, as applicable, the substituents Ri , R2, R3, Rsa, Rsb and R4 (corresponding to the ring having R4a and A2), are as defined in any one of the compounds in Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27. An especially preferred enantiomer of the compounds of formulae VI, XV, XVa, XLII, XLV, XXXI, XXXII, XXXIV, XXV, XXX, XXXVIII, XXXIX, XlXa, XlXb, XXa, XLII, XLIII, and XLV, , as applicable, is the enantiomer having the same spatial arrangement at the stereogenic centre as depicted in formula I’a or I’-A.
The present invention also makes available
• a compound of formula II, wherein A2, Ri , R3, R4a, Rsa, and Rsb are as defined for formula I; accordingly preferred embodiments of A2, Ri , R3, R4a, Rsa, and Rsb for a compound of formula I are likewise preferred embodiments of A2, Ri, R3, R4a, Rsa, and Rsb for a compound of formula II;
• a compound of formulae llaa, llab, Mac, Mad and Mae, wherein Ri is as defined formula I. and R4 is the cyclic group containing A2 and the substituent R4a in formula I, wherein A2 and R4a are as defined as defined formula I; accordingly preferred embodiments of Ri, A2 and R4a for a compound of formula I are likewise preferred embodiments of Ri, A2 and R4a for a any one of a compound of formulae llaa, llab, Mac, Mad and Mae;
• a compound of formula III, wherein R2 is as defined for formula I; accordingly preferred
embodiments of R2 for a compound of formula I are likewise preferred embodiments of R2 for a compound of formula III;
• a compound of formula VI, wherein A2, R3, R4a, Rsa, and Rsb are as defined for formula I; accordingly preferred embodiments of A2, R3, R4a, Rsa, and Rsb for a compound of formula I are likewise preferred embodiments of A2, R3, R4a, Rsa, and Rsb for a compound of a compound of formula XV, wherein A2, R3, R4a, Rsa, and Rsb are as defined for formula I;
accordingly preferred embodiments of A2, R3, R4a, Rsa, and Rsb for a compound of formula I are likewise preferred embodiments of A2, R3, R4a, Rsa, and Rsb for a compound of formula XV;
• a compound of formula XVa, wherein A2, R3, R4a, Rsa, and Rsb are as defined for formula I; accordingly preferred embodiments of A2, R3, R4a, Rsa, and Rsb for a compound of formula I are likewise preferred embodiments of A2, R3, R4a, Rsa, and Rsb for a compound of formula XVa;
• a compound of formula XLII, wherein R3, Rsa, and Rsb are as defined for formula I, X07 is a leaving group like, for example, chlorine, bromine, iodine, and Z3 is NPhth or NB0C2;
accordingly preferred embodiments of R3, Rsa, and Rsb for a compound of formula I are likewise preferred embodiments of R3, Rsa, and Rsb for a compound of formula XLII;
• a compound of formula XLV, wherein R3, Rsa, and Rsb are as defined for formula I and X07 is a leaving group like, for example, chlorine, bromine, iodine; accordingly preferred embodiments of R3, Rsa, and Rsb for a compound of formula I are likewise preferred embodiments of R3, Rsa, and Rsb for a compound of formula XLV;
• a compound of formula XXXI, wherein A2 and R3 are as defined for formula I and å4a is R4a, halogen or NH2; accordingly preferred embodiments of A2, R3, and R4a for a compound of formula I are likewise preferred embodiments of A2, R3 and R4a for a compound of formula XXXI;
• a compound of formula XXXII, wherein A2 and R3 are as defined for formula I and å4a is R4a, halogen or NH2; accordingly preferred embodiments of A2, R3, and R4a for a compound of formula I are likewise preferred embodiments of A2, R3 and R4a for a compound of formula XXXII;
• a compound of formula XXXIV, wherein A2 and R3 are as defined for formula I, å4a is R4a, halogen or NH2, and Zsa and Zsb are independent of each other selected from Rsa, Rsb, halogen, NH2 and OH; accordingly preferred embodiments of A2, R3, R4a, Rsa and Rsb for a compound of formula I are likewise preferred embodiments of A2, R3, R4a, Rsa and Rsb for a compound of formula XXXIV;
• a compound of formula XXV, wherein A2 and R3 are as defined for formula I, and Zsa and Zsb are independent of each other selected from Rsa, Rsb, halogen, NH2 and OH; accordingly preferred embodiments of A2, R3, Rsa and Rsb for a compound of formula I are likewise preferred embodiments A2, R3, Rsa and Rsb for a compound of formula XXV;
• a compound of formula XXX, wherein A2, R3 and R4a are as defined for formula I, and Zsa and Zsb are independent of each other selected from Rsa, Rsb, halogen, NH2 and OH; accordingly preferred embodiments of A2, R3, R4a, Rsa and Rsb for a compound of formula I are likewise preferred embodiments A2, R3, R4a, Rsa and Rsb for a compound of formula XXX;
• a compound of formula XXXVIII, wherein A2, R3, Rsa and Rsb are as defined for formula I, and Z4a is R4a, halogen or NH2; accordingly preferred embodiments of A2, R3, R4a, Rsa and Rsb for a compound of formula I are likewise preferred embodiments A2, R3, R4a, Rsa and Rsb for a compound of formula XXXVIII;
• a compound of formula XXXIX, wherein A2, R3, Rsa and Rsb are as defined for formula I, and Z4a is R4a, halogen or NH2; accordingly preferred embodiments of A2, R3, R4a, Rsa and Rsb for a compound of formula I are likewise preferred embodiments A2, R3, R4a, Rsa and Rsb for a compound of formula XXXIX;
• a compound of formula XlXa, wherein R3, Rsa and Rsb are as defined for formula I, and X07 is a leaving group, for example, chlorine, bromine, iodine; accordingly preferred embodiments of R3, Rsa and Rsb for a compound of formula I are likewise preferred embodiments R3, Rsa and Rsb for a compound of formula XlXa;
• a compound of formula XlXb, wherein Ri, R3, Rsa and Rsb are as defined for formula I, and Xo7 is a leaving group, for example, chlorine, bromine, iodine; accordingly preferred embodiments of Ri, R3, Rsa and Rsb for a compound of formula I are likewise preferred embodiments Ri, R3, Rsa and Rsb for a compound of formula XlXb;
• a compound of formula XXa, wherein Ai, R2a, Råb Ri, R3, Rsa and Rsb are as defined for
formula I, and X07 is a leaving group, for example, chlorine, bromine, iodine; accordingly preferred embodiments of Ai, R2a, Råb Ri, R3, Rsa and Rsb for a compound of formula I are likewise preferred embodiments Ai, R2a, Råb Ri , R3, Rsa and Rsb for a compound of formula XXa;
• a compound of formula XLII, wherein R3, Rsa and Rsb are as defined for formula I, Z3 is NPhth or NB0C2 and X07 is a leaving group, for example, chlorine, bromine, or iodine; accordingly preferred embodiments of R3, Rsa and Rsb for a compound of formula I are likewise preferred embodiments R3, Rsa and Rsb for a compound of formula XLII;
• a compound of formula XLIII, wherein R3, Rsa and Rsb are as defined for formula I and X07 is a leaving group, for example, chlorine, bromine, or iodine; accordingly preferred embodiments of R3, Rsa and Rsb for a compound of formula I are likewise preferred embodiments R3, Rsa and Rsb for a compound of formula XLIII; and • a compound of formula XLV, wherein R3, Rsa and Rsb are as defined for formula I and X07 is a leaving group, for example, chlorine, bromine, or iodine; accordingly preferred embodiments of R3, Rsa and Rsb for a compound of formula I are likewise preferred embodiments R3, Rsa and Rsb for a compound of formula XLV.
The compounds of formula I according to the invention are preventively and/or curatively valuable active ingredients in the field of pest control, even at low rates of application, which have a very favorable biocidal spectrum and are well tolerated by warm-blooded species, fish and plants. The active ingredients according to the invention act against all or individual developmental stages of normally sensitive, but also resistant, animal pests, such as insects or representatives of the order Acarina. The insecticidal or acaricidal activity of the active ingredients according to the invention can manifest itself directly, i. e. in destruction of the pests, which takes place either immediately or only after some time has elapsed, for example during ecdysis, or indirectly, for example in a reduced oviposition and/or hatching rate.
Examples of the above mentioned animal pests are:
from the order Acarina, for example,
Acalitus spp, Aculus spp, Acaricalus spp, Aceria spp, Acarus siro, Amblyomma spp., Argas spp., Boophilus spp., Brevipalpus spp., Bryobia spp, Calipitrimerus spp., Chorioptes spp., Dermanyssus gallinae, Dermatophagoides spp, Eotetranychus spp, Eriophyes spp., Hemitarsonemus spp,
Hyalomma spp., Ixodes spp., Olygonychus spp, Ornithodoros spp., Polyphagotarsone latus,
Panonychus spp., Phyllocoptruta oleivora, Phytonemus spp, Polyphagotarsonemus spp, Psoroptes spp., Rhipicephalus spp., Rhizoglyphus spp., Sarcoptes spp., Steneotarsonemus spp, Tarsonemus spp. and Tetranychus spp.;
from the order Anoplura, for example,
Haematopinus spp., Linognathus spp., Pediculus spp., Pemphigus spp. and Phylloxera spp.;
from the order Coleoptera, for example,
Agriotes spp., Amphimallon majale, Anomala orientalis, Anthonomus spp., Aphodius spp, Astylus atromaculatus, Ataenius spp, Atomaria linearis, Chaetocnema tibialis, Cerotoma spp, Conoderus spp, Cosmopolites spp., Cotinis nitida, Curculio spp., Cyclocephala spp, Dermestes spp., Diabrotica spp., Diloboderus abderus, Epilachna spp., Eremnus spp., Heteronychus arator, Hypothenemus hampei, Lagria vilosa, Leptinotarsa decemlineata, Lissorhoptrus spp., Liogenys spp, Maecolaspis spp,
Maladera castanea, Megascelis spp, Melighetes aeneus, Melolontha spp., Myochrous armatus, Orycaephilus spp., Otiorhynchus spp., Phyllophaga spp, Phlyctinus spp., Popillia spp., Psylliodes spp., Rhyssomatus aubtilis, Rhizopertha spp., Scarabeidae, Sitophilus spp., Sitotroga spp., Somaticus spp, Sphenophorus spp, Sternechus subsignatus, Tenebrio spp., Tribolium spp. and Trogoderma spp.; from the order Diptera, for example,
Aedes spp., Anopheles spp, Antherigona soccata.Bactrocea oleae, Bibio hortulanus, Bradysia spp, Calliphora erythrocephala, Ceratitis spp., Chrysomyia spp., Culex spp., Cuterebra spp., Dacus spp., Delia spp, Drosophila melanogaster, Fannia spp., Gastrophilus spp., Geomyza tripunctata, Glossina spp., Hypoderma spp., Hyppobosca spp., Liriomyza spp., Lucilia spp., Melanagromyza spp., Musca spp., Oestrus spp., Orseolia spp., Oscinella frit, Pegomyia hyoscyami, Phorbia spp., Rhagoletis spp, Rivelia quadrifasciata, Scatella spp, Sciara spp., Stomoxys spp., Tabanus spp., Tannia spp. and Tipula spp.;
from the order Hemiptera, for example,
Acanthocoris scabrator, Acrosternum spp, Adelphocoris lineolatus, Aleurodes spp., Amblypelta nitida, Bathycoelia thalassina, Blissus spp, Cimex spp., Clavigralla tomentosicollis, Creontiades spp, Distantiella theobroma, Dichelops furcatus, Dysdercus spp., Edessa spp, Euchistus spp., Eurydema pulchrum, Eurygaster spp., Halyomorpha halys, Horcias nobilellus, Leptocorisa spp., Lygus spp, Margarodes spp, Murgantia histrionic, Neomegalotomus spp, Nesidiocoris tenuis, Nezara spp., Nysius simulans, Oebalus insularis, Piesma spp., Piezodorus spp, Rhodnius spp., Sahlbergella singularis, Scaptocoris castanea, Scotinophara spp. , Thyanta spp , Triatoma spp., Vatiga illudens;
Acyrthosium pisum, Adalges spp, Agalliana ensigera, Agonoscena targionii, Aleurodicus spp, Aleurocanthus spp, Aleurolobus barodensis, Aleurothrixus floccosus, Aleyrodes brassicae, Amarasca biguttula, Amritodus atkinsoni, Aonidiella spp., Aphididae, Aphis spp., Aspidiotus spp., Aulacorthum solani, Bactericera cockerelli, Bemisia spp, Brachycaudus spp, Brevicoryne brassicae, Cacopsylla spp, Cavariella aegopodii Scop., Ceroplaster spp., Chrysomphalus aonidium, Chrysomphalus dictyospermi, Cicadella spp, Cofana spectra, Cryptomyzus spp, Cicadulina spp, Coccus hesperidum, Dalbulus maidis, Dialeurodes spp, Diaphorina citri, Diuraphis noxia, Dysaphis spp, Empoasca spp., Eriosoma larigerum, Erythroneura spp., Gascardia spp., Glycaspis brimblecombei, Hyadaphis pseudobrassicae, Hyalopterus spp, Hyperomyzus pallidus, Idioscopus clypealis, Jacobiasca lybica, Laodelphax spp., Lecanium corni, Lepidosaphes spp., Lopaphis erysimi, Lyogenys maidis,
Macrosiphum spp., Mahanarva spp, Metcalfa pruinosa, Metopolophium dirhodum, Myndus crudus, Myzus spp., Neotoxoptera sp, Nephotettix spp., Nilaparvata spp., Nippolachnus piri Mats, Odonaspis ruthae, Oregma lanigera Zehnter, Parabemisia myricae, Paratrioza cockerelli, Parlatoria spp., Pemphigus spp., Peregrinus maidis, Perkinsiella spp, Phorodon humuli, Phylloxera spp, Planococcus spp., Pseudaulacaspis spp., Pseudococcus spp., Pseudatomoscelis seriatus, Psylla spp., Pulvinaria aethiopica, Quadraspidiotus spp., Quesada gigas, Recilia dorsalis, Rhopalosiphum spp., Saissetia spp., Scaphoideus spp., Schizaphis spp., Sitobion spp., Sogatella furcifera, Spissistilus festinus, Tarophagus Proserpina, Toxoptera spp, Trialeurodes spp, Tridiscus sporoboli, Trionymus spp, Trioza erytreae , Unaspis citri, Zygina flammigera, Zyginidia scutellaris, ;
from the order Hymenoptera, for example,
Acromyrmex, Arge spp, Atta spp., Cephus spp., Diprion spp., Diprionidae, Gilpinia polytoma, Hoplo- campa spp., Lasius spp., Monomorium pharaonis, Neodiprion spp., Pogonomyrmex spp, Slenopsis invicta, Solenopsis spp. and Vespa spp.;
from the order Isoptera, for example,
Coptotermes spp, Corniternes cumulans, Incisitermes spp, Macrotermes spp, Mastotermes spp, Microtermes spp, Reticulitermes spp.; Solenopsis geminate from the order Lepidoptera, for example,
Acleris spp., Adoxophyes spp., Aegeria spp., Agrotis spp., Alabama argillaceae, Amylois spp., Anticarsia gemmatalis, Archips spp., Argyresthia spp, Argyrotaenia spp., Autographa spp., Bucculatrix thurberiella, Busseola fusca, Cadra cautella, Carposina nipponensis, Chilo spp., Choristoneura spp., Chrysoteuchia topiaria, Clysia ambiguella, Cnaphalocrocis spp., Cnephasia spp., Cochylis spp., Coleophora spp., Colias lesbia, Cosmophila flava, Crambus spp, Crocidolomia binotalis, Cryptophlebia leucotreta, Cydalima perspectalis, Cydia spp., Diaphania perspectalis, Diatraea spp., Diparopsis castanea, Earias spp., Elasmopalpus lignosellus, Eldana saccharina, Ephestia spp., Epinotia spp, Estigmene acrea, Etiella zinckinella, Eucosma spp., Eupoecilia ambiguella, Euproctis spp., Euxoa spp., Feltia jaculiferia, Grapholita spp., Hedya nubiferana, Heliothis spp., Hellula undalis,
Herpetogramma spp, Hyphantria cunea, Keiferia lycopersicella, Lasmopalpus lignosellus, Leucoptera scitella, Lithocollethis spp., Lobesia botrana, Loxostege bifidalis, Lymantria spp., Lyonetia spp., Malacosoma spp., Mamestra brassicae, Manduca sexta, Mythimna spp, Noctua spp, Operophtera spp., Orniodes indica, Ostrinia nubilalis, Pammene spp., Pandemis spp., Panolis flammea, Papaipema nebris, Pectinophora gossypiela, Perileucoptera coffeella, Pseudaletia unipuncta, Phthorimaea operculella, Pieris rapae, Pieris spp., Plutella xylostella, Prays spp., Pseudoplusia spp, Rachiplusia nu, Richia albicosta, Scirpophaga spp., Sesamia spp., Sparganothis spp., Spodoptera spp., Sylepta derogate, Synanthedon spp., Thaumetopoea spp., Tortrix spp., Trichoplusia ni, Tufa absoluta, and Yponomeuta spp.;
from the order Mallophaga, for example,
Damalinea spp. and Trichodectes spp.;
from the order Orthoptera, for example,
Blatta spp., Blattella spp., Gryllotalpa spp., Leucophaea maderae, Locusta spp., Neocurtilla hexadactyla, Periplaneta spp. , Scapteriscus spp, and Schistocerca spp.;
from the order Psocoptera, for example,
Liposcelis spp.;
from the order Siphonaptera, for example,
Ceratophyllus spp., Ctenocephalides spp. and Xenopsylla cheopis;
from the order Thysanoptera, for example,
Calliothrips phaseoli, Frankliniella spp., Heliothrips spp, Hercinothrips spp., Parthenothrips spp, Scirtothrips aurantii, Sericothrips variabilis, Taeniothrips spp., Thrips spp;
from the order Thysanura, for example, Lepisma saccharina.
In a further aspect, the invention may also relate to a method of controlling damage to plant and parts thereof by plant parasitic nematodes (Endoparasitic-, Semiendoparasitic- and Ectoparasitic nematodes), especially plant parasitic nematodes such as root knot nematodes, Meloidogyne hapla, Meloidogyne incognita, Meloidogyne javanica, Meloidogyne arenaria and other Meloidogyne species; cyst-forming nematodes, Globodera rostochiensis and other Globodera species; Heterodera avenae, Heterodera glycines, Heterodera schachtii, Heterodera trifolii, and other Heterodera species; Seed gall nematodes, Anguina species; Stem and foliar nematodes, Aphelenchoides species; Sting nematodes, Belonolaimus longicaudatus and other Belonolaimus species; Pine nematodes, Bursaphelenchus xylophilus and other Bursaphelenchus species; Ring nematodes, Criconema species, Criconemella species, Criconemoides species, Mesocriconema species; Stem and bulb nematodes, Ditylenchus destructor, Ditylenchus dipsaci and other Ditylenchus species; Awl nematodes, Dolichodorus species; Spiral nematodes, Heliocotylenchus multicinctus and other Helicotylenchus species; Sheath and sheathoid nematodes, Hemicycliophora species and Hemicriconemoides species; Hirshmanniella species; Lance nematodes, Hoploaimus species; false rootknot nematodes, Nacobbus species;
Needle nematodes, Longidorus elongatus and other Longidorus species; Pin nematodes,
Pratylenchus species; Lesion nematodes, Pratylenchus neglectus, Pratylenchus penetrans,
Pratylenchus curvitatus, Pratylenchus goodeyi and other Pratylenchus species; Burrowing nematodes, Radopholus similis and other Radopholus species; Reniform nematodes, Rotylenchus robustus, Rotylenchus reniformis and other Rotylenchus species; Scutellonema species; Stubby root nematodes, Trichodorus primitivus and other Trichodorus species, Paratrichodorus species; Stunt nematodes, Tylenchorhynchus claytoni, Tylenchorhynchus dubius and other Tylenchorhynchus species; Citrus nematodes, Tylenchulus species; Dagger nematodes, Xiphinema species; and other plant parasitic nematode species, such as Subanguina spp., Hypsoperine spp., Macroposthonia spp., Melinius spp., Punctodera spp., and Quinisulcius spp..
The compounds of the invention may also have activity against the molluscs. Examples of which include, for example, Ampullariidae; Arion (A. ater, A. circumscriptus, A. hortensis, A. rufus);
Bradybaenidae (Bradybaena fruticum); Cepaea (C. hortensis, C. Nemoralis); ochlodina; Deroceras (D. agrestis, D. empiricorum, D. laeve, D. reticulatum); Discus (D. rotundatus); Euomphalia; Galba (G. trunculata); Helicelia (H. itala, H. obvia); Helicidae Helicigona arbustorum); Helicodiscus; Helix (H. aperta); Limax (L. cinereoniger, L. flavus, L. marginatus, L. maximus, L. tenellus); Lymnaea; Milax (M. gagates, M. marginatus, M. sowerbyi); Opeas; Pomacea (P. canaticulata); Vallonia and Zanitoides.
The active ingredients according to the invention can be used for controlling, i. e. containing or destroying, pests of the abovementioned type which occur in particular on plants, especially on useful plants and ornamentals in agriculture, in horticulture and in forests, or on organs, such as fruits, flowers, foliage, stalks, tubers or roots, of such plants, and in some cases even plant organs which are formed at a later point in time remain protected against these pests.
Suitable target crops are, in particular, cereals, such as wheat, barley, rye, oats, rice, maize or sorghum; beet, such as sugar or fodder beet; fruit, for example pomaceous fruit, stone fruit or soft fruit, such as apples, pears, plums, peaches, almonds, cherries or berries, for example strawberries, raspberries or blackberries; leguminous crops, such as beans, lentils, peas or soya; oil crops, such as oilseed rape, mustard, poppies, olives, sunflowers, coconut, castor, cocoa or ground nuts; cucurbits, such as pumpkins, cucumbers or melons; fibre plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruit or tangerines; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes or bell peppers; Lauraceae, such as avocado, Cinnamonium or camphor; and also tobacco, nuts, coffee, eggplants, sugarcane, tea, pepper, grapevines, hops, the plantain family and latex plants.
The compositions and/or methods of the present invention may be also used on any ornamental and/or vegetable crops, including flowers, shrubs, broad-leaved trees and evergreens.
For example the invention may be used on any of the following ornamental species: Ageratum spp., Alonsoa spp., Anemone spp., Anisodontea capsenisis, Anthemis spp., Antirrhinum spp., Aster spp., Begonia spp. (e.g. B. elatior, B. semperfiorens, B. tubereux), Bougainvillea spp., Brachycome spp., Brassica spp. (ornamental), Calceolaria spp., Capsicum annuum, Catharanthus roseus, Canna spp., Centaurea spp., Chrysanthemum spp., Cineraria spp. (C. maritime), Coreopsis spp., Crassula coccinea, Cuphea ignea, Dahlia spp., Delphinium spp., Dicentra spectabilis, Dorotheantus spp., Eustoma grandiflorum, Forsythia spp., Fuchsia spp., Geranium gnaphalium, Gerbera spp.,
Gomphrena globosa, Heliotropium spp., Helianthus spp., Hibiscus spp., Hortensia spp., Hydrangea spp., Hypoestes phyllostachya, I mpatiens spp. (/. Walleriana), Iresines spp., Kalanchoe spp., Lantana camara, Lavatera trimestris, Leonotis leonurus, Lilium spp., Mesembryanthemum spp., Mimulus spp., Monarda spp., Nemesia spp., Tagetes spp., Dianthus spp. (carnation), Canna spp., Oxalis spp., Beilis spp., Pelargonium spp. (P. peltatum, P. Zonale), Viola spp. (pansy), Petunia spp., Phlox spp., Plecthranthus spp., Poinsettia spp., Parthenocissus spp. (P. quinquefolia, P. tricuspidata), Primula spp., Ranunculus spp., Rhododendron spp., Rosa spp. (rose), Rudbeckia spp., Saintpaulia spp., Salvia spp., Scaevola aemola, Schizanthus wisetonensis, Sedum spp., Solanum spp., Surfmia spp., Tagetes spp., Nicotinia spp., Verbena spp., Zinnia spp. and other bedding plants.
For example the invention may be used on any of the following vegetable species: Allium spp. (A. sativum, A. cepa, A. oschaninii, A. Porrum, A. ascalonicum, A. fistulosum), Anthriscus cerefolium, Apium graveolus, Asparagus officinalis, Beta vulgarus, Brassica spp. (B. Oleracea, B. Pekinensis, B. rapa), Capsicum annuum, Cicer arietinum, Cichorium endivia, Cichorum spp. (C. intybus, C. endivia), Citrillus lanatus, Cucumis spp. (C. sativus, C. meld), Cucurbita spp. (C. pepo, C. maxima), Cyanara spp. (C. scolymus, C. cardunculus), Daucus carota, Foeniculum vulgare, Hypericum spp., Lactuca sativa, Lycopersicon spp. (L esculentum, L lycopersicum), Mentha spp., Ocimum basilicum, Petroselinum crispum, Phaseolus spp. (P. vulgaris, P. coccineus), Pisum sativum, Raphanus sativus, Rheum rhaponticum, Rosemarinus spp., Salvia spp., Scorzonera hispanica, Solanum melongena, Spinacea oleracea, Valerianella spp. (V. locusta, V. eriocarpa) and Vicia faba.
Preferred ornamental species include African violet, Begonia, Dahlia, Gerbera, Hydrangea, Verbena, Rosa, Kalanchoe, Poinsettia, Aster, Centaurea, Coreopsis, Delphinium, Monarda, Phlox, Rudbeckia, Sedum, Petunia, Viola, Impatiens, Geranium, Chrysanthemum, Ranunculus, Fuchsia, Salvia, Hortensia, rosemary, sage, St. Johnswort, mint, sweet pepper, tomato and cucumber.
The active ingredients according to the invention are especially suitable for controlling Aphis craccivora, Diabrotica balteata, Heliothis virescens, Myzus persicae, Plutella xylostella and
Spodoptera littoralis in cotton, vegetable, maize, rice and soya crops. The active ingredients according to the invention are further especially suitable for controlling Mamestra (preferably in vegetables), Cydia pomonella (preferably in apples), Empoasca (preferably in vegetables, vineyards), Leptinotarsa (preferably in potatos) and Chilo supressalis (preferably in rice).
The compounds of formula I are particularly suitable for control of
• a pest of the order Hemiptera, for example, one or more of the species Bemisia tabaci , Aphis craccivora, Myzus persicae, Rhopalosiphum Padi, Nilaparvata lugens, and Euschistus heros (preferably in vegetables, soybeans, and sugarcane);
• a pest of the order Lepidoptera, for example, one or more of the species Spodoptera littoralis, Spodoptera frugiperda, Plutella xylostella, Cnaphalocrocis medinalis, Cydia pomonella, Chrysodeixis includes, Chilo suppressalis, Elasmopalpus lignosellus, Pseudoplusia includens, and Tuta absoluta (preferably in vegetables and corn);
• a pest of the order Thysanoptera, such as the family Thripidae, for example, one or more of Thrips tabaci and Frankliniella occidentalis (preferably in vegetables); and
• soil pests (such as of the order Coleoptera), for example, the species Diabrotica balteata, Agriotes spp. and Leptinotarsa decemlineata (preferably in vegetables and corn).
The term "crops" is to be understood as including also crop plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.
Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins, for example insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as d-endotoxins, e.g. CrylAb, CrylAc, Cry1 F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1 , Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example Photorhabdus spp. or
Xenorhabdus spp., such as Photorhabdus luminescens, Xenorhabdus nematophilus; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as Streptomycetes toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.
In the context of the present invention there are to be understood by d-endotoxins, for example CrylAb, CrylAc, Cry1 F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1 , Vip2, Vip3 or Vip3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701). Truncated toxins, for example a truncated CrylAb, are known. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of Cry3A055, a cathepsin-G-recognition sequence is inserted into a Cry3A toxin (see WO 03/018810).
Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO 93/07278, WO 95/34656, EP-A-0 427 529, EP-A-451 878 and WO 03/052073.
The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. Cryl-type
deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0 367 474, EP-A-0 401 979 and WO 90/13651.
The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and moths (Lepidoptera).
Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard® (maize variety that expresses a CrylAb toxin); YieldGard Rootworm® (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus® (maize variety that expresses a CrylAb and a Cry3Bb1 toxin); Starlink® (maize variety that expresses a Cry9C toxin); Herculex I® (maize variety that expresses a Cry1 Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CrylAc toxin); Bollgard I® (cotton variety that expresses a CrylAc toxin); Bollgard II® (cotton variety that expresses a CrylAc and a Cry2Ab toxin); VipCot® (cotton variety that expresses a Vip3A and a CrylAb toxin); NewLeaf® (potato variety that expresses a Cry3A toxin); NatureGard®, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt1 1 corn borer (CB) trait) and Protecta®.
Further examples of such transgenic crops are:
1. Bt11 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer ( Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated Cry1 Ab toxin. Bt11 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.
2. Bt176 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer ( Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a CrylAb toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.
3. MIR604 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Maize which has been rendered insect-resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-G- protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/018810.
4. MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects.
5. IPC 531 Cotton from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/ES/96/02.
6. 1507 Maize from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein Cry1 F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium.
7. NK603 x MON 810 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 c MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from Agrobacterium sp. strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a CrylAb toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain
Lepidoptera, include the European corn borer.
Transgenic crops of insect-resistant plants are also described in BATS (Zentrum fiir Biosicherheit und Nachhaltigkeit, Zentrum BATS, Clarastrasse 13, 4058 Basel, Switzerland) Report 2003,
(http://bats.ch). The term "crops" is to be understood as including also crop plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called "pathogenesis-related proteins" (PRPs, see e.g. EP-A-0 392 225). Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0 392 225, WO 95/33818 and EP-A-0 353 191. The methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.
Crops may also be modified for enhanced resistance to fungal (for example Fusarium, Anthracnose, or Phytophthora), bacterial (for example Pseudomonas) or viral (for example potato leafroll virus, tomato spotted wilt virus, cucumber mosaic virus) pathogens.
Crops also include those that have enhanced resistance to nematodes, such as the soybean cyst nematode.
Crops that are tolerance to abiotic stress include those that have enhanced tolerance to drought, high salt, high temperature, chill, frost, or light radiation, for example through expression of NF-YB or other proteins known in the art.
Antipathogenic substances which can be expressed by such transgenic plants include, for example, ion channel blockers, such as blockers for sodium and calcium channels, for example the viral KP1 , KP4 or KP6 toxins; stilbene synthases; bibenzyl synthases; chitinases; glucanases; the so-called "pathogenesis-related proteins" (PRPs; see e.g. EP-A-0 392 225); antipathogenic substances produced by microorganisms, for example peptide antibiotics or heterocyclic antibiotics (see e.g.
WO 95/33818) or protein or polypeptide factors involved in plant pathogen defence (so-called "plant disease resistance genes", as described in WO 03/000906).
Further areas of use of the compositions according to the invention are the protection of stored goods and store rooms and the protection of raw materials, such as wood, textiles, floor coverings or buildings, and also in the hygiene sector, especially the protection of humans, domestic animals and productive livestock against pests of the mentioned type.
The present invention provides a compound of the first aspect for use in therapy. The present invention provides a compound of the first aspect, for use in controlling parasites in or on an animal. The present invention further provides a compound of the first aspect, for use in controlling ectoparasites on an animal. The present invention further provides a compound of the first aspect, for use in preventing and/or treating diseases transmitted by ectoparasites. The present invention provides the use of a compound of the first aspect, for the manufacture of a medicament for controlling parasites in or on an animal. The present invention further provides the use of a compound of the first aspect, for the manufacture of a medicament for controlling ectoparasites on an animal. The present invention further provides the use of a compound of the first aspect, for the manufacture of a medicament for preventing and/or treating diseases transmitted by ectoparasites.
The present invention provides the use of a compound of the first aspect, in controlling parasites in or on an animal. The present invention further provides the use of a compound of the first aspect , in controlling ectoparasites on an animal.
The term "controlling" when used in context of parasites in or on an animal refers to reducing the number of pests or parasites, eliminating pests or parasites and/or preventing further pest or parasite infestation.
The term "treating" when used used in context of parasites in or on an animal refers to restraining, slowing, stopping or reversing the progression or severity of an existing symptom or disease.
The term "preventing" when used used in context of parasites in or on an animal refers to the avoidance of a symptom or disease developing in the animal.
The term "animal" when used used in context of parasites in or on an animal may refer to a mammal and a non-mammal, such as a bird or fish. In the case of a mammal, it may be a human or non-human mammal. Non-human mammals include, but are not limited to, livestock animals and companion animals. Livestock animals include, but are not limited to, cattle, camellids, pigs, sheep, goats and horses. Companion animals include, but are not limited to, dogs, cats and rabbits.
A "parasite" is a pest which lives in or on the host animal and benefits by deriving nutrients at the host animal's expense. An "endoparasite" is a parasite which lives in the host animal. An "ectoparasite" is a parasite which lives on the host animal. Ectoparasites include, but are not limited to, acari, insects and crustaceans (e.g. sea lice). The Acari (or Acarina) sub-class comprises ticks and mites. Ticks include, but are not limited to, members of the following genera: Rhipicaphalus, for example, Rhipicaphalus (, Boophilus ) microplus and Rhipicephalus sanguineus ; Amblyomrna Dermacentor, Haemaphysalis ; Hyalomma ; Ixodes ; Rhipicentor, Margaropus ; Argas Otobius ; and Ornithodoros. Mites include, but are not limited to, members of the following genera: Chorioptes, for example Chorioptes bovis ; Psoroptes, for example Psoroptes ovis ; Cheyletiella ; Dermanyssus ; for example Dermanyssus gallinae ;
Ortnithonyssus ; Demodex, for example Demodex canis ; Sarcoptes, for example Sarcoptes scabier, and Psorergates. Insects include, but are not limited to, members of the orders: Siphonaptera, Diptera, Phthiraptera, Lepidoptera, Coleoptera and Homoptera. Members of the Siphonaptera order include, but are not limited to, Ctenocephalides felis and Ctenocephatides canis. Members of the Diptera order include, but are not limited to, Musca spp .; bot fly, for example Gasterophilus intestinalis and Oestrus ov/s; biting flies; horse flies, for example Haematopota spp. and Tabunus spp. haematobia, for example haematobia irritans ; Stomoxys ; Lucilia; midges; and mosquitoes. Members of the
Phthiraptera class include, but are not limited to, blood sucking lice and chewing lice, for example Bovicola Ovis and Bovicola Bovis.
The term "effective amount" when used used in context of parasites in or on an animal refers to the amount or dose of the compound of the invention, or a salt thereof, which, upon single or multiple dose administration to the animal, provides the desired effect in or on the animal. The effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the parasite to be controlled and the degree of infestation; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
The compounds of the invention may be administered to the animal by any route which has the desired effect including, but not limited to topically, orally, parenterally' and subcutaneously. Topical administration is preferred. Formulations suitable for topical administration include, for example, solutions, emulsions and suspensions and may take the form of a pour-on, spot-on, spray-on, spray race or dip. In the alternative, the compounds of the invention may be administered by means of an ear tag or collar.
Salt forms of the compounds of the invention include both pharmaceutically acceptable salts and veterinary acceptable salts, which can be different to agrochemically acceptable salts.
Pharmaceutically and veterinary acceptable salts and common methodology for preparing them are well known in the art. See, for example, Gould, P.L., "Salt selection for basic drugs", International Journal of Pharmaceutics, 33: 201 -217 (1986); Bastin, R.J., et al. "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities", Organic Process Research and Development, 4: 427-435 (2000); and Berge, S.M., et a!., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 66: 1-19, (1977). One skilled in the art of synthesis will appreciate that the compounds of the invention are readily converted to and may be isolated as a salt, such as a hydrochloride salt, using techniques and conditions well known to one of ordinary skill in the art. In addition, one skilled in the art of synthesis will appreciate that the compounds of the invention are readily converted to and may be isolated as the corresponding free base from the corresponding salt. The present invention also provides a method for controlling pests (such as mosquitoes and other disease vectors; see also http://www.who.int/malaria/vector_control/irs/en/). In one embodiment, the method for controlling pests comprises applying the compositions of the invention to the target pests, to their locus or to a surface or substrate by brushing, rolling, spraying, spreading or dipping. By way of example, an IRS (indoor residual spraying) application of a surface such as a wall, ceiling or floor surface is contemplated by the method of the invention. In another embodiment, it is contemplated to apply such compositions to a substrate such as non-woven or a fabric material in the form of (or which can be used in the manufacture of) netting, clothing, bedding, curtains and tents.
In one embodiment, the method for controlling such pests comprises applying a pesticidally effective amount of the compositions of the invention to the target pests, to their locus, or to a surface or substrate so as to provide effective residual pesticidal activity on the surface or substrate. Such application may be made by brushing, rolling, spraying, spreading or dipping the pesticidal composition of the invention. By way of example, an IRS application of a surface such as a wall, ceiling or floor surface is contemplated by the method of the invention so as to provide effective residual pesticidal activity on the surface. In another embodiment, it is contemplated to apply such compositions for residual control of pests on a substrate such as a fabric material in the form of (or which can be used in the manufacture of) netting, clothing, bedding, curtains and tents.
Substrates including non-woven, fabrics or netting to be treated may be made of natural fibres such as cotton, raffia, jute, flax, sisal, hessian, or wool, or synthetic fibres such as polyamide, polyester, polypropylene, polyacrylonitrile or the like. The polyesters are particularly suitable. The methods of textile treatment are known, e.g. WO 2008/151984, WO 2003/034823, US 5631072, WO 2005/64072, W02006/128870, EP 1724392, WO 20051 13886 or WO 2007/090739.
Further areas of use of the compositions according to the invention are the field of tree injection/trunk treatment for all ornamental trees as well all sort of fruit and nut trees.
In the field of tree injection/trunk treatment, the compounds according to the present invention are especially suitable against wood-boring insects from the order Lepidoptera as mentioned above and from the order Coleoptera, especially against woodborers listed in the following tables A and B:
Table A. Examples of exotic woodborers of economic importance.
Table B. Examples of native woodborers of economic importance.
The present invention may be also used to control any insect pests that may be present in turfgrass, including for example beetles, caterpillars, fire ants, ground pearls, millipedes, sow bugs, mites, mole crickets, scales, mealybugs, ticks, spittlebugs, southern chinch bugs and white grubs. The present invention may be used to control insect pests at various stages of their life cycle, including eggs, larvae, nymphs and adults.
In particular, the present invention may be used to control insect pests that feed on the roots of turfgrass including white grubs (such as Cyclocephala spp. (e.g. masked chafer, C. lurida),
Rhizotrogus spp. (e.g. European chafer, R. majalis), Cotinus spp. (e.g. Green June beetle, C. nitida), Popillia spp. (e.g. Japanese beetle, P. japonica), Phyllophaga spp. (e.g. May/June beetle), Ataenius spp. (e.g. Black turfgrass ataenius, A. spretulus), Maladera spp. (e.g. Asiatic garden beetle, M.
castanea) and Tomarus spp.), ground pearls ( Margarodes spp.), mole crickets (tawny, southern, and short-winged; Scapteriscus spp., Gryllotalpa africana ) and leatherjackets (European crane fly, Tipula spp.).
The present invention may also be used to control insect pests of turfgrass that are thatch dwelling, including armyworms (such as fall armyworm Spodoptera frugiperda, and common armyworm Pseudaletia unipuncta), cutworms, billbugs ( Sphenophorus spp. , such as S. venatus verstitus and S. parvulus), and sod webworms (such as Crambus spp. and the tropical sod webworm, Herpetogramma phaeopteralis).
The present invention may also be used to control insect pests of turfgrass that live above the ground and feed on the turfgrass leaves, including chinch bugs (such as southern chinch bugs, Blissus insularis), Bermudagrass mite (Eriophyes cynodoniensis), rhodesgrass mealybug (Antonina graminis), two-lined spittlebug ( Propsapia bicincta), leafhoppers, cutworms ( Noctuidae family), and greenbugs.
The present invention may also be used to control other pests of turfgrass such as red imported fire ants ( Solenopsis invicta) that create ant mounds in turf.
In the hygiene sector, the compositions according to the invention are active against ectoparasites such as hard ticks, soft ticks, mange mites, harvest mites, flies (biting and licking), parasitic fly larvae, lice, hair lice, bird lice and fleas.
Examples of such parasites are:
Of the order Anoplurida: Haematopinus spp., Linognathus spp., Pediculus spp. and Phtirus spp., Solenopotes spp..
Of the order Mallophagida: Trimenopon spp., Menopon spp., Trinoton spp., Bovicola spp.,
Werneckiella spp., Lepikentron spp., Damalina spp., Trichodectes spp. and Felicola spp.. Of the order Diptera and the suborders Nematocerina and Brachycerina, for example Aedes spp., Anopheles spp., Culex spp., Simulium spp., Eusimulium spp., Phlebotomus spp., Lutzomyia spp., Culicoides spp., Chrysops spp., Hybomitra spp., Atylotus spp., Tabanus spp., Haematopota spp., Philipomyia spp., Braula spp., Musca spp., Hydrotaea spp., Stomoxys spp., Haematobia spp., Morellia spp., Fannia spp., Glossina spp., Calliphora spp., Lucilia spp., Chrysomyia spp., Wohlfahrtia spp., Sarcophaga spp., Oestrus spp., Hypoderma spp., Gasterophilus spp., Hippobosca spp., Lipoptena spp. and Melophagus spp..
Of the order Siphonapterida, for example Pulex spp., Ctenocephalides spp., Xenopsylla spp., Ceratophyllus spp..
Of the order Heteropterida, for example Cimex spp., Triatoma spp., Rhodnius spp., Panstrongylus spp..
Of the order Blattarida, for example Blatta orientalis, Periplaneta americana, Blattelagermanica and Supella spp..
Of the subclass Acaria (Acarida) and the orders Meta- and Meso-stigmata, for example Argas spp., Ornithodorus spp., Otobius spp., Ixodes spp., Amblyomma spp., Boophilus spp., Dermacentor spp., Haemophysalis spp., Hyalomma spp., Rhipicephalus spp., Dermanyssus spp., Raillietia spp., Pneumonyssus spp., Sternostoma spp. and Varroa spp..
Of the orders Actinedida (Prostigmata) and Acaridida (Astigmata), for example Acarapis spp., Cheyletiella spp., Ornithocheyletia spp., Myobia spp., Psorergatesspp., Demodex spp., Trombicula spp., Listrophorus spp., Acarus spp., Tyrophagus spp., Caloglyphus spp., Hypodectes spp.,
Pterolichus spp., Psoroptes spp., Chorioptes spp., Otodectes spp., Sarcoptes spp., Notoedres spp., Knemidocoptes spp., Cytodites spp. and Laminosioptes spp..
The compositions according to the invention are also suitable for protecting against insect infestation in the case of materials such as wood, textiles, plastics, adhesives, glues, paints, paper and card, leather, floor coverings and buildings.
The compositions according to the invention can be used, for example, against the following pests: beetles such as Hylotrupes bajulus, Chlorophorus pilosis, Anobium punctatum, Xestobium
rufovillosum, Ptilinuspecticornis, Dendrobium pertinex, Ernobius mollis, Priobium carpini, Lyctus brunneus, Lyctus africanus, Lyctus planicollis, Lyctus linearis, Lyctus pubescens, Trogoxylon aequale, Minthesrugicollis, Xyleborus spec.,Tryptodendron spec., Apate monachus, Bostrychus capucins, Heterobostrychus brunneus, Sinoxylon spec and Dinoderus minutus, and also hymenopterans such as Sirex juvencus, Urocerus gigas, Urocerus gigas taignus and Urocerus augur, and termites such as Kalotermes flavicollis, Cryptotermes brevis, Heterotermes indicola, Reticulitermes flavipes,
Reticulitermes santonensis, Reticulitermes lucifugus, Mastotermes darwiniensis, Zootermopsis nevadensis and Coptotermes formosanus, and bristletails such as Lepisma saccharina.The compounds of formulae I, and I’a, or salts thereof, are especially suitable for controlling one or more pests selected from the family: Noctuidae, Plutellidae, Chrysomelidae, Thripidae, Pentatomidae, Tortricidae, Delphacidae, Aphididae, Noctuidae, Crambidae, Meloidogynidae, and Heteroderidae. In a preferred embodiment of each aspect, a compound TX (where the abbreviation“TX” means“one compound selected from the compounds defined in the Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27, and Table P”) controls one or more of pests selected from the family: Noctuidae, Plutellidae, Chrysomelidae, Thripidae, Pentatomidae, Tortricidae, Delphacidae, Aphididae, Noctuidae, Crambidae, Meloidogynidae, and Heteroderidae.
The compounds of formulae I, and I’a, or salts thereof, are especially suitable for controlling one or more of pests selected from the genus: Spodoptera spp, Plutella spp, Frankliniella spp, Thrips spp, Euschistus spp, Cydia spp, Nilaparvata spp, Myzus spp, Aphis spp, Diabrotica spp, Rhopalosiphum spp, Pseudoplusia spp and Chilo spp. . In a preferred embodiment of each aspect, a compound TX (where the abbreviation“TX” means“one compound selected from the compounds defined in the Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27, and Table P”) controls one or more of pests selected from the genus: Spodoptera spp, Plutella spp, Frankliniella spp, Thrips spp, Euschistus spp, Cydia spp, Nilaparvata spp, Myzus spp, Aphis spp, Diabrotica spp, Rhopalosiphum spp, Pseudoplusia spp and Chilo spp.
The compounds of formulae I, and I’a, or salts thereof, are especially suitable for controlling one or more of Spodoptera littoralis, Plutella xylostella, Frankliniella occidentalis, Thrips tabaci, Euschistus herns, Cydia pomonella, Nilaparvata lugens, Myzus persicae, Chrysodeixis includens, Aphis craccivora, Diabrotica balteata, Rhopalosiphum padi, and Chilo suppressalis.
In a preferred embodiment of each aspect, a compound TX (where the abbreviation“TX” means“one compound selected from the compounds defined in the Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27, and Table P”) controls one or more of Spodoptera littoralis, Plutella xylostella, Frankliniella occidentalis, Thrips tabaci, Euschistus herns, Cydia pomonella, Nilaparvata lugens, Myzus persicae, Chrysodeixis includens, Aphis craccivora, Diabrotica balteata,
Rhopalosiphum Padia, and Chilo Suppressalis, such as Spodoptera littoralis + TX, Plutella xylostella + TX; Frankliniella occidentalis + TX, Thrips tabaci + TX, Euschistus herns + TX, Cydia pomonella + TX, Nilaparvata lugens + TX, Myzus persicae + TX, Chrysodeixis includens + TX, Aphis craccivora + TX, Diabrotica balteata + TX, Rhopalosiphum Padi + TX, and Chilo suppressalis + TX. In an embodiment, of each aspect, one compound selected from the compounds defined in the Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27, and Table P, is suitable for controlling Spodoptera littoralis, Plutella xylostella, Frankliniella occidentalis, Thrips tabaci, Euschistus herns, Cydia pomonella, Nilaparvata lugens, Myzus persicae, Chrysodeixis includens, Aphis craccivora, Diabrotica balteata, Rhopalosiphum Padia, and Chilo Suppressalis in cotton, vegetable, maize, cereal, rice and soya crops.
In an embodiment, one compound from selected from the compounds defined in the Tables A-1 to A- 27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27, and Table P, is suitable for controlling Mamestra (preferably in vegetables), Cydia pomonella (preferably in apples), Empoasca (preferably in vegetables, vineyards), Leptinotarsa (preferably in potatos) and Chilo supressalis (preferably in rice).
Compounds according to the invention may possess any number of benefits including, inter alia, advantageous levels of biological activity for protecting plants against insects or superior properties for use as agrochemical active ingredients (for example, greater biological activity, an advantageous spectrum of activity, an increased safety profile (against non-target organisms above and below ground (such as fish, birds and bees), improved physico-chemical properties, or increased biodegradability). In particular, it has been surprisingly found that certain compounds of formula I may show an advantageous safety profile with respect to non-target arthropods, in particular pollinators such as honey bees, solitary bees, and bumble bees. Most particularly, Apis mellifera.
The compounds according to the invention can be used as pesticidal agents in unmodified form, but they are generally formulated into compositions in various ways using formulation adjuvants, such as carriers, solvents and surface-active substances. The formulations can be in various physical forms, e.g. in the form of dusting powders, gels, wettable powders, water-dispersible granules, water- dispersible tablets, effervescent pellets, emulsifiable concentrates, microemulsifiable concentrates, oil- in-water emulsions, oil-flowables, aqueous dispersions, oily dispersions, suspo-emulsions, capsule suspensions, emulsifiable granules, soluble liquids, water-soluble concentrates (with water or a water- miscible organic solvent as carrier), impregnated polymer films or in other forms known e.g. from the Manual on Development and Use of FAO and WHO Specifications for Pesticides, United Nations, First Edition, Second Revision (2010). Such formulations can either be used directly or diluted prior to use. The dilutions can be made, for example, with water, liquid fertilisers, micronutrients, biological organisms, oil or solvents.
The formulations can be prepared e.g. by mixing the active ingredient with the formulation adjuvants in order to obtain compositions in the form of finely divided solids, granules, solutions, dispersions or emulsions. The active ingredients can also be formulated with other adjuvants, such as finely divided solids, mineral oils, oils of vegetable or animal origin, modified oils of vegetable or animal origin, organic solvents, water, surface-active substances or combinations thereof. The active ingredients can also be contained in very fine microcapsules. Microcapsules contain the active ingredients in a porous carrier. This enables the active ingredients to be released into the environment in controlled amounts (e.g. slow-release). Microcapsules usually have a diameter of from 0.1 to 500 microns. They contain active ingredients in an amount of about from 25 to 95 % by weight of the capsule weight. The active ingredients can be in the form of a monolithic solid, in the form of fine particles in solid or liquid dispersion or in the form of a suitable solution. The encapsulating membranes can comprise, for example, natural or synthetic rubbers, cellulose, styrene/butadiene copolymers, polyacrylonitrile, polyacrylate, polyesters, polyamides, polyureas, polyurethane or chemically modified polymers and starch xanthates or other polymers that are known to the person skilled in the art. Alternatively, very fine microcapsules can be formed in which the active ingredient is contained in the form of finely divided particles in a solid matrix of base substance, but the microcapsules are not themselves encapsulated.
The formulation adjuvants that are suitable for the preparation of the compositions according to the invention are known per se. As liquid carriers there may be used: water, toluene, xylene, petroleum ether, vegetable oils, acetone, methyl ethyl ketone, cyclohexanone, acid anhydrides, acetonitrile, acetophenone, amyl acetate, 2-butanone, butylene carbonate, chlorobenzene, cyclohexane, cyclohexanol, alkyl esters of acetic acid, diacetone alcohol, 1 ,2-dichloropropane, diethanolamine, p- diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, A/,A/-dimethylformamide, dimethyl sulfoxide, 1 ,4- dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkylpyrrolidone, ethyl acetate, 2-ethylhexanol, ethylene carbonate, 1 ,1 ,1 -trichloroethane, 2- heptanone, alpha-pinene, d-limonene, ethyl lactate, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol acetate, glycerol diacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropylbenzene, isopropyl myristate, lactic acid, laurylamine, mesityl oxide, methoxy- propanol, methyl isoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octylamine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol, propionic acid, propyl lactate, propylene carbonate, propylene glycol, propylene glycol methyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylenesulfonic acid, paraffin, mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol methyl ether, diethylene glycol methyl ether, methanol, ethanol, isopropanol, and alcohols of higher molecular weight, such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, ethylene glycol, propylene glycol, glycerol, /V-methyl-2- pyrrolidone and the like. Suitable solid carriers are, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, limestone, calcium carbonate, bentonite, calcium montmorillonite, cottonseed husks, wheat flour, soybean flour, pumice, wood flour, ground walnut shells, lignin and similar substances.
A large number of surface-active substances can advantageously be used in both solid and liquid formulations, especially in those formulations which can be diluted with a carrier prior to use. Surface- active substances may be anionic, cationic, non-ionic or polymeric and they can be used as emulsifiers, wetting agents or suspending agents or for other purposes. Typical surface-active substances include, for example, salts of alkyl sulfates, such as diethanolammonium lauryl sulfate; salts of alkylarylsulfonates, such as calcium dodecylbenzenesulfonate; alkylphenol/alkylene oxide addition products, such as nonylphenol ethoxylate; alcohol/alkylene oxide addition products, such as tridecylalcohol ethoxylate; soaps, such as sodium stearate; salts of alkylnaphthalenesulfonates, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2- ethylhexyl)sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryltrimethylammonium chloride, polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono- and di- alkylphosphate esters; and also further substances described e.g. in McCutcheon's Detergents and Emulsifiers Annual, MC Publishing Corp., Ridgewood New Jersey (1981).
Further adjuvants that can be used in pesticidal formulations include crystallisation inhibitors, viscosity modifiers, suspending agents, dyes, anti-oxidants, foaming agents, light absorbers, mixing auxiliaries, antifoams, complexing agents, neutralising or pH-modifying substances and buffers, corrosion inhibitors, fragrances, wetting agents, take-up enhancers, micronutrients, plasticisers, glidants, lubricants, dispersants, thickeners, antifreezes, microbicides, and liquid and solid fertilisers.
The compositions according to the invention can include an additive comprising an oil of vegetable or animal origin, a mineral oil, alkyl esters of such oils or mixtures of such oils and oil derivatives. The amount of oil additive in the composition according to the invention is generally from 0.01 to 10 %, based on the mixture to be applied. For example, the oil additive can be added to a spray tank in the desired concentration after a spray mixture has been prepared. Preferred oil additives comprise mineral oils or an oil of vegetable origin, for example rapeseed oil, olive oil or sunflower oil, emulsified vegetable oil, alkyl esters of oils of vegetable origin, for example the methyl derivatives, or an oil of animal origin, such as fish oil or beef tallow. Preferred oil additives comprise alkyl esters of C8-C22 fatty acids, especially the methyl derivatives of C12-C18 fatty acids, for example the methyl esters of lauric acid, palmitic acid and oleic acid (methyl laurate, methyl palmitate and methyl oleate, respectively). Many oil derivatives are known from the Compendium of Herbicide Adjuvants, 10th Edition, Southern Illinois University, 2010. The inventive compositions generally comprise from 0.1 to 99 % by weight, especially from 0.1 to 95 % by weight, of compounds of the present invention and from 1 to 99.9 % by weight of a formulation adjuvant which preferably includes from 0 to 25 % by weight of a surface-active substance. Whereas commercial products may preferably be formulated as concentrates, the end user will normally employ dilute formulations.
The rates of application vary within wide limits and depend on the nature of the soil, the method of application, the crop plant, the pest to be controlled, the prevailing climatic conditions, and other factors governed by the method of application, the time of application and the target crop. As a general guideline compounds may be applied at a rate of from 1 to 2000 l/ha, especially from 10 to 1000 l/ha.
Preferred formulations can have the following compositions (weight %):
Emulsifiable concentrates:
active ingredient: 1 to 95 %, preferably 60 to 90 %
surface-active agent: 1 to 30 %, preferably 5 to 20 %
liquid carrier: 1 to 80 %, preferably 1 to 35 %
Dusts:
active ingredient: 0.1 to 10 %, preferably 0.1 to 5 %
solid carrier: 99.9 to 90 %, preferably 99.9 to 99 %
Suspension concentrates:
active ingredient: 5 to 75 %, preferably 10 to 50 %
water: 94 to 24 %, preferably 88 to 30 %
surface-active agent: 1 to 40 %, preferably 2 to 30 %
Wettable powders:
active ingredient: 0.5 to 90 %, preferably 1 to 80 %
surface-active agent: 0.5 to 20 %, preferably 1 to 15 %
solid carrier: 5 to 95 %, preferably 15 to 90 %
Granules:
active ingredient: 0.1 to 30 %, preferably 0.1 to 15 %
solid carrier: 99.5 to 70 %, preferably 97 to 85 %
The following Examples further illustrate, but do not limit, the invention.
The combination is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions of the desired concentration.
The combination is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording powders that can be used directly for seed treatment.
Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water.
Ready-for-use dusts are obtained by mixing the combination with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry dressings for seed.
The combination is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.
The finely ground combination is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granules are obtained in this manner.
Suspension concentrate
The finely ground combination is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion.
Flowable concentrate for seed treatment
active ingredients 40 %
The finely ground combination is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion.
Slow Release Capsule Suspension
28 parts of the combination are mixed with 2 parts of an aromatic solvent and 7 parts of toluene diisocyanate/polymethylene-polyphenylisocyanate-mixture (8:1). This mixture is emulsified in a mixture of 1 .2 parts of polyvinylalcohol, 0.05 parts of a defoamer and 51 .6 parts of water until the desired particle size is achieved. To this emulsion a mixture of 2.8 parts 1 ,6-diaminohexane in 5.3 parts of water is added. The mixture is agitated until the polymerization reaction is completed. The obtained capsule suspension is stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersing agent. The capsule suspension formulation contains 28% of the active ingredients. The medium capsule diameter is 8-15 microns. The resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable for that purpose.
Formulation types include an emulsion concentrate (EC), a suspension concentrate (SC), a suspo- emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion, oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low volume suspension (SU), an ultra-low volume liquid (UL), a technical concentrate (TK), a dispersible concentrate (DC), a wettable powder (WP), a soluble granule (SG) or any technically feasible formulation in combination with agriculturally acceptable adjuvants.
Preparatory Examples:
LCMS Methods:
Method 1 :
Spectra were recorded on a Mass Spectrometer from Waters (SQD, SQDII Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions, Capillary: 3.00 kV, Cone range: 30 V, Extractor: 2.00 V, Source Temperature: 150°C, Desolvation Temperature: 350°C, Cone Gas Flow: 50 l/h, Desolvation Gas Flow: 650 l/h, Mass range: 100 to 900 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment , diode-array detector and ELSD detector. Column: Waters UPLC HSS T3, 1 .8 Dm, 30 x 2.1 mm, Temp: 60 °C,
DAD Wavelength range (nm): 210 to 500, Solvent Gradient: A = water + 5% MeOH + 0.05 % HCOOH, B= Acetonitrile + 0.05 % HCOOH, gradient: 10-100% B in 1 .2 min; Flow (ml/min) 0.85
Method 2:
Spectra were recorded on a Mass Spectrometer from Waters (SQD, SQDII or ZQ Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions), Capillary: 3.00 kV, Cone range: 30 V, Extractor: 2.00 V, Source Temperature: 150°C,
Desolvation Temperature: 350°C, Cone Gas Flow: 50 l/h, Desolvation Gas Flow: 650 l/h, Mass range: 100 to 900 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment , diode- array detector and ELSD detector. Column: Waters UPLC HSS T3, 1 .8 mhi, 30 x 2.1 mm, Temp: 60 °C, DAD Wavelength range (nm): 210 to 500, Solvent Gradient: A = water + 5% MeOH + 0.05 % HCOOH, B= Acetonitrile + 0.05 % HCOOH, gradient: 0-10% B in 2.5 min; Flow (ml/min) 0.85
Chiral SFC method 1 : Spectra were recorded on a SFC from Waters (Waters Acquity UPC2/QDa) equipped with a PDA Detector Waters Acquity UPC2. Column: Daicel SFC CHIRALPAK® IC, (3 pm, 0.3cm x 10cm, 40 °C; Mobile phase: A: C02 B: MeOH isocratic: 10% B in 2.0 min; ABPR: 1800 psi; Flow rate: 2.0 ml/min; Detection: 220 nm; Sample concentration: 1 mg/mL in ACN; Injection: 1 pL
Chiral SFC method 2: Spectra were recorded on a SFC from Waters (Waters Acquity UPC2/QDa) equipped with a PDA Detector Waters Acquity UPC2. Column: Daicel SFC CHIRALPAK® IG, (3 pm, 0.3cm x 10cm, 40 °C; Mobile phase: A: CO2 B: MeOH isocratic: 15% B in 4.8 min; ABPR: 1800 psi; Flow rate: 2.0 ml/min; Detection: 270 nm; Sample concentration: 1 mg/mL in ACN/MeOH (1 :1); Injection: 1 pL
Preparation of 2-chloro-5-(2.2-difluoroethoxy)pyrimidine
2-Chloropyrimidin-5-ol ([CAS: 4983-28-2] 5.00 g, 38.3 mmol) was dissolved in DMF (30.0 mL). Potassium carbonate (10.6 g, 76.6 mmol) and 1 ,1 -difluoro-2-iodoethane (8.8 g, 46.0 mmol) were added. The resulting reaction mixture was stirred at 80°C for 12 h before being cooled to room temperature. It was then poured into a mixture ice cold water and extracted twice with ethyl acetate (200 mL each). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (eluting with ethyl acetate in hexanes) to afford 2-chloro-5-(2,2-difluoroethoxy)pyrimidine.
LC-MS (method 1): m/z 195.1 [M+H]+. Preparation of tributyl-[5-(2.2-difluoroethoxy)pyrimidin-2-yl1stannane
2-Chloro-5-(2,2-difluoroethoxy)pyrimidine (2.00 g, 9.251 mmol) was dissolved in toluene (40.0 ml_) and hexa-n-butylditin (8.05g, 13.877 mmol) was added. The reaction mixture was purged with argon for 5 minutes, tetrakis(triphenylphosphine)palladium(0) (0.5345 g, 0.4626 mmol) was added, the reaction mixture was purged with argon for another 5 minutes and subsequently stirred at 100°C for 16 h. It was filtered through a pad of Celite and the filtrate was concentrated in vacuo. The crude material was purified by neutral alumina chromatography (eluting with ethyl acetate in hexanes) to afford tributyl-[5- (2,2-difluoroethoxy)pyrimidin-2-yl]stannane.
Ή NMR (400 MHz, chloroform-d) d ppm: 0.87 (t, 9 H) 1.15 (t, 6 H) 1 .30 - 1.35 (q, 6 H) 1.54 - 1.62 (m, 6 H) 4.21 - 4.30 (dt, 2 H) 5.95 - 6.26 (br tt, 1 H) 8.47 (s, 2 H)
Preparation of 1-[3-[5-(2.2-difluoroethoxy)pyrimidin-2-yllpyrazin-2-yl1ethanone (15)
Tributyl-[5-(2,2-difluoroethoxy)pyrimidin-2-yl]stannane (1 .00 g, 2.00 mmol) was dissolved in toluene (15 mL), then 1 -(3-chloropyrazin-2-yl)ethanone ([CAS: 121246-90-0] 0.439 g, 2.52 mmol) was added. The mixture was purged with argon fir 5 minutes, then copper(l) iodide (0.0763 g, 0.401 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.232 g, 0.200 mmol) were added and the resulting reaction mixture was stirred at 100°C for 4h. After cooling to room temperature, it was filtered through a pad of Celite and the filtrate was concentrated in vacuo. The crude product was purified by flash chromate- graphy (silica gel, 0 - 100% ethyl acetate in hexanes) to afford 1 -[3-[5-(2,2-difluoroethoxy)pyrimidin-2- yl]pyrazin-2-yl]ethanone.
LC-MS (method 1): m/z 281 .1 [M+H]+; Ή NMR (400 MHz, DMSO-d6) d ppm: 8.90 (s, 1 H), 8.70-8.90 (m, 3H), 6.48 (t, 1 H), 4.63 (td, 2H), 2.62 (s, 3H).
Preparation of 1 -[3-[5-(2.2-difluoroethoxy)pyrimidin-2-yllpyrazin-2-yl1ethanamine (11 1)
1 -[3-[5-(2,2-Difluoroethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanone (0.80 g, 0.285 mmol) was dissolved in a saturated solution of ammonium acetate in ethanol (10 mL). Ammonia solution 30% in water (5.0 mL) and sodium cyanoborohydride (0.0538 g, 0.856 mmol) were added and the reaction mixture was stirred at reflux for 18h. The reaction mixture was cooled to room temperature and washed with dichloro- methane (50mL). The aqueous layer was concentrated in vacuo to afford a crude product which was purified by reverse phase chromatography (C18 column, 0 to 50% acetonitrile in water) to afford 1 -[3- [5-(2,2-difluoroethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanamine.
LC-MS (method 1): m/z 282.1 [M+H]+; Ή NMR (400 MHz, DMSO-d6) d ppm: 8.80-9.00 (m, 4H), 6.50 (tt, 1 H), 4.90 (m, 1 H), 4.78 (td, 2H), 1 .45 (d, 3H)
Preparation of 2-chloro-5-(difluoromethoxy)pyrimidine
2-Chloropyrimidin-5-ol ([CAS: 4983-28-2] 5.00 g, 38.3 mmol) was dissolved in DMF (20.0 mL). Potassium carbonate (10.6 g, 76.6 mmol) and sodium 2-chloro-2,2-difluoroacetate (8.76 g, 57.5 mmol) were added. The resulting reaction mixture was stirred at 80°C for 4 h before being cooled to room temperature and diluted with ethyl acetate. This organic layer was washed twice with cold water (100 mL each), dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (eluting with ethyl acetate in hexanes) to afford 2-chloro-5- (difluoromethoxy)pyrimidine.
Ή NMR (400 MHz, chloroform-d) d ppm: 6.45 - 6.82 (br t, 1 H) 8.55 (s, 2 H)
Preparation of tributyl-[5-(difluoromethoxy)pyrimidin-2-yl1stannane
To a solution of 2-chloro-5-(difluoromethoxy)pyrimidine (2.70 g, 13.5 mmol) in toluene (50 mL) was added bis(tributyltin) (10.2 mL, 20.2 mmol) . The reaction mixture was purged with argon for 5 minutes then tetrakis(triphenylphosphine)palladium(0) (778 mg, 0.673 mmol) was added and the reaction mixture was purged again with argon for another 2 minutes. The resulting reaction mixture was stirred at 100 °C for 16h. The reaction mixture was cooled to 0°C, diluted with water and extracted twice with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in n-hexane) afforded tributyl-[5-(difluoromethoxy)pyrimidin-2-yl]stannane. 1H-NMR (400 MHz, CDCh): d ppm: 8.60 (s, 1 H), 7.26 (s, 1 H), 6.57 (t, 1 H), 1 .50-1 .70 (m, 6H), 1 .25-1 .40 (m, 6H), 1 .10-1 .20 (m, 6H), 0.88 (m, 9H).
Preparation of 1 -[3-[5-(difluoromethoxy)pyrimidin-2-yllpyrazin-2-yl1ethanone (16)
To a mixture oftributyl-[5-(difluoromethoxy)pyrimidin-2-yl]stannane (3.20 g, 6.62 mmol) in toluene (50.0 ml_) was added 1 -(4-chloropyrimidin-5-yl)ethanone (1267 mg, 7.28 mmol) . The reaction mixture was purged with argon for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (382 mg, 0.331 mmol) and copper iodide (252 mg, 1 .32 mmol) were added to the reaction mixture and purged again with argon for another 2 minutes. The resulting reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was cooled to 0°C, diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 ml_). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (gradient of ethyl acetate in hexanes) to afford 1 - [3-[5-(difluoromethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethenone as a light brown solid.
Ή NMR (400 MHz, DMSO-d6) d ppm: 8.80-9.00 (m, 4H), 7.50 (t, 1 H), 2.65 (s, 3H)
Preparation of 1 -[3-[5-(difluoromethoxy)pyrimidin-2-yllpyrazin-2-yl1ethanamine (112)
To a solution of 1 -[3-[5-(difluoromethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanone (1 .70 g, 6.39 mmol) in a solution of saturated ammonium acetate in ethanol (130 ml_) were added sodium cyanoborohydride (1.19 g, 19.2 mmol) and 30% aqueous ammonia (50 ml_). The mixture was stirred at reflux for 16 h, cooled to room temperature, and concentrated in vacuo. The crude material was purified by reverse phase chromatography (C18 column, gradient of acetonitrile in water) to give 1-[3-[5- (difluoromethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanamine as a light brown gum.
Ή NMR (400 MHz, DMSO-d6) d ppm: 8.80-9.10 (m, 4H), 7.51 (t, 1 H), 4.88 (m, 1 H), 1.50 (d, 3H)
Preparation of 2-bromo-5-(2.2.2-trifluoroethoxy)pyridine
To a solution of 6-bromopyridin-3-ol (20.0 g, 115 mmol) and potassium carbonate (31.8 g, 230 mmol) in acetonitrile (200 ml_), stirred at room temperature for 5 min, was added 2,2,2-Trifluoroethyl trifluoromethanesulfonate (29.3 g, 126 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was poured in ice cold water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in n-hexane) afforded 2-bromo-5-(2,2,2-trifluoroethoxy)pyridine.
Ή-NMR (400 MHz, CDCb): <5 ppm: 8.15 (d, 1 H), 7.45 (d, 1 H), 7.2 (dd, 1 H), 4.4 (q, 2H).
Preparation of tributyl-[5-(2.2.2-trifluoroethoxy)-2-pyridyl1stannane
To a solution of 2-bromo-5-(2,2,2-trifluoroethoxy)pyridine (9.00 g, 31 .6 mmol) in toluene (300 ml_) was added bis(tributyltin) (20.7 ml_, 41 .1 mmol) . The reaction mixture was purged with argon for 20 minutes then tetrakis(triphenylphosphine)palladium(0) (2.74 g, 2.37 mmol) was added and the reaction mixture was purged again with argon for another 2 minutes. The resulting reaction mixture was stirred at 100 °C for 48h. The reaction mixture was cooled to 0°C, diluted with water and extracted with ethyl acetate. Combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in n-hexane) afforded tributyl-[5-(2,2,2-trifluoroethoxy)-2-pyridyl]stannane.
Ή-NMR (400 MHz, CDC ): d ppm; 8.55 (d, 1 h), 7.4 (dd, 1 H), 7.15 (m, 1 H), 4.4 (q, 2H), 1 .55 (m, 6H), 1 .35 (m, 6H), 1 .15 (m, 6H), 0.95 (m, 9H).
Preparation of 1 -[3-[5-(2.2.2-trifluoroethoxy)-2-pyridyllpyrazin-2-yl1ethanone (18)
To a solution of tributyl-[5-(2,2,2-trifluoroethoxy)-2-pyridyl]stannane (550 mg, 1 .06 mmol) in toluene (20ml_) were added 1 -(3-chloropyrazin-2-yl)ethanone ( 203 mg, 1 .17 mmol) and copper(l) iodide (40.4 mg, 0.212 mmol). The reaction mixture was purged with argon for 10 min and tetrakis(triphenylphosphine)palladium(0) (61 .4 mg, 0.0531 mmol) was added . The reaction was stirred at 100°C for 2h. The reaction mixture was cooled to 0°C, diluted with water and extracted with ethyl acetate. Organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in n-hexane) afforded 1 -[3-[5-(2,2,2-trifluoroethoxy)-2-pyridyl]pyrazin-2-yl]ethanone.
1H-NMR (400 MHz, DMSO-d6): d ppm: 8.85 (d, 1 H), 8.7 (m, 1 H), 8.45 (s, 1 H), 8.25 (d, 1 H), 7.75 (d, 1 H), 5 (q, 2H), 2.6 (s, 3H).
Preparation of 1 -[3-[5-(2.2.2-trifluoroethoxy)-2-pyridyllpyrazin-2-yl1ethanamine (113) To a solution of 1-[3-[5-(2,2,2-trifluoroethoxy)-2-pyridyl]pyrazin-2-yl]ethanone (1.80 g, 5.45 mmol) in a saturated solution of ammonium acetate in ethanol (120 ml_) were added at room temperature sodium cyanoborohydride (1.01 g, 16.4 mmol) and ammonia (30% in water, 50 ml_). The reaction mixture was stirred at reflux for 18 hours. After cooling down to room temperature, it was concentrated under reduced pressure. Purification of the crude material by reverse-phase chromatography (C18 column, eluting acetonitrile in water) afforded 1-[3-[5-(2,2,2-trifluoroethoxy)-2-pyridyl]pyrazin-2-yl]ethanamine.
Ή-NMR (400 MHz, DMSO-d6): d ppm: 8.8 (s, 2H), 8.65 (d, 1 H), 8.15 (d, 1 H), 7.8 (m, 1 H), 7.45 (br s, 2H), 7.25 (m, 1 H), 7.15 (m, 1 H), 5.2 (br s, 1 H), 5 (q, 2H), 1.5 (m, 3H).
Preparation of 2-chloro-5-(2.2.2-trifluoroethoxy)pyrimidine
To a solution of 2-chloropyrimidin-5-ol (1.0 g, 7.7 mmol) in N,N-dimethylformamide (7.7 ml_), was added cesium carbonate (3.2 g, 10 mmol). 2,2,2-trifluoroethyl trifluoromethanesulfonate (2.2 g, 9.2 mmol) was added dropwise to the mixture. The mixture was stirred at room temperature for 18 hours. The reaction mixture was poured into ice-water then extracted with ethyl acetate. The combined organic layers were washed four times with water, then with brine, They were dried over sodium sulfate and concentrated in vacuo. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in n-hexane) afforded 2-chloro-5-(2,2,2-trifluoroethoxy)pyrimidine as a light yellow oil.
Ή NMR (400 MHz, Chloroform) d ppm: 4.46 - 4.52 (m, 2 H) 8.40 (s, 2 H); 19F NMR (377 MHz, Chloroform) d ppm: -73.74 (s) Preparation of tributyl-[5-(2.2.2-trifluoroethoxy)pyrimidin-2-yl1stannane
To a solution of 2-chloro-5-(2,2,2-trifluoroethoxy)pyrimidine (1 .00 g, 4.70 mmol) in toluene (10 ml_) was added bis(tributyltin) (4.09 g, 7.06 mmol) . The reaction mixture was purged with argon for 5 minutes then tetrakis(triphenylphosphine)palladium(0) (0.544 g, 0.470 mmol) was added and the reaction mixture was purged again with argon for another 5 minutes. The resulting reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was filtered over Celite and the filtrate was concentrated under reduced pressure. Purification of the crude material by flash chromatography over neutral alumina (eluting with ethyl acetate in n-hexane) afforded tributyl-[5-(2,2,2-trifluoroethoxy)pyrimidin-2- yljstannane.
Ή-NMR (400 MHz, CDCb): d ppm: 8.50 (s, 1 H), 8.40 (s, 1 H), 4.43 (m, 2H), 4.12 (q, 2H), 1 .50-1 .70 (m, 6H), 1 .20-1 .45 (m, 6H), 1 .10-1 .20 (m, 6H), 0.83-0.98 (m, 9H). Preparation of 1 -[3-[5-(2.2.2-trifluoroethoxy)pyrimidin-2-yllpyrazin-2-yl1ethanone (17)
To a solution of tributyl-[5-(2,2,2-trifluoroethoxy)-2-pyridyl]stannane (1 .00 g, 2.14 mmol) in toluene (20 ml_) were added 1 -(3-chloropyrazin-2-yl)ethanone (0.402 g, 2.57 mmol). The reaction mixture was purged with argon for 5 min then copper(l) iodide (0.0815 g, 0.428 mmol) and [1 ,1 - bis(diphenylphosphino)ferrocene] dichloropalladium (II) (1 .57 g, 2.14 mmol) were added . The reaction was stirred at 100°C for 4 hours. The reaction mixture was cooled to 0°C, filtered through celite and the filtrate was concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in n-hexane) afforded 1 -[3-[5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanone.
m/z = 299.1 [M+H]+ Preparation of 1 -[3-[5-(2.2.2-trifluoroethoxy)pyrimidin-2-yllpyrazin-2-yl1ethanamine (113)
To a solution of 1 -[3-[5-(2,2,2-trifluoroethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanone (700 mg, 1 .88 mmol) in a saturated solution of ammonium acetate in ethanol (100 ml_) were added at room temperature sodium cyanoborohydride (0.354 g, 5.63 mmol) and ammonia (30% in water, 30 ml_). The reaction mixture was stirred at reflux for 18 hours. After cooling down to room temperature, the mixture was washed with dichloromethane. The aqeous layer was concentrated in vacuo. Purification of the crude material by reverse-phase chromatography (C18 column, eluting acetonitrile in water) afforded 1 -[3-[5- (2,2,2-trifluoroethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanamine.
Ή-NMR (400 MHz, DMSO-d6): d ppm: 8.95 (s, 2H), 8.60-9.00 (m, 2H), 7.8-8.30 (br s, 2H), 5.08-5.20 (m, 2H), 4.95-5.05 (m, 1 H), 1 .5 (m, 3H).
Preparation of 6-tributylstannylpyridine-3-carbonitrile To a solution of 6-chloropyridine-3-carbonitrile (250 mg, 1.80 mmol) in toluene (10 ml_) was added hexa- n-butylditin (1.00 ml_, 1.98 mmol). The reaction mixture was purged with argon for 2 minutes. Then tetrakis(triphenylphosphine)palladium(0) (146 mg, 0.126 mmol) was added and it was purged again with argon for additional 2 minutes. The resulting reaction mixture was heated up to 130 °C and stirred for 16 hours. After cooling down to room temperature, the reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure. Purification of the crude material by neutral alumina flash chromatography (eluting with ethyl acetate in hexane) afforded 6-tributylstannylpyridine-3- carbonitrile.
1H-NMR (400 MHz, CDC ): d ppm: 8.90-9.00 (m, 1 H), 7.65-7.75 (m, 1 H), 7.50-7.60 (m, 1 H), 7.25-7.40 (m, 2H), 1.45-1.65 (m, 4H), 1.25-1.40 (m, 7H), 1.10-1.20 (m, 5H), 0.80-0.95 (m, 9H).
Preparation of 6-(3-acetylpyrazin-2-yl)pyridine-3-carbonitrile (I4)
To a solution of 6-tributylstannylpyridine-3-carbonitrile (24.0 g, 48.8 mmol) in toluene (600 ml_) were added 1-(4-chloropyrimidin-5-yl)ethanone (9.18 g, 52.7 mmol) and copper(l) iodide (1.86 g, 9.77 mmol). The reaction mixture was purged with argon for 10 minutes. Then tetrakis(triphenylphosphine)palladium(0) (2.82 g, 2.44 mmol) was added. The reaction mixture was heated up to 95 °C and stirred for 5 hours. After cooling down to room temperature, it was filtered through Celite and the filtrate was concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in hexane) afforded 6-(3-acetylpyrazin- 2-yl) pyridine-3-carbonitrile.
Ή-NMR (400 MHz, d6-DMSO): d ppm: 9.1 (m, 2H), 8.92 (m, 1 H), 8.83 (m, 1 H) 8.53 (d, 1 H) 8.32 (d, 1 H) 2.65 (s, 3H).
Preparation of 6-[3-(1 -aminoethyl)pyrazin-2-yllpyridine-3-carbonitrile (110)
To a solution of 6-(3-acetylpyrazin-2-yl)pyridine-3-carbonitrile (0.200 g, 0.803 mmol) in a saturated solution of ammonium acetate in ethanol (30 ml_) were added at room temperature aqueous ammonia (20 ml_) and sodium cyanoborohydride (154 mg, 2.41 mmol). The reaction mixture was heated up to reflux and stirred for 12 hours. After cooling down to room temperature, it was concentrated under reduced pressure. Purification of the crude material by reverse-phase chromatography (eluting acetonitrile in water) afforded 6-[3-(1 -aminoethyl)pyrazin-2-yl]pyridine-3-carbonitrile.
1H-NMR (400 MHz, d6-DMSO): d ppm: 9.22 (s, 1 H), 8.85-8.95 (m, 2H), 8.50-8.60 (m, 1 H), 8.30-8.40 (m, 1 H) 7.80-8.10 (br. s, 2H), 5.25-5.35 (m, 1 H), 1 .52 (d, 3H).
Preparation of 1 -(3-chloropyrazin-2-yl)ethanamine
To a of 1 -(3-chloropyrazin-2-yl)ethanone (0.200 g, 1 .28 mmol) in methanol (4.5 ml_) were added at room temperature ammonium acetate (0.995 g, 12.8 mmol) and sodium cyanoborohydride (0.0591 g, 0.894 mmol). The resulting suspension was stirred at room temperature for 18 hours, then concentrated in vacuo. The crude material was purified by reverse phase chromatography (C18 column, gradient of acetonitrile in water) to afford 1 -(3-chloropyrazin-2-yl)ethanamine.
Ή NMR (400 MHz, CDCb) d ppm: 8.49 (d, 1 H), 8.26 (d, 1 H), 4.56 (q, 1 H), 1 .95 (br s, 2H), 1 .44 (d, 3H)
Preparation of (1 S)-1 -(3-chloropyrazin-2-yl)ethanamine (117) To a solution if 1 -(3-chloropyrazin-2-yl)ethanamine (202.2 mg, 1 .20 mmol) in tert-butyl methyl ether (1 1 ml_) was added Novozym® 435 (240 mg), followed by ethyl methoxyacetate (1 .44 ml_, 12.0 mmol) at room temperature. The mixture was stirred at 40 °C for 5.5 hours. The reaction mixture was diluted with dichloromethane and filtered. The filtrate was concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (eluting with a gradient of methanol in dichloromethane) to afford (1 S)-1 -(3-chloropyrazin-2-yl)ethanamine.
Ή NMR (400 MHz, CDCb) d ppm: 8.49 (d, 1 H), 8.27 (d, 1 H), 4.56 (q, 1 H), 1 .73 (br s, 2H), 1 .44 (d, 3H) ppm; [a]D 20: -32.3° (c: 1 .157, CHCb)
Preparation of (1 R)-1 -(3-chloropyrazin-2-yl)ethanol (19)
1 -(3-chloropyrazin-2-yl)ethanone (157 mg, 1 .00 mmol) was dissolved in dichloromethane (10.0 ml_) and the flask was evacuated and backfilled with argon three times. Then RuBF4[(R,R)-TsDPEN](p-cymene) (0.0362 g, 0.0526 mmol) was added. A cooled solution of triethylamine (0.348 ml_, 2.50 mmol.) and formic acid (0.160 ml_, 4.29 mmol) was added dropwise to the reaction mixture, which was stirred at room temperature for 4 hours.The reaction mixture was concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (eluting with a gradient of ethyl acetate in cyclohexane) to afford (1 R)-1 -(3-chloropyrazin-2-yl)ethanol.
1H-NMR (400 MHz, CDCb) d ppm: 8.49 (d, 1 H), 8.34 (d, 1 H), 5.18 (m, 1 H), 3.81 (d, 1 H), 1 .52 (d, 3H); Chiral SFC (method 2): 1 .98 min (minor enantiomer), 2.55 min (major enantiomer); ee = 85%
Preparation of (1 S)-1 -(3-chloropyrazin-2-yl)ethanamine (117)
(1 R)-1 -(3-chloropyrazin-2-yl)ethanol (87.8 mg, 0.554 mmol) was dissolved in tetrahydrofuran (1 .9 ml_). Then, 1 ,8-diazabicyclo[5.4.0]undec-7-ene (0.10 ml_, 0.66 mmol) was added dropwise to the reaction mixture followed by diphenylphosphine azide (0.130 ml_, 0.585 mmol). The reaction mixture was stirred at rt for 19 hours. Tetrahydrofuran (1 .4 mL) was added, followed by triphenylphosphine (179.4 mg, 0.677 mmol). The reaction mixture was stirred at room temperature for 2 hours. Water (0.15 mL) was added, and the reaction mixture was stirred at room temperature for 46 hours.
The reaction mixture was concentrated to a volume of 1 mL then diluted with dichloromethane. 1 M hydrochloric acid was added, then the aqueous layer was washed with dichloromethane. The aqueous layer was basified to pH = 14 with 4 M sodium hydroxide solution and extracted with dichloromethane. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (eluting with a gradient of methanol in dichloromethane) to afford (1 S)-1 -(3-chloropyrazin-2-yl)ethanamine.
Ή NMR (400 MHz, CDCb) d ppm: 8.49 (d, 1 H), 8.27 (d, 1 H), 4.56 (q, 1 H), 1 .84 (s, 2H), 1 .44 (d, 3H); [a]D 20: -26.0° (c: 0.960, CHCb)
Preparation of (2R)-N-[(1 S)-1 -(3-chloropyrazin-2-yl)ethyl1-2-hvdroxy-2-phenyl-acetamide
To a solution of 1 -(3-chloropyrazin-2-yl)ethanamine;hydrochloride (700 mg, 3.61 mmol) in dichloromethane (18 mL) were added (R)-(-)-mandelic acid (610 mg, 3.97 mmol), N- ethyldiisopropylamine (1 .26 mL, 7.21 mmol), 1 -hydroxybenzotriazole (50.8 mg, 0.361 mmol) and N,N’- dicylohexylcarbodiimide (844 mg, 3.97 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was diluted with saturated aqueous sodium carbonate solution and extracted with dichloromethane. The organic layers were dried over magnesium sulfate and concentrated in vacuo. Purification of the crude material by flash chromatography over silica gel (eluting with methanol in dichloromethane) afforded (2R)-N-[(1 R)-1 -(3-chloropyrazin-2-yl)ethyl]-2-hydroxy-2- phenyl-acetamide and (2R)-N-[(1 R)-1 -(3-chloropyrazin-2-yl)ethyl]-2-hydroxy-2-phenyl-acetamide. The relative stereochemistry of (2R)-N-[(1 R)-1 -(3-chloropyrazin-2-yl)ethyl]-2-hydroxy-2-phenyl-acetamide was determined by X-ray crystallography (crystallized from acetonitrile/water).
LCMS: Rt 0.74, m/z = 291 (M+H+)
Preparation of (1 S)-1 -(3-chloropyrazin-2-yl)ethanamine;hvdrochloride
A solution of (2R)-N-[(1 S)-1 -(3-chloropyrazin-2-yl)ethyl]-2-hydroxy-2-phenyl-acetamide (0.93 g, 3.2 mmol) in hydrochloric acid (32% in water, 13 mL) was heated up to reflux and stirred for 2 hours. After cooling down to room temperature, the reaction mixture was basified with 3 N sodium hydroxide and diluted and extracted with ethyl acetate. The aqueous layer was freeze-dried overnight and the resulting solid was suspended in acetone. The suspension was filtered and the filtrate was concentrated under reduced pressure. The resulting oil was dissolved in ethyl acetate and 1 N hydrochloric acid was added. A precipitate appeared, it was filtered and dried under reduced pressure to afford the desired product. LCMS: Rt 0.19, m/z = 158 (M+H+).
Preparation of (1 S)-1 -(3-chloropyrazin-2-yl)-N-(cvclopropylmethyl)ethanamine (118)
Sodium triacetoxyborohydride (59.4 mg, 0.267 mmol) was added to a stirred solution of (1 S)-1 -(3- chloropyrazin-2-yl)ethanamine (30.0 mg, 0.190 mmol), cyclopropanecarboxyladehyde (15.0 mg, 0.209 mmol) and acetic acid (0.0109 ml_, 0.190 mmol ) in 1 ,2-dichloroethane (0.95 ml_). The mixture was stirred at room temperature for 4 hours. Saturated aqueous sodium carbonate solution was added, the aqueous layer was extracted with dichloromethane. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) to afford (1 S)-1 -(3-chloropyrazin-2-yl)-N- (cyclopropylmethyl)ethanamine.1H NMR (400 MHz, Solvent) d ppm: -0.03 - 0.10 (m, 2 H) 0.38 - 0.52 (m, 2 H) 0.83 - 1 .00 (m, 1 H) 1 .40 (d, 3 H) 2.07 (dd, 1 H) 2.15 - 2.29 (m, 1 H) 2.53 (dd, 1 H) 4.39 (q, 1 H) 8.26 (d, 1 H) 8.51 (d, 1 H); [a]D 20 = -54° (c 0.327, CHCb)
Preparation of tert-butyl N-[(1 S)-3-(5-bromo-2-pyridyl)-2-hvdroxy-1 -methyl-3-oxo-propyllcarbamate
In a round-bottomed flask was prepared a solution of tert-butyl N-[(1 S)-1 -methyl-2-oxo-ethyl]carbamate (CAS 79069-50-4, 1 .07 g, 6.18 mmol) in dichloromethane (12 ml_). The flask was evacuated and refilled with argon three times. Then, 2-(3-benzyl-4-methyl-thiazol-3-ium-5-yl)ethanol;bromide (0.388 g, 1 .24 mmol), 5-bromopyridine-2-carbaldehyde (CAS 31 181 -90-5, 1 .81 g, 9.27 mmol) and dichloromethane (6 ml_) were added successively, followed by N,N-diisopropylethylamine (2.16 ml_, 12.4 mmol). The reaction mixture was stirred for 1 hour at room temperature. It was quenched with ammonium chloride sat. aq. and extracted three times with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded tert-butyl N- [(1 S)-3-(5-bromo-2-pyridyl)-2-hydroxy-1 -methyl-3-oxo-propyl]carbamate as an orange gum.
LCMS: Rt 0.98, m/z = 359-361 (M+H+) (Bromo pattern); Ή-NMR (400 MHz, CDCb) d ppm: 1 .37 - 1 .40 (m, 3 H) 1 .43 - 1 .44 (m, 9 H) 4.34 - 4.69 (m, 2 H) 5.22 - 5.36 (m, 1 H) 7.86 - 8.08 (m, 2 H) 8.73 (d, J = 2.20 Hz, 1 H).
Preparation of tert-butyl N-[(1 S)-3-(5-bromo-2-pyridvD-1-methyl-2,3-dioxo-propyl1carbamate
To a solution of tert-butyl N-[(1 S)-3-(5-bromo-2-pyridyl)-2-hydroxy-1 -methyl-3-oxo-propyl]carbamate (15.2 g, 42.3 mmol) in dichloromethane (100 ml_) and dimethyl sulfoxide (20 ml_) were added at 0 °C N,N-diisopropylethylamine (21 .8 ml_, 127 mmol, 3.00 equiv.) and in two portions sulfur trioxide pyridine complex (13.9 g, 84.6 mmol, 2.00 equiv.). The reaction mixture was stirred at 0 °C for 1 hour. It was quenched water and diluted with dichloromethane and 1 N hydrochloric acid. The aqueous layer was extracted twice with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded tert-butyl N-[(1 S)-3- (5-bromo-2-pyridyl)-1 -methyl-2, 3-dioxo-propyl]carbamate as an orange oil.
1 H-NMR (400 MHz, CDCI3) d ppm: 1 .36 - 1 .41 (m, 9 H) 1 .45 - 1 .48 (m, 3 H) 4.82 - 4.96 (m, 1 H) 5.10
(br s, 1 H) 7.91 - 8.00 (m, 1 H) 8.01 - 8.1 1 (m, 1 H) 8.79 (d, J = 1 .83 Hz, 1 H).
Preparation of tert-butyl N-[(1 S)-1 -[3-(5-bromo-2-pyridyl)pyrazin-2-yl1ethyl1carbamate
To a solution of tert-butyl N-[(1 S)-3-(5-bromo-2-pyridyl)-1 -methyl-2,3-dioxo-propyl]carbamate (375 mg, 1 .05 mmol) in ethanol (22 ml_) was added ethylenediamine (0.36 ml_, 5.24 mmol). The reaction mixture was stirred at room temperature for 60 h in the presence of air. It was concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded tert-butyl N-[(1 S)-1 -[3-(5-bromo-2-pyridyl)pyrazin-2-yl]ethyl]carbamate as a colorless gum.
LCMS: Rt 1 .09, m/z = 379-381 (M+H+) (Bromo pattern); Ή-NMR (400 MHz, CDCb) d ppm: 1 .33 - 1 .45 (m, 9 H) 1 .52 - 1 .56 (m, 3 H) 5.65 - 5.83 (m, 2 H) 7.96 - 8.02 (m, 2 H) 8.53 - 8.60 (m, 2 H) 8.79 (dd, J = 2.20, 1 .10 Hz, 1 H); Chiral SFC (method 1): 1 .80 min (major enantiomer), 1 .1 1 min (minor enantiomer); ee = 92%
Preparation of tert-butyl N-[(1 S)-1 -[6-amino-3-(5-bromo-2-pyridyl)pyrazin-2-yl1ethyl1carbamate (137)
To a solution of tert-butyl N-[(1 S)-3-(5-bromo-2-pyridyl)-1 -methyl-2,3-dioxo-propyl]carbamate (500 mg, 0.894 mmol) in isopropanol (13.4 ml_) was added 2-aminoacetamidine dihydrobromide (1 .21 g, 4.1 1 mmol). Potassium acetate (266 mg, 2.68 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 hours in the presence of air. The reaction was quenched with water and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by reverse phase chromatography (C18, eluting with ACN in water) afforded tert-butyl N-[(1 S)-1 -[6- amino-3-(5-bromo-2-pyridyl)pyrazin-2-yl]ethyl]carbamate.
LCMS: Rt 1 .00, m/z = 394-396 (M+H+) (Bromo pattern); 1H-NMR (600 MHz, CDCb) d ppm: 1 .45 (br s, 9H) 1 .47 (d, J=6.7 Hz, 3H) 4.84 (br s, 2H) 5.66 - 5.74 (m, 1 H) 5.89 (br s, 1 H) 7.86 - 7.88 (m, 1 H) 7.89 (br d, J=2.0 Hz, 1 H) 7.90 (s, 1 H) 8.72 (s, 1 H).
Preparation of tert-butyl N-[(1 S)-1 -[3-(5-cvano-2-pyridyl)pyrazin-2-yl1ethyl1carbamate (119) Degassed 1 ,4-dioxane (9.20 mL) was added to a mixture of tert-butyl N-[(1 S)-1 -[3-(5-bromo-2- pyridyl)pyrazin-2-yl]ethyl]carbamate (1 .396 g, 3.681 mmol), potassium ferricyanide (1 .224 g, 3.681 mmol), tBuXPhos Pd-G3 (0.151 g, 0.184 mmol) and tBuXPhos (0.082 g, 0.18 mmol) at room temperature under argon. A degassed solution of potassium acetate (0.05 M in water, 9.20 mL, 0.500 mmol) was added and the mixture was stirred at 100 °C for 5 hours. The reaction mixture was diluted with water, then extracted three times with ethyl acetate. The combined organic layers were concentrated in vacuo. The crude material was purified by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) to afford tert-butyl N-[(1 S)-1 -[3-(5-cyano-2-pyridyl)pyrazin-2- yl]ethyl]carbamate as a white solid.
Ή-NMR (400 MHz, CDCb) d ppm: 1 .38 (br s, 9 H), 1 .55 (d, 3 H), 5.66 - 5.78 (m, 2 H), 8.1 1 (dd, 1 H), 8.30 (d, 1 H), 8.59 (d, 1 H), 8.63 (d, 1 H), 8.93 - 9.04 (m, 1 H).
Preparation of 6-[3-[(1 S)-1 -aminoethyllpyrazin-2-yllpyridine-3-carbonitrile (115)
Trifluoroacetic acid (0.69 mL, 8.7 mmol) was added to a solution of tert-butyl N-[(1 S)-1 -[3-(5-cyano-2- pyridyl)pyrazin-2-yl]ethyl]carbamate (0.520 g, 1 .60 mmol) in dichloromethane (3.5 mL). The mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo. The residue was dissolved in dichloromethane, then washed with saturated aqueous sodium carbonate, dried over magnesium sulfate and concentrated in vacuo to afford 6-[3-[(1 S)-1 -aminoethyl]pyrazin-2-yl]pyridine-3- carbonitrile. LCMS (method 1): Rt 0.28, m/z = 226 [M+H]+; Ή-NMR (400 MHz, CDCb) d ppm: 1 .48 (d, J=6.60 Hz, 3H) 1 .96 (s, 2H) 4.74 (q, J=6.60 Hz, 1 H) 8.09 - 8.14 (m, 1 H) 8.19 - 8.23 (m, 1 H) 8.55 (d, J=2.57 Hz, 1 H) 8.65 (d, J=2.20 Hz, 1 H) 8.97 (dd, J=2.20, 0.73 Hz, 1 H)
Preparation of 6-[3-[(1 S)-1 -(cvclopropylmethylamino)ethyllPyrazin-2-yllPyridine-3-carbonitrile (1161
To a solution of 6-[3-[(1 S)-1 -aminoethyl]pyrazin-2-yl]pyridine-3-carbonitrile (0.200 g, 0.888 mmol) in 1 ,2- dichloroethane (4.4 ml_) were added cyclopropanecarboxaldehyde (0.0745 ml_, 0.977 mmol), acetic acid (0.051 ml_, 0.89 mmol) and sodium triacetoxyborohydride (0.277 g, 1 .24 mmol). The mixture was stirred at room temperature for 1 .5 hour. Saturated aqueous sodium carbonate was added, the aqueous layer was extracted with ethyl acetate. The combined organic layers were dired over magnesium sulfate and concentrated in vacuo. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded 6-[3-[(1 S)-1 -(cyclopropylmethylamino)ethyl]pyrazin-2- yl]pyridine-3-carbonitrile as a yellow oil.
1 H NMR (400 MHz, CDCI3) d ppm: -0.05 (dd, 2H) 0.39 (td, 2H) 0.81 - 0.94 (m, 1 H) 1 .50 (d, 3H) 1 .98 (dd, 1 H) 2.44 (dd, 1 H) 2.49 - 2.89 (m, 1 H) 4.73 (q, 1 H) 8.1 1 - 8.18 (m, 1 H) 8.20 - 8.27 (m, 1 H) 8.57 (d,
1 H) 8.69 (d, 1 H) 9.00 (dd, 1 H)
Preparation of 1 -(3-chloropyrazin-2-yl)ethanamine hydrochloride
At room temperature, to a solution of 1 -(3-chloropyrazin-2-yl)ethanone [CAS 121246-90-0] (5.00 g, 31 .9 mmol) in methanol (80 ml_) were added portionwise ammonium acetate (49.7 g, 639 mmol) and sodium cyanoborohydride (2.1 1 g, 31 .9 mmol). The resulting suspension was stirred at room temp overnight before being concentrated in vacuo. The residual was picked up in ethyl acetate and 2M NaOH. The organic layer was dried (MgSC ), filtered and evaporated. The residue was dissolved in diethyl ether and HCI in ethyl acetate (25 ml_) was added dropwise. The formed precipitate was filtered aft and dried to afford 1-(3-chloropyrazin-2-yl)ethanamine hydrochloride as a beige solid.
Ή NMR (400 MHz, DMSO-d) d ppm:1.52 (s, 3 H) 4.77 (br s, 1 H) 8.61 (d, J = 2.57 Hz, 1 H) 8.78 (d, J = 2.2 Hz, 1 H); LC-MS (method 1): Rt 0.17 min, m/z 158 [M+H+]
Preparation of N-[1-(3-chloropyrazin-2-vDethyl1-3.5-bis(trifluoromethvDbenzamide (1201
1-(3-chloropyrazin-2-yl)ethanamine hydrochloride (2.50 g, 12.9 mmol) was suspended in 2-methyl- tetrahydrofuran (51 ml_). N,N-diisopropylethylamine (6.68 mL, 38.6 mmol) was added followed by 3,5- bis(trifluoromethyl)benzoyl chloride [CAS 785-56-8] (2.41 mL, 12.9 mmol). The resulting suspension was stirred at room temp overnight. The reaction mixture was diluted with ethyl acetate and water was added. Organic layer was isolated, dried (MgS04), filtered and evaporated. Purification by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded N-[1-(3- chloropyrazin-2-yl)ethyl]-3,5-bis(trifluoromethyl)benzamide as colorless solid.
Ή NMR (400 MHz, Chloroform-d) d ppm: 1.65 (d, J = 6.97 Hz, 3 H) 5.77 - 5.83 (m, 1 H ) 7.63 (br d, J = 6.97 Hz, 1 H) 8.08 (s, 1 H) 8.30 (s, 2 H) 8.41 (d, J = 2.57 Hz, 1 H) 8.54 (d, J = 2.57 Hz, 1 H)
LC-MS (method 1): Rt 1.09 min, m/z 398 [M+H+] Preparation of N-[1-[3-(5-cvano-2-pyridyl)pyrazin-2-yl1ethyl1-3,5-bis(trifluoromethyl)benzamide (P31)
A solution of N-[1-(3-chloropyrazin-2-yl)ethyl]-3,5-bis(trifluoromethyl)benzamide (step 2, 300 mg, 0.754 mmol) in 8 ml DMF was purged with Ar, followed by the addition of (5-cyano-2-pyridyl)boronic acid [CAS 910547-29-4] (223 mg, 1.51 mmol), diacetoxypalladium (25 mg, 0.0377 mmol, 5 mol%) and dppf (42 mg, 0.0754 mmol, 10 mol%), copper(ll) chloride (101 mg, 0.754 mmol) and cesium carbonate (492 mg, 1 .51 mmol). After purging again with Ar, the reaction mixture was heated overnight at 100°C. After cooling, the reaction mixture was poured into a saturated ammonium chloride solution and extracted twice with ethyl acetate, the combined organic phases were washed with water, dried over sodium sulfate, filtered and concentrated to get a brown gum which was purified by by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) to afford N-[1 -[3-(5-cyano-2-pyridyl)pyrazin-2- yl]ethyl]-3,5-bis(trifluoromethyl)benzamide.
Ή NMR (400 MHz, CDCb) d ppm:1 .71 (d, 3 H) 6.46 (m, 1 H) 7.69 (b, d, 1 H) 8.03 (m, 1 H) 8.19 (d, 1 H) 8.25 (s, 2 H) 8.39 (d, 1 H) 8.70 (s, 2 H) 9.10 (s, 1 H); LC-MS (method 1): Rt 1 .1 1 min, m/z 466
[M+H+]
Preparation of N-[(1 S)-1 -(3-chloropyrazin-2-yl)ethyl1-3-(difluoromethoxy)-5-(trifluoromethyl)benzamide (intermediate 13)
To a solution of 3-(difluoromethoxy)-5-(trifluoromethyl)benzoic acid (0.140 g, 0.547 mmol) in dichloromethane (1 .4 ml_) were added triethylamine (0.230 ml_, 1 .60 mmol) and one drop of N,N- dimethylformamide. Then oxalyl chloride (0.0950 ml_, 1 .10 mmol) was added and the resulting mixture was stirred at room temperature for 20 minutes. It was concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane (0.7 ml_) and a suspension of (1 S)-1 -(3- chloropyrazin-2-yl)ethanamine (80 mg, 0.41 mmol) and triethylamine (0.23 ml_, 1 .6 mmol) in dichloromethane (0.7 ml_) was added dropwise at 0 °C to the previous solution of acid chloride. The reaction mixture was stirred at room temperature for 1 .5 hours. It was quenched dropwise at 0 °C by addition of sodium bicarbonate sat. aq. and diluted with dichloromethane. The aqueous layer was extracted three times with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. A first purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) failed. Thus the recovered fractions containing the desired product were dissolved in ethyl acetate and washed several times with sodium bicarbonate sat. aq., then brine, to remove the carboxylic acid as the impurity. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to afford N-[(1 S)-1 -(3-chloropyrazin-2-yl)ethyl]-3-(difluoromethoxy)-5-(trifluoromethyl)benzamide as an orange gum.
LCMS (method 1): Rt 1 .04, m/z = 396 [M+H+]; 1H-NMR (400 MHz, CDCb) d ppm:1 .63 (d, J = 6.60 Hz,
3 H) 5.77 (quin, J = 6.97 Hz, 1 H) 6.41 -6.84 (m, 1 H) 7.55 (s, 1 H) 7.58 (br s, 1 H) 7.81 (s, 1 H) 7.92 (s,
1 H) 8.40 (d, J = 2.57 Hz, 1 H) 8.52 (d, J = 2.57 Hz, 1 H). Preparation of N-[(1 S)-1 -[3-(5-bromo-2-pyridvDpyrazin-2-yl1ethyl1-3.5-bis(trifluoromethvDbenzamide
To a solution of (1 S)-1 -[3-(5-bromo-2-pyridyl)pyrazin-2-yl]ethanamine (0.539 g, 1 .93 mmol) in ethyl acetate (8 ml_) were added sodium bicarbonate (1 N solution in water, 7.7 mL, 7.7 mmol) and 3,5- bis(trifluoromethyl)benzoyl chloride (0.385 mL, 2.12 mmol). The biphasic reaction mixture was stirred vigorously at room temperature for 1 .5 hours. The layers were separated and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded N-[(1 S)-1 -[3-(5- bromo-2-pyridyl)pyrazin-2-yl]ethyl]-3,5-bis(trifluoromethyl)benzamide as a beige solid.
LC-MS (method 1): Rt 1 .21 min, m/z 519/521 [M+H+], bromo pattern; Ή-NMR (400 MHz, CDCb) d ppm:1 .66 (d, J = 6.60 Hz, 3 H) 6.27-6.34 (m, 1 H) 7.86 (br d, J = 7.70 Hz, 1 H) 8.00-8.09 (m, 3 H) 8.25 (s, 2 H) 8.63 (q, J = 2.20 Hz, 2 H) 8.86 (dd, J = 2.20, 0.73 Hz, 1 H). Example P34: Preparation of N-[(1 S)-1 -[3-(5-cvano-2-pyridyl)pyrazin-2-yl1ethyl1-3,5- bis(trifluoromethyl)benzamide (P34)
In a microwave vial under argon, were charged N-[(1 S)-1 -[3-(5-bromo-2-pyridyl)pyrazin-2-yl]ethyl]-3,5- bis(trifluoromethyl)benzamide (intermediate I-5 prepared as described above, 0.200 g, 0.385 mmol), potassium ferricyanide (0.064 g, 0.19 mmol, 0.50 equiv.), [(2-di-tert-butylphosphino-2',4',6'-triisopropyl- 1 ,T-biphenyl)-2-(2'-amino-1 , 1 '-biphenyl)] palladium(ll) methanesulfonate (tBuXPhos Pd G3) (7.9 mg, 9.6 pmol, 0.025 equiv.) and 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (tBuXPhos) (4.3 mg, 9.6 mmol, 0.025 equiv.). The vial was sealed and degassed three times with argon. Then previously degassed 1 ,4-dioxane (0.96 mL) and previously prepared and degassed potassium acetate (0.05 M solution in water, 0.96 mL, 0.10 equiv.) were added to the reaction mixture. It was heated up to 100 °C and stirred overnight. After cooling down to room temperature, the reaction mixture was diluted with water and extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded the desired product as a white solid (36 mg, 77 pmol).
LC-MS (method 1): Rt 1 .10, /z = 465 [M+H+]; Ή-NMR (400 MHz, CDCI3) d ppm:1.72 (d, J = 6.60 Hz, 3 H) 6.29-6.40 (m, 1 H) 7.68 (br d, J = 7.70 Hz, 1 H) 8.03 (s, 1 H) 8.19 (dd, J = 8.44, 2.20 Hz, 1 H) 8.24 (s, 2 H) 8.39 (dd, J = 8.44, 0.73 Hz, 1 H) 8.67-8.73 (m, 2 H) 9.09 (dd, J = 2.02, 0.92 Hz, 1 H). Chiral SFC (method 2): 13.31 min (minor enantiomer), 15.02 min (major enantiomer); ee = 88%
Preparation of N-[(1 S)-1 -[3-[5-hvdroxy-2-pyridyllpyrazin-2-yl1ethyl1-3,5-bis(trifluoromethyl)benzamide
In a flask under argon, were charged N-[(1 S)-1-[3-(5-bromo-2-pyridyl)pyrazin-2-yl]ethyl]-3,5- bis(trifluoromethyl)benzamide (0.150 g, 0.289 mmol), 1 ,4-dioxane (2.9 mL), water (1 ,2 mL), potassium carbonate (56.5 mg, 0.867 mmol), 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropyl-1 ,T- biphenyl (1.46 mg, 2.89 pmol) and tris(dibenzylideneacetone)dipalladium(0) (5.51 mg, 5.78 pmol). The reaction mixture was heated up to 80 °C and stirred overnight. After cooling down to room
temperature, it was diluted with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded N-[(1 S)-1-[3-[5-hydroxy-2-pyridyl]pyrazin-2- yl]ethyl]-3,5-bis(trifluoromethyl)benzamide.
LC-MS (method 1): Rt 1.01 , m/z = 457 [M+H+]; 1H-NMR (400 MHz, CDCb) d ppm:1.69 (d, J = 6.60 Hz, 3 H) 6.38-6.53 (m, 1 H) 7.30 (dd, J = 8.80, 2.93 Hz, 1 H) 7.99 (d, J = 8.44 Hz, 1 H) 8.05 (s, 1 H) 8.26 (br d, J = 8.07 Hz, 1 H) 8.30 (s, 2 H) 8.35 (d, J = 2.93 Hz, 1 H) 8.61 (dd, J = 14.12, 2.38 Hz, 2 H).
Example P24: Preparation of N-[(1 S)-1-[3-[5-(difluoromethoxy)-2-pyridyllpyrazin-2-yl1ethyl1-3,5- bis(trifluoromethyl)benzamide
In a flask, were charged N-[(1 S)-1-[3-(5-bromo-2-pyridyl)pyrazin-2-yl]ethyl]-3,5- bis(trifluoromethyl)benzamide (91.0 mg, 0.199 mmol), N,N-dimethylformamide (2 ml_), potassium carbonate (0.281 g, 1.99 mmol) and chlorodifluoroacetic acid (88.9 pL, 0.997 mmol). The reaction mixture was heated up to 80 °C and stirred for 4 hours. After cooling down to room temperature, it was diluted with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with ethyl acetate in cyclohexane) afforded N-[(1 S)-1-[3-[5-(difluoromethoxy)-2-pyridyl]pyrazin-2-yl]ethyl]-3,5- bis(trifluoromethyl)benzamide as a yellow solid.
LC-MS (method 1): Rt 1.16, m/z = 507 [M+H+]; 1H-NMR (400 MHz, CDCh) d ppm: 1.68 (d, J = 6.60 Hz, 3 H) 6.27-6.40 (m, 1 H) 6.45-6.91 (m, 1 H) 7.70 (dd, J = 8.8, 2.6 Hz, 1 H) 7.94 (br d, J = 7.7 Hz, 1 H) 8.02 (s, 1 H) 8.23 (d, J = 8.8 Hz, 1 H) 8.27 (s, 2 H) 8.58 - 8.73 (m, 3 H); 19F-NMR (377 MHz, CDCh) d ppm: -81.58 (s, 2 F, -CHF2) -62.88 (s, 6 F, -CF3).
Example P23: Preparation of 3-bromo-N-[1-[3-[5-(difluoromethoxy)pyrimidin-2-yllpyrazin-2-yl1ethyl1-5-
(trifluoromethyl)benzamide
To a solution of 3-bromo-5-(trifluoromethyl)benzoic acid (150 mg, 0.558 mmol) in toluene (3.0 ml_) was added thionyl chloride (0.122 ml_, 1.67 mmol) dropwise. The reaction mixture was stirred at reflux for 2 hours, cooled to room temperature, and concentrated under reduced pressure to afford the crude acyl chloride. The acyl chloride was dissolved in dichloromethane (3.0 ml_) and a solution of 1 - [3-[5-(difluoromethoxy)pyrimidin-2-yl]pyrazin-2-yl]ethanamine (182 mg, 0.669 mmol) in
dichloromethane (3.0 ml_) and triethylamine (0.235 ml_, 1 .67 mmol) was added dropwise over 5 minutes. The reaction mixture was stirred at room temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by flash chromatography over silica gel (eluting with methanol in dichloromethane) afforded 3-bromo-N-[1 -[3-[5-(difluoromethoxy)pyrimidin-2-yl]pyrazin-2- yl]ethyl]-5-(trifluoromethyl)benzamide as a pale yellow solid.
Ή-NMR (400 MHz, DMSO-d6) d ppm: 1.59 (d, 3 H) 5.50-5.65 (m, 1 H) 7.48 (t, 1 H) 8.03 (s, 1 H) 8.12 (s, 1 H) 8.20 (s, 1 H) 8.68 (s, 1 H) 8.77 (s, 1 H) 8.94 (s, 1 H) 9.19 (m, 1 H)
Example P25: Preparation of N-[1 -[3-(5-cvano-2-pyridyl)pyrazin-2-yl1ethyl1-3-(2.2.2-trifluoroethoxy)-5- (trifluoromethyl)benzamide
Thionyl chloride (0.0721 ml_, 0.989 mmol) was added dropwise to a stirred solution of 3-(2,2,2- trifluoroethoxy)-5-(trifluoromethyl)benzoic acid (150 mg, 0.495 mmol) in toluene (8.00 ml_) at 0 °C.
The reaction mixture was heated to 90 °C for 2.5 hours, then cooled down to room temperature and concentrated under reduced pressure. The crude acyl chloride was dissolved in dichloromethane (10 ml_) and added to a stirred solution of 6-[3-(1 -aminoethyl)pyrazin-2-yl]pyridine-3-carbonitrile (129 mg, 0.544 mmol) and triethylamine (0.139 ml_, 0.989 mmol) in dichloromethane (10 ml_) at 0 °C. the reaction mixture was stirred for 5 hours at room temperature. Dichloromethane and water were added. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by reverse-phase chromatography (C18 column, eluting with acetonitrile in water) afforded N-[1 -[3-(5-cyano-2-pyridyl)pyrazin-2-yl]ethyl]-3-(2,2,2-trifluoroethoxy)-5- (trifluoromethyl)benzamide as an off-white solid.
1H-NMR (400 MHz, DMSO-d6) d ppm:1 .65 (d, 3 H) 4.85-5.00 (m, 2H) 5.70-5.80 (m, 1 H) 7.55 (s, 1 H) 7.70-7.80 (m, 2H) 8.12-8.21 (m, 1 H) 8.48-8.53 (m, 1 H) 8.68-8.80 (m, 2H) 9.10-9.20 (m, 2H); 19F-NMR (377 MHz, DMSO-d6) d ppm: -72.53 (s, 3H) -61 .1 1 (s, 3H) Example P10: Preparation of 3-bromo-N-[1 -[3-(5-cvano-2-pyridvDpyrazin-2-yl1ethyl1-5- (trifluoromethvDbenzamide
Thionyl chloride (0.140 mL, 1 .91 mmol) was added dropwise to a stirred solution of 3-bromo-5-
(trifluoromethyl)benzoic acid (130 mg, 0.478 mmol) in toluene (20.00 mL) at 0 °C. The reaction mixture was heated to 90 °C for 2 hours, then cooled down to room temperature and concentrated under reduced pressure. The crude acyl chloride was dissolved in dichloromethane (10 mL) and added to a stirred solution of 6-[3-(1 -aminoethyl)pyrazin-2-yl]pyridine-3-carbonitrile (148 mg, 0.593 mmol) and triethylamine (0.269 mL, 1 .91 mmol) in dichloromethane (10 mL) at 0 °C. The reaction mixture was stirred for 2 hours at room temperature. Dichloromethane and water were added. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification of the crude material by reverse-phase chromatography (C18 column, eluting with acetonitrile in water) afforded 3-bromo-N-[1 -[3-(5-cyano-2-pyridyl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide as an off- white solid.
Ή-NMR (400 MHz, DMSO-d6) d ppm: 1.63 (d, 3 H) 5.70-5.81 (m, 1 H) 8.08 (s, 1 H) 8.12 (s, 1 H) 8.15- 8.21 (m, 1 H), 8.23 (s, 1 H) 8.48-8.52 (m, 1 H) 8.68-8.72 (m, 1 H) 8.72-8.80 (m, 1 H) 9.15-9.19 (m, 1 H) 9.22-9.30 (m, 1 H); 19F-NMR (377 MHz, DMSO-d6) d ppm: -61 .25 (s, 3H)
Table P: Examples of compounds of formula I
Table I: Table of Intermediates
1> 1H NMR (400 MHz, DMSO-d6) d ppm: 8.90 (s, 1H), 8.70-8.90 (m, 3H), 6.48 (t, 1H), 4.63 (td, 2H), 2.62 (s, 3H)
2> Ή NMR (400 MHz, DMSO-d6) d ppm: 8.80-9.00 (m, 4H), 7.50 (t, 1H), 2.65 (s, 3H)
3> 1H-NMR (400 MHz, DMSO-d6): d ppm 8.85 (d, 1 H), 8.70 (m, 1 H), 8.45 (s, 1 H), 8.25 (d, 1 H), 7.75 (d,
1 H), 5 (q, 2H), 2.6 (s, 3H)
4> 1H-NMR (400 MHz, DMSO-d6): d ppm 9.22 (s, 1H), 8.85-8.95 (m, 2H), 8.50-8.60 (m, 1H), 8.30-8.40 (m, 1 H) 7.80-8.10 (br. s, 2H), 5.25-5.35 (m, 1 H), 1.52 (d, 3H)
5> Ή NMR (400 MHz, DMSO-d6) d ppm: 8.80-9.00 (m, 4H), 6.50 (tt, 1H), 4.90 (m, 1H), 4.78 (td, 2H), 1.45 (d, 3H)
6) 1H NMR (400 MHz, DMSO-d6) d ppm: 8.80-9.10 (m, 4H), 7.51 (t, 1H), 4.88 (m, 1H), 1.50 (d, 3H)
7> 1H-NMR (400 MHz, DMSO-d6): d ppm: 8.95 (s, 2H), 8.60-9.00 (m, 2H), 7.8-8.30 (brs, 2H), 5.08-5.20 (m, 2H), 4.95-5.05 (m, 1H), 1.5 (m, 3H) 8> Ή-NMR (400 MHz, DMSO-d6): d ppm: 8.8 (s, 2H), 8.65 (d, 1 H), 8.15 (d, 1 H), 7.8 (m, 1 H), 7.45 (br s, 2H), 7.25 (m, 1 H), 7.15 (m, 1 H), 5.2 (br s, 1 H), 5 (q, 2H), 1 .5 (m, 3H)
9> Ή NMR (400 MHz, chloroform-d) d ppm -0.05 (dd, 2H) 0.39 (td, 2H) 0.81 - 0.94 (m, 1 H) 1.50 (d, 3H) 1.98 (dd, 1 H) 2.44 (dd, 1 H) 2.49 - 2.89 (m, 1 H) 4.73 (q, 1 H) 8.11 - 8.18 (m, 1 H) 8.20 - 8.27 (m, 1 H) 8.57 (d, 1 H) 8.69 (d, 1 H) 9.00 (dd, 1 H)
The activity of the compositions according to the invention can be broadened considerably, and adapted to prevailing circumstances, by adding other insecticidally, acaricidally and/or fungicidally active ingredients. The mixtures of the compounds of formula I with other insecticidally, acaricidally and/or fungicidally active ingredients may also have further surprising advantages which can also be described, in a wider sense, as synergistic activity. For example, better tolerance by plants, reduced phytotoxicity, insects can be controlled in their different development stages or better behaviour during their production, for example during grinding or mixing, during their storage or during their use.
Suitable additions to active ingredients here are, for example, representatives of the following classes of active ingredients: organophosphorus compounds, nitrophenol derivatives, thioureas, juvenile hormones, formamidines, benzophenone derivatives, ureas, pyrrole derivatives, carbamates, pyrethroids, chlorinated hydrocarbons, acylureas, pyridylmethyleneamino derivatives, macrolides, neonicotinoids and Bacillus thuringiensis preparations.
The following mixtures of the compounds of formula I with active ingredients are preferred (where the abbreviation“TX” means“one compound selected from the compounds defined in the Tables A-1 to A- 27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27, and Table P”):
an adjuvant selected from the group of substances consisting of petroleum oils (alternative name)
(628) + TX,
an insect control active substance selected from Abamectin + TX, Acequinocyl + TX, Acetamiprid +
TX, Acetoprole + TX, Acrinathrin + TX, Acynonapyr + TX, Afidopyropen + TX, Afoxalaner + TX, Alanycarb + TX, Allethrin + TX, Alpha-Cypermethrin + TX, Alphamethrin + TX, Amidoflumet + TX, Aminocarb + TX, Azocyclotin + TX, Bensultap + TX, Benzoximate + TX, Benzpyrimoxan + TX, Betacyfluthrin + TX, Beta-cypermethrin + TX, Bifenazate + TX, Bifenthrin + TX, Binapacryl + TX, Bioallethrin + TX, Bioallethrin S)-cyclopentylisomer + TX, Bioresmethrin + TX, Bistrifluron + TX, Broflanilide + TX, Brofluthrinate + TX, Bromophos-ethyl + TX, Buprofezine + TX, Butocarboxim + TX, Cadusafos + TX, Carbaryl + TX, Carbosulfan + TX, Cartap + TX, CAS number: 1472050-04-6 + TX, CAS number: 1632218-00-8 + TX, CAS number: 1808115-49-2 + TX, CAS number: 2032403-97-5 + TX, CAS number: 2044701-44-0 + TX, CAS number: 2128706-05-6 + TX, CAS number: 2249718-27-0 + TX, Chlorantraniliprole + TX, Chlordane + TX, Chlorfenapyr + TX, Chloroprallethrin + TX,
Chromafenozide + TX, Clenpirin + TX, Cloethocarb + TX, Clothianidin + TX, 2-chlorophenyl N- methylcarbamate (CPMC) + TX, Cyanofenphos + TX, Cyantraniliprole + TX, Cyclaniliprole + TX, Cyclobutrifluram + TX, Cycloprothrin + TX, Cycloxaprid + TX, Cycloxaprid + TX, Cyenopyrafen + TX, Cyetpyrafen (or Etpyrafen) + TX, Cyflumetofen + TX, Cyfluthrin + TX, Cyhalodiamide + TX,
Cyhalothrin + TX, Cypermethrin + TX, Cyphenothrin + TX, Cyromazine + TX, Deltamethrin + TX, Diafenthiuron + TX, Dialifos + TX, Dibrom + TX, Dicloromezotiaz + TX, Diflovidazine + TX,
Diflubenzuron + TX, dimpropyridaz + TX, Dinactin + TX, Dinocap + TX, Dinotefuran + TX,
Dioxabenzofos + TX, Emamectin + TX, Empenthrin + TX, Epsilon - momfluorothrin + TX, Epsilon- metofluthrin + TX, Esfenvalerate + TX, Ethion + TX, Ethiprole + TX, Etofenprox + TX, Etoxazole + TX, Famphur + TX, Fenazaquin + TX, Fenfluthrin + TX, Fenitrothion + TX, Fenobucarb + TX, Fenothiocarb + TX, Fenoxycarb + TX, Fenpropathrin + TX, Fenpyroxymate + TX, Fensulfothion + TX, Fenthion +
TX, Fentinacetate + TX, Fenvalerate + TX, Fipronil + TX, Flometoquin + TX, Flonicamid + TX, Fluacrypyrim + TX, Fluazaindolizine + TX, Fluazuron + TX, Flubendiamide + TX, Flubenzimine + TX, Flucitrinate + TX, Flucycloxuron + TX, Flucythrinate + TX, Fluensulfone + TX, Flufenerim + TX, Flufenprox + TX, Flufiprole + TX, Fluhexafon + TX, Flumethrin + TX, Fluopyram + TX, Flupentiofenox + TX, Flupyradifurone + TX, Flupyrimin + TX, Fluralaner + TX, Fluvalinate + TX, Fluxametamide + TX, Fosthiazate + TX, Gamma-Cyhalothrin + TX, Gossyplure™ + TX, Guadipyr + TX, Halofenozide + TX, Halofenozide + TX, Halofenprox + TX, Heptafluthrin + TX, Hexythiazox + TX, Hydramethylnon + TX, Imicyafos + TX, Imidacloprid + TX, Imiprothrin + TX, Indoxacarb + TX, lodomethane + TX, Iprodione + TX, Isocycloseram + TX, Isothioate + TX, Ivermectin + TX, Kappa-bifenthrin + TX, Kappa-tefluthrin + TX, Lambda-Cyhalothrin + TX, Lepimectin + TX, Lufenuron + TX, Metaflumizone + TX, Metaldehyde + TX, Metam + TX, Methomyl + TX, Methoxyfenozide + TX, Metofluthrin + TX, Metolcarb + TX, Mexacarbate + TX, Milbemectin + TX, Momfluorothrin + TX, Niclosamide + TX, Nitenpyram + TX, Nithiazine + TX, Omethoate + TX, Oxamyl + TX, Oxazosufyl + TX, Parathion-ethyl + TX, Permethrin + TX, Phenothrin + TX, Phosphocarb + TX, Piperonylbutoxide + TX, Pirimicarb + TX, Pirimiphos-ethyl + TX, Polyhedrosis virus + TX, Prallethrin + TX, Profenofos + TX, Profenofos + TX, Profluthrin + TX, Propargite + TX, Propetamphos + TX, Propoxur + TX, Prothiophos + TX, Protrifenbute + TX, Pyflubumide + TX, Pymetrozine + TX, Pyraclofos + TX, Pyrafluprole + TX, Pyridaben + TX, Pyridalyl + TX, Pyrifluquinazon + TX, Pyrimidifen + TX, Pyrimostrobin + TX, Pyriprole + TX, Pyriproxyfen + TX, Resmethrin + TX, Sarolaner + TX, Selamectin + TX, Silafluofen + TX, Spinetoram + TX, Spinosad + TX, Spirodiclofen + TX, Spiromesifen + TX, Spiropidion + TX, Spirotetramat + TX, Sulfoxaflor + TX, Tebufenozide + TX, Tebufenpyrad + TX, Tebupirimiphos + TX, Tefluthrin + TX, Temephos + TX, Tetrachloraniliprole + TX, Tetradiphon + TX, Tetramethrin + TX, Tetramethylfluthrin + TX, Tetranactin + TX, Tetraniliprole + TX, Theta-cypermethrin + TX, Thiacloprid + TX, Thiamethoxam + TX,
Thiocyclam + TX, Thiodicarb + TX, Thiofanox + TX, Thiometon + TX, Thiosultap + TX, Tioxazafen + TX, Tolfenpyrad + TX, Toxaphene + TX, Tralomethrin + TX, Transfluthrin + TX, Triazamate + TX, Triazophos + TX, Trichlorfon + TX, Trichloronate + TX, Trichlorphon + TX, Triflumezopyrim + TX, Tyclopyrazoflor + TX, Zeta-Cypermethrin + TX, Extract of seaweed and fermentation product derived from melasse + TX, Extract of seaweed and fermentation product derived from melasse comprising urea + TX, amino acids + TX, potassium and molybdenum and EDTA-chelated manganese + TX, Extract of seaweed and fermented plant products + TX, Extract of seaweed and fermented plant products comprising phytohormones + TX, vitamins + TX, EDTA-chelated copper + TX, zinc + TX, and iron + TX, Azadirachtin + TX, Bacillus aizawai + TX, Bacillus chitinosporus AQ746 (NRRL Accession No B-21 618) + TX, Bacillus firmus + TX, Bacillus kurstaki + TX, Bacillus mycoides AQ726 (NRRL Accession No. B-21664) + TX, Bacillus pumilus (NRRL Accession No B-30087) + TX, Bacillus pumilus AQ717 (NRRL Accession No. B-21662) + TX, Bacillus sp. AQ178 (ATCC Accession No. 53522) + TX, Bacillus sp. AQ175 (ATCC Accession No. 55608) + TX, Bacillus sp. AQ177 (ATCC Accession No. 55609) + TX, Bacillus subtilis unspecified + TX, Bacillus subtilis AQ153 (ATCC Accession No. 55614)
+ TX, Bacillus subtilis AQ30002 (NRRL Accession No. B-50421) + TX, Bacillus subtilis AQ30004 (NRRL Accession No. B- 50455) + TX, Bacillus subtilis AQ713 (NRRL Accession No. B-21661) + TX, Bacillus subtilis AQ743 (NRRL Accession No. B-21665) + TX, Bacillus thuringiensis AQ52 (NRRL Accession No. B-21619) + TX, Bacillus thuringiensis BD#32 (NRRL Accession No B-21530) + TX, Bacillus thuringiensis subspec. kurstaki BMP 123 + TX, Beauveria bassiana + TX, D-limonene + TX, Granulovirus + TX, Harpin + TX, Helicoverpa armigera Nucleopolyhedrovirus + TX, Helicoverpa zea Nucleopolyhedrovirus + TX, Heliothis virescens Nucleopolyhedrovirus + TX, Heliothis punctigera Nucleopolyhedrovirus + TX, Metarhizium spp. + TX, Muscodor albus 620 (NRRL Accession No.
30547) + TX, Muscodor roseus A3-5 (NRRL Accession No. 30548) + TX, Neem tree based products + TX, Paecilomyces fumosoroseus + TX, Paecilomyces lilacinus + TX, Pasteuria nishizawae + TX, Pasteuria penetrans + TX, Pasteuria ramosa + TX, Pasteuria thornei + TX, Pasteuria usgae + TX, P- cymene + TX, Plutella xylostella Granulosis virus + TX, Plutella xylostella Nucleopolyhedrovirus + TX, Polyhedrosis virus + TX, pyrethrum + TX, QRD 420 (a terpenoid blend) + TX, QRD 452 (a terpenoid blend) + TX, QRD 460 (a terpenoid blend) + TX, Quillaja saponaria + TX, Rhodococcus globerulus AQ719 (NRRL Accession No B-21663) + TX, Spodoptera frugiperda Nucleopolyhedrovirus + TX, Streptomyces galbus (NRRL Accession No. 30232) + TX, Streptomyces sp. (NRRL Accession No. B- 30145) + TX, Terpenoid blend + TX, and Verticillium spp.,
an algicide selected from the group of substances consisting of bethoxazin [CCN] + TX, copper dioctanoate (IUPAC name) (170) + TX, copper sulfate (172) + TX, cybutryne [CCN] + TX, dichlone (1052) + TX, dichlorophen (232) + TX, endothal (295) + TX, fentin (347) + TX, hydrated lime [CCN] + TX, nabam (566) + TX, quinoclamine (714) + TX, quinonamid (1379) + TX, simazine (730) + TX, triphenyltin acetate (IUPAC name) (347) and triphenyltin hydroxide (IUPAC name) (347)
+ TX,
an anthelmintic selected from the group of substances consisting of abamectin (1 ) + TX, crufomate (101 1 ) + TX, Cyclobutrifluram + TX, doramectin (alternative name) [CCN] + TX, emamectin (291) + TX, emamectin benzoate (291 ) + TX, eprinomectin (alternative name) [CCN] + TX, ivermectin (alternative name) [CCN] + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, piperazine [CCN] + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) and thiophanate (1435) + TX,
an avicide selected from the group of substances consisting of chloralose (127) + TX, endrin (1 122) + TX, fenthion (346) + TX, pyridin-4-amine (IUPAC name) (23) and strychnine (745) + TX, a bactericide selected from the group of substances consisting of 1 -hydroxy-1 /-/-pyridine-2-thione (IUPAC name) (1222) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748) + TX, 8-hydroxyquinoline sulfate (446) + TX, bronopol (97) + TX, copper dioctanoate (lUPAC name) (170) + TX, copper hydroxide (lUPAC name) (169) + TX, cresol [CCN] + TX, dichlorophen (232) + TX, dipyrithione (1 105) + TX, dodicin (1 1 12) + TX, fenaminosulf (1 144) + TX, formaldehyde (404) +
TX, hydrargaphen (alternative name) [CCN] + TX, kasugamycin (483) + TX, kasugamycin hydrochloride hydrate (483) + TX, nickel bis(dimethyldithiocarbamate) (lUPAC name) (1308) + TX, nitrapyrin (580) + TX, octhilinone (590) + TX, oxolinic acid (606) + TX, oxytetracycline (61 1) + TX, potassium hydroxyquinoline sulfate (446) + TX, probenazole (658) + TX, streptomycin (744) + TX, streptomycin sesquisulfate (744) + TX, tecloftalam (766) + TX, and thiomersal (alternative name) [CCN] + TX,
a biological agent selected from the group of substances consisting of Adoxophyes orana GV
(alternative name) (12) + TX, Agrobacterium radiobacter (alternative name) (13) + TX, Amblyseius spp. (alternative name) (19) + TX, Anagrapha falcifera NPV (alternative name) (28) + TX, Anagrus atomus (alternative name) (29) + TX, Aphelinus abdominalis (alternative name) (33) + TX, Aphidius colemani (alternative name) (34) + TX, Aphidoletes aphidimyza (alternative name) (35) + TX, Autographa californica NPV (alternative name) (38) + TX, Bacillus firmus (alternative name) (48) + TX, Bacillus sphaericus Neide (scientific name) (49) + TX, Bacillus thuringiensis Berliner (scientific name) (51) + TX, Bacillus thuringiensis subsp. aizawai (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. israelensis (scientific name) (51) + TX, Bacillus thuringiensis subsp. japonensis (scientific name) (51 ) + TX, Bacillus thuringiensis subsp. kurstaki (scientific name) (51) + TX,
Bacillus thuringiensis subsp. tenebrionis (scientific name) (51) + TX, Beauveria bassiana (alternative name) (53) + TX, Beauveria brongniartii (alternative name) (54) + TX, Chrysoperla carnea
(alternative name) (151 ) + TX, Cryptolaemus montrouzieri (alternative name) (178) + TX, Cydia pomonella GV (alternative name) (191 ) + TX, Dacnusa sibirica (alternative name) (212) + TX, Diglyphus isaea (alternative name) (254) + TX, Encarsia formosa (scientific name) (293) + TX, Eretmocerus eremicus (alternative name) (300) + TX, Helicoverpa zea NPV (alternative name) (431) + TX, Heterorhabditis bacteriophora and H. megidis (alternative name) (433) + TX, Hippodamia convergens (alternative name) (442) + TX, Leptomastix dactylopii (alternative name) (488) + TX, Macrolophus caliginosus (alternative name) (491 ) + TX, Mamestra brassicae NPV (alternative name) (494) + TX, Metaphycus helvolus (alternative name) (522) + TX, Metarhizium anisopliae var.
acridum (scientific name) (523) + TX, Metarhizium anisopliae var. anisopliae (scientific name) (523) + TX, Neodiprion sertifer NPV and N. lecontei NPV (alternative name) (575) + TX, Orius spp.
(alternative name) (596) + TX, Paecilomyces fumosoroseus (alternative name) (613) + TX,
Phytoseiulus persimilis (alternative name) (644) + TX, Spodoptera exigua multicapsid nuclear polyhedrosis virus (scientific name) (741 ) + TX, Steinernema bibionis (alternative name) (742) + TX, Steinernema carpocapsae (alternative name) (742) + TX, Steinernema feltiae (alternative name) (742) + TX, Steinernema glaseri (alternative name) (742) + TX, Steinernema riobrave (alternative name) (742) + TX, Steinernema riobravis (alternative name) (742) + TX, Steinernema scapterisci (alternative name) (742) + TX, Steinernema spp. (alternative name) (742) + TX, Trichogramma spp. (alternative name) (826) + TX, Typhlodromus occidentalis (alternative name) (844) and Verticillium lecanii (alternative name) (848) + TX,
a soil sterilant selected from the group of substances consisting of iodomethane (lUPAC name) (542) and methyl bromide (537) + TX,
a chemosterilant selected from the group of substances consisting of apholate [CCN] + TX, bisazir (alternative name) [CCN] + TX, busulfan (alternative name) [CCN] + TX, diflubenzuron (250) + TX, dimatif (alternative name) [CCN] + TX, hemel [CCN] + TX, hempa [CCN] + TX, metepa [CCN] + TX, methiotepa [CCN] + TX, methyl apholate [CCN] + TX, morzid [CCN] + TX, penfluron (alternative name) [CCN] + TX, tepa [CCN] + TX, thiohempa (alternative name) [CCN] + TX, thiotepa (alternative name) [CCN] + TX, tretamine (alternative name) [CCN] and uredepa (alternative name) [CCN] + TX, an insect pheromone selected from the group of substances consisting of (E)-dec-5-en-1 -yl acetate with (E)-dec-5-en-1 -ol (lUPAC name) (222) + TX, (E)-tridec-4-en-1 -yl acetate (lUPAC name) (829) + TX, (E)-6-methylhept-2-en-4-ol (lUPAC name) (541) + TX, (E,Z)-tetradeca-4,10-dien-1 -yl acetate (lUPAC name) (779) + TX, (Z)-dodec-7-en-1 -yl acetate (lUPAC name) (285) + TX, (Z)-hexadec-1 1 - enal (lUPAC name) (436) + TX, (Z)-hexadec-1 1 -en-1 -yl acetate (lUPAC name) (437) + TX, (Z)- hexadec-13-en-1 1 -yn-1 -yl acetate (lUPAC name) (438) + TX, (Z)-icos-13-en-10-one (lUPAC name) (448) + TX, (Z)-tetradec-7-en-1 -al (lUPAC name) (782) + TX, Z)-tetradec-9-en-1 -ol (lUPAC name) (783) + TX, (Z)-tetradec-9-en-1 -yl acetate (lUPAC name) (784) + TX, (7E,9Z)-dodeca-7,9-dien-1 -yl acetate (lUPAC name) (283) + TX, (9Z,1 1 E)-tetradeca-9,1 1 -dien-1 -yl acetate (lUPAC name) (780) + TX, (9Z, 12E)-tetradeca-9,12-dien-1 -yl acetate (lUPAC name) (781) + TX, 14-methyloctadec-1 -ene (lUPAC name) (545) + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one (lUPAC name) (544) + TX, alpha-multistriatin (alternative name) [CCN] + TX, brevicomin (alternative name) [CCN] + TX, codlelure (alternative name) [CCN] + TX, codlemone (alternative name) (167) + TX, cuelure (alternative name) (179) + TX, disparlure (277) + TX, dodec-8-en-1 -yl acetate (lUPAC name) (286)
+ TX, dodec-9-en-1 -yl acetate (lUPAC name) (287) + TX, dodeca-8 + TX, 10-dien-1 -yl acetate (lUPAC name) (284) + TX, dominicalure (alternative name) [CCN] + TX, ethyl 4-methyloctanoate (lUPAC name) (317) + TX, eugenol (alternative name) [CCN] + TX, frontalin (alternative name) [CCN] + TX, gossyplure (alternative name) (420) + TX, grandlure (421) + TX, grandlure I
(alternative name) (421) + TX, grandlure II (alternative name) (421) + TX, grandlure III (alternative name) (421) + TX, grandlure IV (alternative name) (421 ) + TX, hexalure [CCN] + TX, ipsdienol (alternative name) [CCN] + TX, ipsenol (alternative name) [CCN] + TX, japonilure (alternative name) (481) + TX, lineatin (alternative name) [CCN] + TX, litlure (alternative name) [CCN] + TX, looplure (alternative name) [CCN] + TX, medlure [CCN] + TX, megatomoic acid (alternative name) [CCN] + TX, methyl eugenol (alternative name) (540) + TX, muscalure (563) + TX, octadeca-2,13-dien-1 -yl acetate (lUPAC name) (588) + TX, octadeca-3,13-dien-1 -yl acetate (lUPAC name) (589) + TX, orfralure (alternative name) [CCN] + TX, oryctalure (alternative name) (317) + TX, ostramone (alternative name) [CCN] + TX, siglure [CCN] + TX, sordidin (alternative name) (736) + TX, sulcatol (alternative name) [CCN] + TX, tetradec-1 1 -en-1 -yl acetate (lUPAC name) (785) + TX, trimedlure (839) + TX, trimedlure A (alternative name) (839) + TX, trimedlure Bi (alternative name) (839) + TX, trimedlure B2 (alternative name) (839) + TX, trimedlure C (alternative name) (839) and trunc-call (alternative name) [CCN] + TX,
an insect repellent selected from the group of substances consisting of 2-(octylthio)ethanol (lUPAC name) (591) + TX, butopyronoxyl (933) + TX, butoxy(polypropylene glycol) (936) + TX, dibutyl adipate (lUPAC name) (1046) + TX, dibutyl phthalate (1047) + TX, dibutyl succinate (lUPAC name) (1048) + TX, diethyltoluamide [CCN] + TX, dimethyl carbate [CCN] + TX, dimethyl phthalate [CCN] + TX, ethyl hexanediol (1 137) + TX, hexamide [CCN] + TX, methoquin-butyl (1276) + TX, methylneodecanamide [CCN] + TX, oxamate [CCN] and picaridin [CCN] + TX,
a molluscicide selected from the group of substances consisting of bis(tributyltin) oxide (lUPAC name) (913) + TX, bromoacetamide [CCN] + TX, calcium arsenate [CCN] + TX, cloethocarb (999) + TX, copper acetoarsenite [CCN] + TX, copper sulfate (172) + TX, fentin (347) + TX, ferric phosphate (lUPAC name) (352) + TX, metaldehyde (518) + TX, methiocarb (530) + TX, niclosamide (576) + TX, niclosamide-olamine (576) + TX, pentachlorophenol (623) + TX, sodium pentachlorophenoxide (623) + TX, tazimcarb (1412) + TX, thiodicarb (799) + TX, tributyltin oxide (913) + TX, trifenmorph (1454) + TX, trimethacarb (840) + TX, triphenyltin acetate (lUPAC name) (347) and triphenyltin hydroxide (lUPAC name) (347) + TX, pyriprole [394730-71 -3] + TX,
a nematicide selected from the group of substances consisting of AKD-3088 (compound code) + TX,
1 ,2-dibromo-3-chloropropane (lUPAC/Chemical Abstracts name) (1045) + TX, 1 ,2-dichloropropane (lUPAC/ Chemical Abstracts name) (1062) + TX, 1 ,2-dichloropropane with 1 ,3-dichloropropene (lUPAC name) (1063) + TX, 1 ,3-dichloropropene (233) + TX, 3,4-dichlorotetrahydrothiophene 1 ,1 - dioxide (lUPAC/Chemical Abstracts name) (1065) + TX, 3-(4-chlorophenyl)-5-methylrhodanine (lUPAC name) (980) + TX, 5-methyl-6-thioxo-1 ,3,5-thiadiazinan-3-ylacetic acid (lUPAC name) (1286)
+ TX, 6-isopentenylaminopurine (alternative name) (210) + TX, abamectin (1) + TX, acetoprole [CCN] + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, AZ 60541
(compound code) + TX, benclothiaz [CCN] + TX, benomyl (62) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, carbofuran (1 18) + TX, carbon disulfide (945) + TX, carbosulfan (1 19) + TX, chloropicrin (141) + TX, chlorpyrifos (145) + TX, cloethocarb (999) + TX, Cyclobutrifluram + TX, cytokinins (alternative name) (210) + TX, dazomet (216) + TX, DBCP (1045) + TX, DCIP (218) + TX, diamidafos (1044) + TX, dichlofenthion (1051) + TX, dicliphos (alternative name) + TX, dimethoate (262) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291)
+ TX, emamectin benzoate (291) + TX, eprinomectin (alternative name) [CCN] + TX, ethoprophos (312) + TX, ethylene dibromide (316) + TX, fenamiphos (326) + TX, fen pyrad (alternative name) + TX, fensulfothion (1 158) + TX, fosthiazate (408) + TX, fosthietan (1 196) + TX, furfural (alternative name) [CCN] + TX, GY-81 (development code) (423) + TX, heterophos [CCN] + TX, iodomethane (lUPAC name) (542) + TX, isamidofos (1230) + TX, isazofos (1231 ) + TX, ivermectin (alternative name) [CCN] + TX, kinetin (alternative name) (210) + TX, mecarphon (1258) + TX, metam (519) + TX, metam-potassium (alternative name) (519) + TX, metam-sodium (519) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, Myrothecium verrucaha composition (alternative name) (565) + TX, NC-184 (compound code) + TX, oxamyl (602) + TX, phorate (636) + TX,
phosphamidon (639) + TX, phosphocarb [CCN] + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachlorothiophene (lUPAC/ Chemical Abstracts name) (1422) + TX, thiafenox (alternative name) + TX, thionazin (1434) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, xylenols [CCN] + TX, YI-5302 (compound code) and zeatin (alternative name) (210) + TX, fluensulfone [318290-98-1 ] + TX, fluopyram + TX,
a nitrification inhibitor selected from the group of substances consisting of potassium ethylxanthate [CCN] and nitrapyrin (580) + TX,
a plant activator selected from the group of substances consisting of acibenzolar (6) + TX, acibenzolar-S-methyl (6) + TX, probenazole (658) and Reynoutha sachalinensis extract (alternative name) (720) + TX,
a rodenticide selected from the group of substances consisting of 2-isovalerylindan-1 ,3-dione (lUPAC name) (1246) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (lUPAC name) (748) + TX, alpha- chlorohydrin [CCN] + TX, aluminium phosphide (640) + TX, antu (880) + TX, arsenous oxide (882) + TX, barium carbonate (891) + TX, bisthiosemi (912) + TX, brodifacoum (89) + TX,
bromadiolone (91 ) + TX, bromethalin (92) + TX, calcium cyanide (444) + TX, chloralose (127) +
TX, chlorophacinone (140) + TX, cholecalciferol (alternative name) (850) + TX, coumachlor (1004) + TX, coumafuryl (1005) + TX, coumatetralyl (175) + TX, crimidine (1009) + TX, difenacoum (246) + TX, difethialone (249) + TX, diphacinone (273) + TX, ergocalciferol (301) + TX, flocoumafen (357) + TX, fluoroacetamide (379) + TX, flupropadine (1 183) + TX, flupropadine hydrochloride (1 183) + TX, gamma-HCH (430) + TX, HCH (430) + TX, hydrogen cyanide (444) + TX, iodomethane (lUPAC name) (542) + TX, lindane (430) + TX, magnesium phosphide (lUPAC name) (640) + TX, methyl bromide (537) + TX, norbormide (1318) + TX, phosacetim (1336) + TX, phosphine (lUPAC name) (640) + TX, phosphorus [CCN] + TX, pindone (1341) + TX, potassium arsenite [CCN] + TX, pyrinuron (1371) + TX, scilliroside (1390) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoroacetate (735) + TX, strychnine (745) + TX, thallium sulfate [CCN] + TX, warfarin (851) and zinc phosphide (640) + TX,
a synergist selected from the group of substances consisting of 2-(2-butoxyethoxy)ethyl piperonylate (lUPAC name) (934) + TX, 5-(1 ,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone (lUPAC name) (903) + TX, farnesol with nerolidol (alternative name) (324) + TX, MB-599 (development code) (498) + TX, MGK 264 (development code) (296) + TX, piperonyl butoxide (649) + TX, piprotal (1343) + TX, propyl isomer (1358) + TX, S421 (development code) (724) + TX, sesamex (1393) + TX, sesasmolin (1394) and sulfoxide (1406) + TX,
an animal repellent selected from the group of substances consisting of anthraquinone (32) + TX, chloralose (127) + TX, copper naphthenate [CCN] + TX, copper oxychloride (171) + TX, diazinon (227) + TX, dicyclopentadiene (chemical name) (1069) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, methiocarb (530) + TX, pyridin-4-amine (lUPAC name) (23) + TX, thiram (804) + TX, trimethacarb (840) + TX, zinc naphthenate [CCN] and ziram (856) + TX, a virucide selected from the group of substances consisting of imanin (alternative name) [CCN] and ribavirin (alternative name) [CCN] + TX,
a wound protectant selected from the group of substances consisting of mercuric oxide (512) + TX, octhilinone (590) and thiophanate-methyl (802) + TX,
a biologically active substance selected from 1 ,1-bis(4-chloro-phenyl)-2-ethoxyethanol + TX, 2,4- dichlorophenyl benzenesulfonate + TX, 2-fluoro-N-methyl-N-1-naphthylacetamide + TX, 4- chlorophenyl phenyl sulfone + TX, acetoprole + TX, aldoxycarb + TX, amidithion + TX, amidothioate + TX, amiton + TX, amiton hydrogen oxalate + TX, amitraz + TX, aramite + TX, arsenous oxide + TX, azobenzene + TX, azothoate + TX, benomyl + TX, benoxa-fos + TX, benzyl benzoate + TX, bixafen + TX, brofenvalerate + TX, bromo-cyclen + TX, bromophos + TX, bromopropylate + TX, buprofezin +
TX, butocarboxim + TX, butoxycarboxim + TX, butylpyridaben + TX, calcium polysulfide + TX, camphechlor + TX, carbanolate + TX, carbophenothion + TX, cymiazole + TX, chino-methionat + TX, chlorbenside + TX, chlordimeform + TX, chlordimeform hydrochloride + TX, chlorfenethol + TX, chlorfenson + TX, chlorfensulfide + TX, chlorobenzilate + TX, chloromebuform + TX, chloromethiuron + TX, chloropropylate + TX, chlorthiophos + TX, cinerin I + TX, cinerin II + TX, cinerins + TX, closantel + TX, coumaphos + TX, crotamiton + TX, crotoxyphos + TX, cufraneb + TX, cyanthoate + TX, DCPM + TX, DDT + TX, demephion + TX, demephion-O + TX, demephion-S + TX, demeton-methyl + TX, demeton-O + TX, demeton-O-methyl + TX, demeton-S + TX, demeton-S-methyl + TX, demeton-S- methylsulfon + TX, dichlofluanid + TX, dichlorvos + TX, dicliphos + TX, dienochlor + TX, dimefox + TX, dinex + TX, dinex-diclexine + TX, dinocap-4 + TX, dinocap-6 + TX, dinocton + TX, dino-penton + TX, dinosulfon + TX, dinoterbon + TX, dioxathion + TX, diphenyl sulfone + TX, disulfiram + TX, DNOC + TX, dofenapyn + TX, doramectin + TX, endothion + TX, eprinomectin + TX, ethoate-methyl + TX, etrimfos + TX, fenazaflor + TX, fenbutatin oxide + TX, fenothiocarb + TX, fenpyrad + TX,
fen-pyroximate + TX, fenpyrazamine + TX, fenson + TX, fentrifanil + TX, flubenzimine + TX, flucycloxuron + TX, fluenetil + TX, fluorbenside + TX, FMC 1 137 + TX, formetanate + TX, formetanate hydrochloride + TX, formparanate + TX, gamma-HCH + TX, glyodin + TX, halfenprox + TX, hexadecyl cyclopropanecarboxylate + TX, isocarbophos + TX, jasmolin I + TX, jasmolin II + TX, jodfenphos + TX, lindane + TX, malonoben + TX, mecarbam + TX, mephosfolan + TX, mesulfen + TX, methacrifos +
TX, methyl bromide + TX, metolcarb + TX, mexacarbate + TX, milbemycin oxime + TX, mipafox + TX, monocrotophos + TX, morphothion + TX, moxidectin + TX, naled + TX, 4-chloro-2-(2-chloro-2-methyl- propyl)-5-[(6-iodo-3-pyridyl)methoxy]pyridazin-3-one + TX, nifluridide + TX, nikkomycins + TX, nitrilacarb + TX, nitrilacarb 1 :1 zinc chloride complex + TX, omethoate + TX, oxydeprofos + TX, oxydisulfoton + TX, pp'-DDT + TX, parathion + TX, permethrin + TX, phenkapton + TX, phosalone + TX, phosfolan + TX, phosphamidon + TX, polychloroterpenes + TX, polynactins + TX, proclonol + TX, promacyl + TX, propoxur + TX, prothidathion + TX, prothoate + TX, pyrethrin I + TX, pyrethrin II + TX, pyrethrins + TX, pyridaphenthion + TX, pyrimitate + TX, quinalphos + TX, quintiofos + TX, R-1492 + TX, phosglycin + TX, rotenone + TX, schradan + TX, sebufos + TX, selamectin + TX, sophamide + TX, SSI-121 + TX, sulfiram + TX, sulfluramid + TX, sulfotep + TX, sulfur + TX, diflovidazin + TX, tau- fluvalinate + TX, TEPP + TX, terbam + TX, tetradifon + TX, tetrasul + TX, thiafenox + TX, thiocarboxime + TX, thiofanox + TX, thiometon + TX, thioquinox + TX, thuringiensin + TX, triamiphos + TX, triarathene + TX, triazophos + TX, triazuron + TX, trifenofos + TX, trinactin + TX, vamidothion +
TX, vaniliprole + TX, bethoxazin + TX, copper dioctanoate + TX, copper sulfate + TX, cybutryne + TX, dichlone + TX, dichlorophen + TX, endothal + TX, fentin + TX, hydrated lime + TX, nabam + TX, quinoclamine + TX, quinonamid + TX, simazine + TX, triphenyltin acetate + TX, triphenyltin hydroxide + TX, crufomate + TX, piperazine + TX, thiophanate + TX, chloralose + TX, fenthion + TX, pyridine- amine + TX, strychnine + TX, 1 -hydroxy-1 H-pyridine-2-thione + TX, 4-(quinoxalin-2- ylamino)benzenesulfonamide + TX, 8-hydroxyquinoline sulfate + TX, bronopol + TX, copper hydroxide + TX, cresol + TX, dipyrithione + TX, dodicin + TX, fenaminosulf + TX, formaldehyde + TX, hydrargaphen + TX, kasugamycin + TX, kasugamycin hydrochloride hydrate + TX, nickel
bis(dimethyldithiocarbamate) + TX, nitrapyrin + TX, octhilinone + TX, oxolinic acid + TX,
oxytetracycline + TX, potassium hydroxyquinoline sulfate + TX, probenazole + TX, streptomycin + TX, streptomycin sesquisulfate + TX, tecloftalam + TX, thiomersal + TX, Adoxophyes orana GV + TX, Agrobacterium radiobacter + TX, Amblyseius spp. + TX, Anagrapha falcifera NPV + TX, Anagrus atomus + TX, Aphelinus abdominalis + TX, Aphidius colemani + TX, Aphidoletes aphidimyza + TX, Autographa californica NPV + TX, Bacillus sphaericus Neide + TX, Beauveria brongniartii + TX, Chrysoperla carnea + TX, Cryptolaemus montrouzieri + TX, Cydia pomonella GV + TX, Dacnusa sibirica + TX, Diglyphus isaea + TX, Encarsia formosa + TX, Eretmocerus eremicus + TX,
Heterorhabditis bacteriophora and H. megidis + TX, Hippodamia convergens + TX, Leptomastix dactylopii + TX, Macrolophus caliginosus + TX, Mamestra brassicae NPV + TX, Metaphycus helvolus + TX, Metarhizium anisopliae var. acridum + TX, Metarhizium anisopliae var. anisopliae + TX, Neodiprion sertifer NPV and N. lecontei NPV + TX, Orius spp. + TX, Paecilomyces fumosoroseus + TX, Phytoseiulus persimilis + TX, Steinernema bibionis + TX, Steinernema carpocapsae + TX, Steinernema feltiae + TX, Steinernema glaseri + TX, Steinernema riobrave + TX, Steinernema riobravis + TX, Steinernema scapterisci + TX, Steinernema spp. + TX, Trichogramma spp. + TX, Typhlodromus occidentalis + TX , Verticillium lecanii + TX, apholate + TX, bisazir + TX, busulfan + TX, dimatif + TX, hemel + TX, hempa + TX, metepa + TX, methiotepa + TX, methyl apholate + TX, morzid + TX, penfluron + TX, tepa + TX, thiohempa + TX, thiotepa + TX, tretamine + TX, uredepa + TX, (E)- dec-5-en-1 -yl acetate with (E)-dec-5-en-1 -ol + TX, (E)-tridec-4-en-1 -yl acetate + TX, (E)-6-methylhept- 2-en-4-ol + TX, (E,Z)-tetradeca-4,10-dien-1 -yl acetate + TX, (Z)-dodec-7-en-1 -yl acetate + TX, (Z)- hexadec-1 1 -enal + TX, (Z)-hexadec-l 1 -en-1 -yl acetate + TX, (Z)-hexadec-13-en-1 1 -yn-1 -yl acetate + TX, (Z)-icos-13-en-10-one + TX, (Z)-tetradec-7-en-1 -al + TX, (Z)-tetradec-9-en-1 -ol + TX, (Z)-tetradec- 9-en-1 -yl acetate + TX, (7E,9Z)-dodeca-7,9-dien-1 -yl acetate + TX, (9Z,1 1 E)-tetradeca-9,1 1 -dien-1 -yl acetate + TX, (9Z,12E)-tetradeca-9,12-dien-1 -yl acetate + TX, 14-methyloctadec-1 -ene + TX, 4- methylnonan-5-ol with 4-methylnonan-5-one + TX, alpha-multistriatin + TX, brevicomin + TX, codlelure + TX, codlemone + TX, cuelure + TX, disparlure + TX, dodec-8-en-1 -yl acetate + TX, dodec-9-en-1 -yl acetate + TX, dodeca-8 + TX, 10-dien-1 -yl acetate + TX, dominicalure + TX, ethyl 4-methyloctanoate + TX, eugenol + TX, frontalin + TX, grandlure + TX, grandlure I + TX, grandlure II + TX, grandlure III + TX, grandlure IV + TX, hexalure + TX, ipsdienol + TX, ipsenol + TX, japonilure + TX, lineatin + TX, litlure + TX, looplure + TX, medlure + TX, megatomoic acid + TX, methyl eugenol + TX, muscalure + TX, octadeca-2,13-dien-1 -yl acetate + TX, octadeca-3,13-dien-1 -yl acetate + TX, orfralure + TX, oryctalure + TX, ostramone + TX, siglure + TX, sordidin + TX, sulcatol + TX, tetradec-1 1 -en-1 -yl acetate + TX, trimedlure + TX, trimedlure A + TX, trimedlure Bi + TX, trimedlure B2 + TX, trimedlure C + TX, trunc-call + TX, 2-(octylthio)-ethanol + TX, butopyronoxyl + TX, butoxy(polypropylene glycol) + TX, dibutyl adipate + TX, dibutyl phthalate + TX, dibutyl succinate + TX, diethyltoluamide + TX, dimethyl carbate + TX, dimethyl phthalate + TX, ethyl hexanediol + TX, hexamide + TX, methoquin- butyl + TX, methylneodecanamide + TX, oxamate + TX, picaridin + TX, 1 -dichloro-1 -nitroethane + TX,
1 ,1 -dichloro-2,2-bis(4-ethylphenyl)-ethane + TX, 1 ,2-dichloropropane with 1 ,3-dichloropropene + TX, 1 -bromo-2-chloroethane + TX, 2,2,2-trichloro-1 -(3,4-dichloro-phenyl)ethyl acetate + TX, 2,2- dichlorovinyl 2-ethylsulfinylethyl methyl phosphate + TX, 2-(1 ,3-dithiolan-2-yl)phenyl
dimethylcarbamate + TX, 2-(2-butoxyethoxy)ethyl thiocyanate + TX, 2-(4,5-dimethyl-1 ,3-dioxolan-2- yl)phenyl methylcarbamate + TX, 2-(4-chloro-3,5-xylyloxy)ethanol + TX, 2-chlorovinyl diethyl phosphate + TX, 2-imidazolidone + TX, 2-isovalerylindan-1 ,3-dione + TX, 2-methyl(prop-2- ynyl)aminophenyl methylcarbamate + TX, 2-thiocyanatoethyl laurate + TX, 3-bromo-1 -chloroprop-1 - ene + TX, 3-methyl-1 -phenylpyrazol-5-yl dimethyl-carbamate + TX, 4-methyl(prop-2-ynyl)amino-3,5- xylyl methylcarbamate + TX, 5,5-dimethyl-3-oxocyclohex-1 -enyl dimethylcarbamate + TX, acethion + TX, acrylonitrile + TX, aldrin + TX, allosamidin + TX, allyxycarb + TX, alpha-ecdysone + TX, aluminium phosphide + TX, aminocarb + TX, anabasine + TX, athidathion + TX, azamethiphos + TX, Bacillus thuringiensis delta endotoxins + TX, barium hexafluorosilicate + TX, barium polysulfide + TX, barthrin + TX, Bayer 22/190 + TX, Bayer 22408 + TX, beta-cyfluthrin + TX, beta-cypermethrin + TX, bioethanomethrin + TX, biopermethrin + TX, bis(2-chloroethyl) ether + TX, borax + TX, bromfenvinfos + TX, bromo-DDT + TX, bufencarb + TX, butacarb + TX, butathiofos + TX, butonate + TX, calcium arsenate + TX, calcium cyanide + TX, carbon disulfide + TX, carbon tetrachloride + TX, cartap hydrochloride + TX, cevadine + TX, chlorbicyclen + TX, chlordane + TX, chlordecone + TX, chloroform + TX, chloropicrin + TX, chlorphoxim + TX, chlorprazophos + TX, cis-resmethrin + TX, cismethrin +
TX, clocythrin + TX, copper acetoarsenite + TX, copper arsenate + TX, copper oleate + TX, coumithoate + TX, cryolite + TX, CS 708 + TX, cyanofenphos + TX, cyanophos + TX, cyclethrin + TX, cythioate + TX, d-tetramethrin + TX, DAEP + TX, dazomet + TX, decarbofuran + TX, diamidafos + TX, dicapthon + TX, dichlofenthion + TX, dicresyl + TX, dicyclanil + TX, dieldrin + TX, diethyl 5- methylpyrazol-3-yl phosphate + TX, dilor + TX, dimefluthrin + TX, dimetan + TX, dimethrin + TX, dimethylvinphos + TX, dimetilan + TX, dinoprop + TX, dinosam + TX, dinoseb + TX, diofenolan + TX, dioxabenzofos + TX, dithicrofos + TX, DSP + TX, ecdysterone + TX, El 1642 + TX, EMPC + TX, EPBP + TX, etaphos + TX, ethiofencarb + TX, ethyl formate + TX, ethylene dibromide + TX, ethylene dichloride + TX, ethylene oxide + TX, EXD + TX, fenchlorphos + TX, fenethacarb + TX, fenitrothion + TX, fenoxacrim + TX, fenpirithrin + TX, fensulfothion + TX, fenthion-ethyl + TX, flucofuron + TX, fosmethilan + TX, fospirate + TX, fosthietan + TX, furathiocarb + TX, furethrin + TX, guazatine + TX, guazatine acetates + TX, sodium tetrathiocarbonate + TX, halfenprox + TX, HCH + TX, HEOD + TX, heptachlor + TX, heterophos + TX, HHDN + TX, hydrogen cyanide + TX, hyquincarb + TX, IPSP + TX, isazofos + TX, isobenzan + TX, isodrin + TX, isofenphos + TX, isolane + TX, isoprothiolane + TX, isoxathion + TX, juvenile hormone I + TX, juvenile hormone II + TX, juvenile hormone III + TX, kelevan + TX, kinoprene + TX, lead arsenate + TX, leptophos + TX, lirimfos + TX, lythidathion + TX, m- cumenyl methylcarbamate + TX, magnesium phosphide + TX, mazidox + TX, mecarphon + TX, menazon + TX, mercurous chloride + TX, mesulfenfos + TX, metam + TX, metam-potassium + TX, metam-sodium + TX, methanesulfonyl fluoride + TX, methocrotophos + TX, methoprene + TX, methothrin + TX, methoxychlor + TX, methyl isothiocyanate + TX, methylchloroform + TX, methylene chloride + TX, metoxadiazone + TX, mirex + TX, naftalofos + TX, naphthalene + TX, NC-170 + TX, nicotine + TX, nicotine sulfate + TX, nithiazine + TX, nornicotine + TX, 0-5-dichloro-4-iodophenyl O- ethyl ethylphosphonothioate + TX, O,O-diethyl 0-4-methyl-2-oxo-2H-chromen-7-yl phosphorothioate + TX, O,O-diethyl 0-6-methyl-2-propylpyrimidin-4-yl phosphorothioate + TX, O,O,O',O'-tetrapropyl dithiopyrophosphate + TX, oleic acid + TX, para-dichlorobenzene + TX, parathion-methyl + TX, pentachlorophenol + TX, pentachlorophenyl laurate + TX, PH 60-38 + TX, phenkapton + TX, phosnichlor + TX, phosphine + TX, phoxim-methyl + TX, pirimetaphos + TX,
polychlorodicyclopentadiene isomers + TX, potassium arsenite + TX, potassium thiocyanate + TX, precocene I + TX, precocene II + TX, precocene III + TX, primidophos + TX, profluthrin + TX, promecarb + TX, prothiofos + TX, pyrazophos + TX, pyresmethrin + TX, quassia + TX, quinalphos- methyl + TX, quinothion + TX, rafoxanide + TX, resmethrin + TX, rotenone + TX, kadethrin + TX, ryania + TX, ryanodine + TX, sabadilla) + TX, schradan + TX, sebufos + TX, SI-0009 + TX, thiapronil + TX, sodium arsenite + TX, sodium cyanide + TX, sodium fluoride + TX, sodium hexafluorosilicate +
TX, sodium pentachlorophenoxide + TX, sodium selenate + TX, sodium thiocyanate + TX, sulcofuron + TX, sulcofuron-sodium + TX, sulfuryl fluoride + TX, sulprofos + TX, tar oils + TX, tazimcarb + TX, TDE + TX, tebupirimfos + TX, temephos + TX, terallethrin + TX, tetrachloroethane + TX, thicrofos +
TX, thiocyclam + TX, thiocyclam hydrogen oxalate + TX, thionazin + TX, thiosultap + TX, thiosultap- sodium + TX, tralomethrin + TX, transpermethrin + TX, triazamate + TX, trichlormetaphos-3 + TX, trichloronat + TX, trimethacarb + TX, tolprocarb + TX, triclopyricarb + TX, triprene + TX, veratridine + TX, veratrine + TX, XMC + TX, zetamethrin + TX, zinc phosphide + TX, zolaprofos + TX, and meperfluthrin + TX, tetramethylfluthrin + TX, bis(tributyltin) oxide + TX, bromoacetamide + TX, ferric phosphate + TX, niclosamide-olamine + TX, tributyltin oxide + TX, pyrimorph + TX, trifenmorph + TX,
1 ,2-dibromo-3-chloropropane + TX, 1 ,3-dichloropropene + TX, 3,4-dichlorotetrahydrothio-phene 1 ,1- dioxide + TX, 3-(4-chlorophenyl)-5-methylrhodanine + TX, 5-methyl-6-thioxo-1 ,3,5-thiadiazinan-3- ylacetic acid + TX, 6-isopentenylaminopurine + TX, 2-fluoro-N-(3-methoxyphenyl)-9H-purin-6-amine + TX, benclothiaz + TX, cytokinins + TX, DCIP + TX, furfural + TX, isamidofos + TX, kinetin + TX, Myrothecium verrucaria composition + TX, tetrachlorothiophene + TX, xylenols + TX, zeatin + TX, potassium ethylxanthate + TX .acibenzolar + TX, acibenzolar-S-methyl + TX, Reynoutria sachalinensis extract + TX, alpha-chlorohydrin + TX, antu + TX, barium carbonate + TX, bisthiosemi + TX, brodifacoum + TX, bromadiolone + TX, bromethalin + TX, chlorophacinone + TX, cholecalciferol + TX, coumachlor + TX, coumafuryl + TX, coumatetralyl + TX, crimidine + TX, difenacoum + TX, difethialone + TX, diphacinone + TX, ergocalciferol + TX, flocoumafen + TX, fluoroacetamide + TX, flupropadine + TX, flupropadine hydrochloride + TX, norbormide + TX, phosacetim + TX, phosphorus + TX, pindone + TX, pyrinuron + TX, scilliroside + TX, -sodium fluoroacetate + TX, thallium sulfate + TX, warfarin + TX, -2-(2-butoxyethoxy)ethyl piperonylate + TX, 5-(1 ,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone + TX, farnesol with nerolidol + TX, verbutin + TX, MGK 264 + TX, piperonyl butoxide + TX, piprotal + TX, propyl isomer + TX, S421 + TX, sesamex + TX, sesasmolin + TX, sulfoxide + TX, anthraquinone + TX, copper naphthenate + TX, copper oxychloride + TX, dicyclopentadiene + TX, thiram + TX, zinc naphthenate + TX, ziram + TX, imanin + TX, ribavirin + TX, mercuric oxide + TX, thiophanate-methyl + TX, azaconazole + TX, bitertanol + TX, bromuconazole + TX, cyproconazole + TX, difenoconazole + TX, diniconazole -+ TX, epoxiconazole + TX, fenbuconazole + TX, fluquinconazole + TX, flusilazole + TX, flutriafol + TX, furametpyr + TX, hexaconazole + TX, imazalil- + TX, imiben-conazole + TX, ipconazole + TX, metconazole + TX, myclobutanil + TX, paclobutrazole + TX, pefurazoate + TX, penconazole + TX, prothioconazole + TX, pyrifenox + TX, prochloraz + TX, propiconazole + TX, pyrisoxazole + TX, -simeconazole + TX, tebucon-azole + TX, tetraconazole + TX, triadimefon + TX, triadimenol + TX, triflumizole + TX, triticonazole + TX, ancymidol + TX, fenarimol + TX, nuarimol + TX, bupirimate + TX, dimethirimol + TX, ethirimol + TX, dodemorph + TX, fenpropidine + TX,
fenpropimorph + TX, spiroxamine + TX, tridemorph + TX, cyprodinil + TX, mepanipyrim + TX, pyrimethanil + TX, fenpiclonil + TX, fludioxonil + TX, benalaxyl + TX, furalaxyl + TX, -metalaxyl -+ TX, Rmetalaxyl + TX, ofurace + TX, oxadixyl + TX, carbendazim + TX, debacarb + TX, fuberidazole -+ TX, thiabendazole + TX, chlozolinate + TX, dichlozoline + TX, myclozoline- + TX, procymidone + TX, vinclozoline + TX, boscalid + TX, carboxin + TX, fenfuram + TX, flutolanil + TX, mepronil + TX, oxycarboxin + TX, penthiopyrad + TX, thifluzamide + TX, dodine + TX, iminoctadine + TX, azoxystrobin + TX, dimoxystrobin + TX, enestroburin + TX, fenaminstrobin + TX, flufenoxystrobin +
TX, fluoxastrobin + TX, kresoxim-methyl + TX, metominostrobin + TX, trifloxystrobin + TX, orysastrobin + TX, picoxystrobin + TX, pyraclostrobin + TX, pyrametostrobin + TX, pyraoxystrobin + TX, ferbam + TX, mancozeb + TX, maneb + TX, metiram + TX, propineb + TX, zineb + TX, captafol + TX, captan + TX, fluoroimide + TX, folpet + TX, tolylfluanid + TX, bordeaux mixture + TX, copper oxide + TX, mancopper + TX, oxine-copper + TX, nitrothal-isopropyl + TX, edifenphos + TX, iprobenphos + TX, phosdiphen + TX, tolclofos-methyl + TX, anilazine + TX, benthiavalicarb + TX, blasticidin-S + TX, chloroneb -+ TX, chloro-tha-lonil + TX, cyflufenamid + TX, cymoxanil + TX, cyclobutrifluram + TX, diclocymet + TX, diclomezine -+ TX, dicloran + TX, diethofencarb + TX, dimethomorph -+ TX, flumorph + TX, dithianon + TX, ethaboxam + TX, etridiazole + TX, famoxadone + TX, fenamidone + TX, fenoxanil + TX, ferimzone + TX, fluazinam + TX, fluopicolide + TX, flusulfamide + TX,
fluxapyroxad + TX, -fenhexamid + TX, fosetyl-aluminium -+ TX, hymexazol + TX, iprovalicarb + TX, cyazofamid + TX, methasulfocarb + TX, metrafenone + TX, pencycuron + TX, phthalide + TX, polyoxins + TX, propamocarb + TX, pyribencarb + TX, proquinazid + TX, pyroquilon + TX, pyriofenone + TX, quinoxyfen + TX, quintozene + TX, tiadinil + TX, triazoxide + TX, tricyclazole + TX, triforine +
TX, validamycin + TX, valifenalate + TX, zoxamide + TX, mandipropamid + TX, flubeneteram + TX, isopyrazam + TX, sedaxane + TX, benzovindiflupyr + TX, pydiflumetofen + TX, 3-difluoromethyl-1 - methyl-1 H-pyrazole-4-carboxylic acid (3',4',5'-trifluoro-biphenyl-2-yl)-amide + TX, isoflucypram + TX, isotianil + TX, dipymetitrone + TX, 6-ethyl-5,7-dioxo-pyrrolo[4,5][1 ,4]dithiino[1 ,2-c]isothiazole-3- carbonitrile + TX, 2-(difluoromethyl)-N-[3-ethyl-1 ,1 -dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, 4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine-3-carbonitrile + TX, (R)-3-(difluoromethyl)-1 - methyl-N-[1 ,1 ,3-trimethylindan-4-yl]pyrazole-4-carboxamide + TX, 4-(2-bromo-4-fluoro-phenyl)-N-(2- chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazol-3-amine + TX, 4- (2- bromo- 4- fluorophenyl) - N- (2- chloro- 6- fluorophenyl) - 1 , 3- dimethyl- 1 H- pyrazol- 5- amine + TX, fluindapyr + TX,
coumethoxystrobin (jiaxiangjunzhi) + TX, Ivbenmixianan + TX, dichlobentiazox + TX, mandestrobin + TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1 -yl)quinolone + TX, 2-[2-fluoro-6-[(8-fluoro-2- methyl-3-quinolyl)oxy]phenyl]propan-2-ol + TX, oxathiapiprolin + TX, tert-butyl N-[6-[[[(1 - methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, pyraziflumid + TX, inpyrfluxam + TX, trolprocarb + TX, mefentrifluconazole + TX, ipfentrifluconazole+ TX, 2- (difluoromethyl)-N-[(3R)-3-ethyl-1 ,1 -dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, N'-(2,5- dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX, N'-[4-(4,5-dichlorothiazol-2-yl)oxy- 2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine + TX, [2-[3-[2-[1 -[2-[3,5-bis(difluoromethyl)pyrazol- 1 -yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chloro-phenyl] methanesulfonate + TX, but-3-ynyl N-[6-[[(Z)-[(1 -methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, methyl N-[[5-[4-(2,4-dimethylphenyl)triazol-2-yl]-2-methyl-phenyl]methyl]carbamate + TX, 3-chloro- 6-methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine + TX, pyridachlometyl + TX, 3-(difluoromethyl)-1 - methyl-N-[1 ,1 ,3-trimethylindan-4-yl]pyrazole-4-carboxamide + TX, 1 -[2-[[1 -(4-chlorophenyl)pyrazol-3- yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one + TX, 1 -methyl-4-[3-methyl-2-[[2-methyl-4- (3,4,5-trimethylpyrazol-1 -yl)phenoxy]methyl]phenyl]tetrazol-5-one + TX, aminopyrifen + TX, ametoctradin + TX, amisulbrom + TX, penflufen + TX, (Z,2E)-5-[1 -(4-chlorophenyl)pyrazol-3-yl]oxy-2- methoxyimino-N,3-dimethyl-pent-3-enamide + TX, florylpicoxamid + TX, fenpicoxamid + TX, tebufloquin + TX, ipflufenoquin + TX, quinofumelin + TX, isofetamid + TX, N-[2-[2,4-dichloro- phenoxy]phenyl]-3-(difluoromethyl)-1 -methyl-pyrazole-4-carboxamide + TX, N-[2-[2-chloro-4- (trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-1 -methyl-pyrazole-4-carboxamide + TX, benzothiostrobin + TX, phenamacril + TX, 5-amino-1 ,3,4-thiadiazole-2-thiol zinc salt (2:1) + TX, fluopyram + TX, flutianil + TX, fluopimomide + TX, pyrapropoyne + TX, picarbutrazox + TX, 2- (difluoromethyl)-N-(3-ethyl-1 ,1 -dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2- (difluoromethyl) - N- ((3R) - 1 , 1 , 3- trimethylindan- 4- yl) pyridine- 3- carboxamide + TX, 4-[[6-[2-(2,4-difluorophenyl)- 1 ,1 -difluoro-2-hydroxy-3-(1 ,2,4-triazol-1 -yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, metyltetraprole +
TX, 2- (difluoromethyl) - N- ((3R) - 1 , 1 , 3- trimethylindan- 4- yl) pyridine- 3- carboxamide + TX, a- (1 ,
1 - dimethylethyl) - a- [4'- (trifluoromethoxy) [1 , T- biphenyl] - 4- yl] -5- pyrimidinemethanol + TX, fluoxapiprolin + TX, enoxastrobin + TX, 4-[[6-[2-(2,4-difluorophenyl)-1 ,1 -difluoro-2-hydroxy-3-(1 ,2,4- triazol-1 -yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1 ,1 -difluoro-2-hydroxy- 3-(5-sulfanyl-1 ,2,4-triazol-1 -yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1 ,1 - difluoro-2-hydroxy-3-(5-thioxo-4H-1 ,2,4-triazol-1 -yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, trinexapac + TX, coumoxystrobin + TX, zhongshengmycin + TX, thiodiazole copper + TX, zinc thiazole + TX, amectotractin + TX, iprodione + TX; N'-[5-bromo-2-methyl-6-[(1 S)-1 -methyl-2-propoxy-ethoxy]-3- pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl-6-[(1 R)-1 -methyl-2-propoxy- ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl-6-(1 -methyl-2-propoxy- ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-chloro-2-methyl-6-(1 -methyl-2-propoxy- ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl-6-(1 -methyl-2-propoxy- ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine + TX (these compounds may be prepared from the methods described in WO2015/155075); N'-[5-bromo-2-methyl-6-(2-propoxypropoxy)-3-pyridyl]-N- ethyl-N-methyl-formamidine + TX (this compound may be prepared from the methods described in IPCOM000249876D); N-isopropyl-N’-[5-methoxy-2-methyl-4-(2, 2, 2-trifluoro-1 -hydroxy-1 -phenyl- ethyl)phenyl]-N-methyl-formamidine+ TX, N’-[4-(1 -cyclopropyl-2, 2, 2-trifluoro-1 -hydroxy-ethyl)-5- methoxy-2-methyl-phenyl]-N-isopropyl-N-methyl-formamidine + TX (these compounds may be prepared from the methods described in WO2018/228896); N-ethyl-N’-[5-methoxy-2-methyl-4-[2- trifluoromethyl)oxetan-2-yl]phenyl]-N-methyl-formamidine + TX, N-ethyl-N’-[5-methoxy-2-methyl-4-[2- trifuoromethyl)tetrahydrofuran-2-yl]phenyl]-N-methyl-formamidine + TX (these compounds may be prepared from the methods described in WO2019/1 10427); N-[(1 R)-1 -benzyl-3-chloro-1 -methyl-but-3- enyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1 S)-1 -benzyl-3, 3, 3-trifluoro-1 -methyl-propyl]-8-fluoro- quinoline-3-carboxamide + TX, N-[(1 S)-1 -benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3- carboxamide + TX, 8-fluoro-N-[1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide + TX, N-(1 -benzyl-1 ,3-dimethyl-butyl)-8-fluoro-quinoline-3-carboxamide + TX, N-[(1 R)-1 -benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1 S)-1 -benzyl-1 ,3-dimethyl-butyl]-8-fluoro- quinoline-3-carboxamide + TX, N-(1 -benzyl-3-chloro-1 -methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide + TX (these compounds may be prepared from the methods described in
WO2017/153380); 1 -(6,7-dimethylpyrazolo[1 ,5-a]pyridin-3-yl)-4, 4, 5-trifluoro-3, 3-dimethyl-isoquinoline + TX, 1 -(6, 7-dimethylpyrazolo[1 ,5-a]pyridin-3-yl)-4, 4, 6-trifluoro-3, 3-dimethyl-isoquinoline + TX, 4,4- difluoro-3,3-dimethyl-1 -(6-methylpyrazolo[1 ,5-a]pyridin-3-yl)isoquinoline + TX, 4,4-difluoro-3,3- dimethyl-1 -(7-methylpyrazolo[1 ,5-a]pyridin-3-yl)isoquinoline + TX, 1 -(6-chloro-7-methyl-pyrazolo[1 ,5- a]pyridin-3-yl)-4,4-difluoro-3, 3-dimethyl-isoquinoline + TX (these compounds may be prepared from the methods described in WO2017/025510); 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4,5-trifluoro-3,3- dimethyl-isoquinoline + TX, 1 -(4, 5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3, 3-dimethyl-isoquinoline + TX, 6-chloro-4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 -yl)isoquinoline + TX, 4,4-difluoro-1 - (5-fluoro-4-methyl-benzimidazol-1 -yl)-3, 3-dimethyl-isoquinoline + TX, 3-(4,4-difluoro-3,3-dimethyl-1 - isoquinolyl)-7,8-dihydro-6H-cyclopenta[e]benzimidazole + TX (these compounds may be prepared from the methods described in WO2016/156085); N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide + TX, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide + TX, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-
1 .2.4-oxadiazol-3-yl]phenyl]methyl]propanamide + TX, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-
1 .2.4-oxadiazol-3-yl]phenyl]methyl]urea + TX, 1 ,3-dimethoxy-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl]phenyl]methyl]urea + TX, 3-ethyl-1 -methoxy-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea + TX, N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide + TX, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one + TX, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one + TX, ethyl 1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate + TX, N,N- dimethyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]-1 ,2,4-triazol-3-amine + TX. The compounds in this paragraph may be prepared from the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/1 18689; 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3- pyridyl]-1 -(1 ,2,4-triazol-1 -yl)propan-2-ol + TX (this compound may be prepared from the methods described in WO 2017/029179); 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1 -(1 ,2,4-triazol-1 - yl)propan-2-ol + TX (this compound may be prepared from the methods described in WO
2017/029179); 3-[2-(1 -chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile + TX (this compound may be prepared from the methods described in WO 2016/156290); 3-[2-(1 - chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile + TX (this compound may be prepared from the methods described in WO 2016/156290); (4- phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate + TX (this compound may be prepared from the methods described in WO 2014/006945); 2,6-Dimethyl-1 H,5H-[1 ,4]dithiino[2,3- c:5,6-c']dipyrrole-1 ,3,5,7(2H,6H)-tetrone + TX (this compound may be prepared from the methods described in WO 201 1/138281 ); N-methyl-4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yljbenzenecarbothioamide + TX; N-methyl-4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]benzamide + TX; (Z,2E)-5-[1 -(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide + TX (this compound may be prepared from the methods described in WO 2018/153707); N'-(2-chloro-5- methyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX; N'-[2-chloro-4-(2-fluorophenoxy)-5- methyl-phenyl]-N-ethyl-N-methyl-formamidine + TX (this compound may be prepared from the methods described in WO 2016/202742); 2-(difluoromethyl)-N-[(3S)-3-ethyl-1 ,1 -dimethyl-indan-4- yl]pyridine-3-carboxamide + TX (this compound may be prepared from the methods described in WO 2014/095675); (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methanone + TX, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methanone + TX (these compounds may be prepared from the methods described in WO 2017/220485); 2-oxo-N-propyl-2-[4- [5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]acetamide + TX (this compound may be prepared from the methods described in WO 2018/065414); ethyl 1 -[[5-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]-2- thienyl]methyl]pyrazole-4-carboxylate + TX (this compound may be prepared from the methods described in WO 2018/158365) ; 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]acetamide + TX, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yljbenzamide + TX, N-[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]benzamide + TX, N-[N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]benzamide + TX (these compounds may be prepared from the methods described in WO 2018/202428);
microbials including: Acinetobacter Iwoffii + TX, Acremonium alternatum + TX + TX, Acremonium cephalosporium + TX + TX, Acremonium diospyri + TX, Acremonium obclavatum + TX, Adoxophyes orana granulovirus (AdoxGV) (Capex®) + TX, Agrobacterium radiobacter strain K84 (Galltrol-A®) + TX, Alternaria alternate + TX, Alternaria cassia + TX, Alternaria destruens (Smolder®) + TX,
Ampelomyces quisqualis (AQ10®) + TX, Aspergillus flavus AF36 (AF36®) + TX, Aspergillus flavus NRRL 21882 (Aflaguard®) + TX, Aspergillus spp. + TX, Aureobasidium pullulans + TX, Azospirillum + TX, (MicroAZ® + TX, TAZO B®) + TX, Azotobacter + TX, Azotobacter chroocuccum (Azotomeal®) + TX, Azotobacter cysts (Bionatural Blooming Blossoms®) + TX, Bacillus amyloliquefaciens + TX, Bacillus cereus + TX, Bacillus chitinosporus strain CM-1 + TX, Bacillus chitinosporus strain AQ746 + TX, Bacillus licheniformis strain HB-2 (Biostart™ Rhizoboost®) + TX, Bacillus licheniformis strain 3086 (EcoGuard® + TX, Green Releaf®) + TX, Bacillus circulans + TX, Bacillus firmus (BioSafe® + TX, BioNem-WP® + TX, VOTiVO®) + TX, Bacillus firmus strain 1-1582 + TX, Bacillus macerans + TX, Bacillus marismortui + TX, Bacillus megaterium + TX, Bacillus mycoides strain AQ726 + TX, Bacillus papillae (Milky Spore Powder®) + TX, Bacillus pumilus spp. + TX, Bacillus pumilus strain GB34 (Yield Shield®) + TX, Bacillus pumilus strain AQ717 + TX, Bacillus pumilus strain QST 2808 (Sonata® + TX, Ballad Plus®) + TX, Bacillus spahericus (VectoLex®) + TX, Bacillus spp. + TX, Bacillus spp. strain AQ175 + TX, Bacillus spp. strain AQ177 + TX, Bacillus spp. strain AQ178 + TX, Bacillus subtilis strain QST 713 (CEASE® + TX, Serenade® + TX, Rhapsody®) + TX, Bacillus subtilis strain QST 714 (JAZZ®) + TX, Bacillus subtilis strain AQ153 + TX, Bacillus subtilis strain AQ743 + TX, Bacillus subtilis strain QST3002 + TX, Bacillus subtilis strain QST3004 + TX, Bacillus subtilis var. amyloliquefaciens strain FZB24 (Taegro® + TX, Rhizopro®) + TX, Bacillus thuringiensis Cry 2Ae + TX, Bacillus thuringiensis Cry1 Ab + TX, Bacillus thuringiensis aizawai GC 91 (Agree®) + TX, Bacillus thuringiensis israelensis (BMP123® + TX, Aquabac® + TX, VectoBac®) + TX, Bacillus thuringiensis kurstaki (Javelin® + TX, Deliver® + TX, CryMax® + TX, Bonide® + TX, Scutella WP® + TX, Turilav WP ® +
TX, Astuto® + TX, Dipel WP® + TX, Biobit® + TX, Foray®) + TX, Bacillus thuringiensis kurstaki BMP 123 (Baritone®) + TX, Bacillus thuringiensis kurstaki HD-1 (Bioprotec-CAF / 3P®) + TX, Bacillus thuringiensis strain BD#32 + TX, Bacillus thuringiensis strain AQ52 + TX, Bacillus thuringiensis var. aizawai (XenTari® + TX, DiPel®) + TX, bacteria spp. (GROWMEND® + TX, GROWSWEET® + TX, Shootup®) + TX, bacteriophage of Clavipacter michiganensis (AgriPhage®) + TX, Bakflor® + TX, Beauveria bassiana (Beaugenic® + TX, Brocaril WP®) + TX, Beauveria bassiana GHA (Mycotrol ES® + TX, Mycotrol O® + TX, BotaniGuard®) + TX, Beauveria brongniartii (Engerlingspilz® + TX, Schweizer Beauveria® + TX, Melocont®) + TX, Beauveria spp. + TX, Botrytis cineria + TX,
Bradyrhizobium japonicum (TerraMax®) + TX, Brevibacillus brevis + TX, Bacillus thuringiensis tenebrionis (Novodor®) + TX, BtBooster + TX, Burkholderia cepacia (Deny® + TX, Intercept® + TX, Blue Circle®) + TX, Burkholderia gladii + TX, Burkholderia gladioli + TX, Burkholderia spp. + TX, Canadian thistle fungus (CBH Canadian Bioherbicide®) + TX, Candida butyri + TX, Candida famata + TX, Candida ffuctus + TX, Candida glabrata + TX, Candida guilliermondii + TX, Candida melibiosica + TX, Candida oleophila strain O + TX, Candida parapsilosis + TX, Candida pelliculosa + TX, Candida pulcherrima + TX, Candida reukaufii + TX, Candida saitoana (Bio-Coat® + TX, Biocure®) + TX, Candida sake + TX, Candida spp. + TX, Candida tenius + TX, Cedecea dravisae + TX, Cellulomonas flavigena + TX, Chaetomium cochliodes (Nova-Cide®) + TX, Chaetomium globosum (Nova-Cide®) + TX, Chromobacterium subtsugae strain PRAA4-1T (Grandevo®) + TX, Cladosporium cladosporioides + TX, Cladosporium oxysporum + TX, Cladosporium chlorocephalum + TX, Cladosporium spp. + TX, Cladosporium tenuissimum + TX, Clonostachys rosea (EndoFine®) + TX, Colletotrichum acutatum + TX, Coniothyrium minitans (Cotans WG®) + TX, Coniothyrium spp. + TX, Cryptococcus albidus (YIELDPLUS®) + TX, Cryptococcus humicola + TX, Cryptococcus infirmo-miniatus + TX,
Cryptococcus laurentii + TX, Cryptophlebia leucotreta granulovirus (Cryptex®) + TX, Cupriavidus campinensis + TX, Cydia pomonella granulovirus (CYD-X®) + TX, Cydia pomonella granulovirus (Madex® + TX, Madex Plus® + TX, Madex Max/ Carpovirusine®) + TX, Cylindrobasidium laeve (Stumpout®) + TX, Cylindrocladium + TX, Debaryomyces hansenii + TX, Drechslera hawaiinensis + TX, Enterobacter cloacae + TX, Enterobacteriaceae + TX, Entomophtora virulenta (Vektor®) + TX, Epicoccum nigrum + TX, Epicoccum purpurascens + TX, Epicoccum spp. + TX, Filobasidium floriforme + TX, Fusarium acuminatum + TX, Fusarium chlamydosporum + TX, Fusarium oxysporum (Fusaclean® / Biofox C®) + TX, Fusarium proliferatum + TX, Fusarium spp. + TX, Galactomyces geotrichum + TX, Gliocladium catenulatum (Primastop® + TX, Prestop®) + TX, Gliocladium roseum + TX, Gliocladium spp. (SoilGard®) + TX, Gliocladium virens (Soilgard®) + TX, Granulovirus
(Granupom®) + TX, Halobacillus halophilus + TX, Halobacillus litoralis + TX, Halobacillus trueperi +
TX, Halomonas spp. + TX, Halomonas subglaciescola + TX, Halovibrio variabilis + TX, Hanseniaspora uvarum + TX, Helicoverpa armigera nucleopolyhedrovirus (Helicovex®) + TX, Helicoverpa zea nuclear polyhedrosis virus (Gemstar®) + TX, Isoflavone - formononetin (Myconate®) + TX, Kioeckera apiculata + TX, Kioeckera spp. + TX, Lagenidium giganteum (Laginex®) + TX, Lecanicillium longisporum (Vertiblast®) + TX, Lecanicillium muscarium (Vertiki I®) + TX, Lymantria Dispar nucleopolyhedrosis virus (Disparvirus®) + TX, Marinococcus halophilus + TX, Meira geulakonigii + TX, Metarhizium anisopliae (Met52®) + TX, Metarhizium anisopliae (Destruxin WP®) + TX, Metschnikowia fruticola (Shemer®) + TX, Metschnikowia pulcherrima + TX, Microdochium dimerum (Antibot®) + TX, Micromonospora coerulea + TX, Microsphaeropsis ochracea + TX, Muscodor albus 620 (Muscudor®)
+ TX, Muscodor roseus strain A3-5 + TX, Mycorrhizae spp. (AMykor® + TX, Root Maximizer®) + TX, Myrothecium verrucaria strain AARC-0255 (DiTera®) + TX, BROS PLUS® + TX, Ophiostoma piliferum strain D97 (Sylvanex®) + TX, Paecilomyces farinosus + TX, Paecilomyces fumosoroseus (PFR-97® + TX, PreFeRal®) + TX, Paecilomyces linacinus (Biostat WP®) + TX, Paecilomyces lilacinus strain 251 (MeloCon WG®) + TX, Paenibacillus polymyxa + TX, Pantoea agglomerans (BlightBan C9-1®) + TX, Pantoea spp. + TX, Pasteuria spp. (Econem®) + TX, Pasteuria nishizawae + TX, Penicillium aurantiogriseum + TX, Penicillium billai (Jumpstart® + TX, TagTeam®) + TX, Penicillium
brevicompactum + TX, Penicillium frequentans + TX, Penicillium griseofulvum + TX, Penicillium purpurogenum + TX, Penicillium spp. + TX, Penicillium viridicatum + TX, Phlebiopsis gigantean (Rotstop®) + TX, phosphate solubilizing bacteria (Phosphomeal®) + TX, Phytophthora cryptogea +
TX, Phytophthora palmivora (Devine®) + TX, Pichia anomala + TX, Pichia guilermondii + TX, Pichia membranaefaciens + TX, Pichia onychis + TX, Pichia stipites + TX, Pseudomonas aeruginosa + TX, Pseudomonas aureofasciens (Spot-Less Biofungicide®) + TX, Pseudomonas cepacia + TX,
Pseudomonas chlororaphis (AtEze®) + TX, Pseudomonas corrugate + TX, Pseudomonas fluorescens strain A506 (BlightBan A506®) + TX, Pseudomonas putida + TX, Pseudomonas reactans + TX, Pseudomonas spp. + TX, Pseudomonas syringae (Bio-Save®) + TX, Pseudomonas viridiflava + TX, Pseudomons fluorescens (Zequanox®) + TX, Pseudozyma flocculosa strain PF-A22 UL (Sporodex L®) + TX, Puccinia canaliculate + TX, Puccinia thlaspeos (Wood Warrior®) + TX, Pythium
paroecandrum + TX, Pythium oligandrum (Polygandron® + TX, Polyversum®) + TX, Pythium periplocum + TX, Rhanella aquatilis + TX, Rhanella spp. + TX, Rhizobia (Dormal® + TX, Vault®) + TX, Rhizoctonia + TX, Rhodococcus globerulus strain AQ719 + TX, Rhodosporidium diobovatum + TX, Rhodosporidium toruloides + TX, Rhodotorula spp. + TX, Rhodotorula glutinis + TX, Rhodotorula graminis + TX, Rhodotorula mucilagnosa + TX, Rhodotorula rubra + TX, Saccharomyces cerevisiae + TX, Salinococcus roseus + TX, Sclerotinia minor + TX, Sclerotinia minor (SARRITOR®) + TX, Scytalidium spp. + TX, Scytalidium uredinicola + TX, Spodoptera exigua nuclear polyhedrosis virus (Spod-X® + TX, Spexit®) + TX, Serratia marcescens + TX, Serratia plymuthica + TX, Serratia spp. + TX, Sordaria fimicola + TX, Spodoptera littoralis nucleopolyhedrovirus (Littovir®) + TX,
Sporobolomyces roseus + TX, Stenotrophomonas maltophilia + TX, Streptomyces ahygroscopicus + TX, Streptomyces albaduncus + TX, Streptomyces exfoliates + TX, Streptomyces galbus + TX, Streptomyces griseoplanus + TX, Streptomyces griseoviridis (Mycostop®) + TX, Streptomyces lydicus (Actinovate®) + TX, Streptomyces lydicus WYEC-108 (ActinoGrow®) + TX, Streptomyces violaceus + TX, Tilletiopsis minor + TX, Tilletiopsis spp. + TX, Trichoderma asperellum (T34 Biocontrol®) + TX, Trichoderma gamsii (Tenet®) + TX, Trichoderma atroviride (Plantmate®) + TX, Trichoderma hamatum TH 382 + TX, Trichoderma harzianum rifai (Mycostar®) + TX, Trichoderma harzianum T-22 (Trianum- P® + TX, PlantShield HC® + TX, RootShield® + TX, Trianum-G®) + TX, Trichoderma harzianum T-39 (Trichodex®) + TX, Trichoderma inhamatum + TX, Trichoderma koningii + TX, Trichoderma spp. LC 52 (Sentinel®) + TX, Trichoderma lignorum + TX, Trichoderma longibrachiatum + TX, Trichoderma polysporum (Binab T®) + TX, Trichoderma taxi + TX, Trichoderma virens + TX, Trichoderma virens (formerly Gliocladium virens GL-21) (SoilGuard®) + TX, Trichoderma viride + TX, Trichoderma viride strain ICC 080 (Remedier®) + TX, Trichosporon pullulans + TX, Trichosporon spp. + TX,
Trichothecium spp. + TX, Trichothecium roseum + TX, Typhula phacorrhiza strain 94670 + TX, Typhula phacorrhiza strain 94671 + TX, Ulocladium atrum + TX, Ulocladium oudemansii (Botry-Zen®) + TX, Ustilago maydis + TX, various bacteria and supplementary micronutrients (Natural II®) + TX, various fungi (Millennium Microbes®) + TX, Verticillium chlamydosporium + TX, Verticillium lecanii (Mycotal® + TX, Vertalec®) + TX, Vip3Aa20 (VIPtera®) + TX, Virgibaclillus marismortui + TX, Xanthomonas campestris pv. Poae (Camperico®) + TX, Xenorhabdus bovienii + TX, Xenorhabdus nematophilus ;
Plant extracts including: pine oil (Retenol®) + TX, azadirachtin (Plasma Neem Oil® + TX, AzaGuard® + TX, MeemAzal® + TX, Molt-X® + TX, Botanical IGR (Neemazad® + TX, Neemix®) + TX, canola oil (Lilly Miller Vegol®) + TX, Chenopodium ambrosioides near ambrosioides (Requiem®) + TX,
Chrysanthemum extract (Crisant®) + TX, extract of neem oil (Trilogy®) + TX, essentials oils of Labiatae (Botania®) + TX, extracts of clove rosemary peppermint and thyme oil (Garden insect killer®) + TX, Glycinebetaine (Greenstim®) + TX, garlic + TX, lemongrass oil (GreenMatch®) + TX, neem oil + TX, Nepeta cataria (Catnip oil) + TX, Nepeta catarina + TX, nicotine + TX, oregano oil (MossBuster®)
+ TX, Pedaliaceae oil (Nematon®) + TX, pyrethrum + TX, Quillaja saponaria (NemaQ®) + TX, Reynoutria sachalinensis (Regalia® + TX, Sakalia®) + TX, rotenone (Eco Roten®) + TX, Rutaceae plant extract (Soleo®) + TX, soybean oil (Ortho ecosense®) + TX, tea tree oil (Timorex Gold®) + TX, thymus oil + TX, AGNIQUE® MMF + TX, BugOil® + TX, mixture of rosemary sesame pepermint thyme and cinnamon extracts (EF 300®) + TX, mixture of clove rosemary and peppermint extract (EF 400®) + TX, mixture of clove pepermint garlic oil and mint (Soil Shot®) + TX, kaolin (Screen®) + TX, storage glucam of brown algae (Laminarin®);
pheromones including: blackheaded fireworm pheromone (3M Sprayable Blackheaded Fireworm Pheromone®) + TX, Codling Moth Pheromone (Paramount dispenser-(CM)/ Isomate C-Plus®) + TX, Grape Berry Moth Pheromone (3M MEC-GBM Sprayable Pheromone®) + TX, Leafroller pheromone (3M MEC - LR Sprayable Pheromone®) + TX, Muscamone (Snip7 Fly Bait® + TX, Starbar Premium Fly Bait®) + TX, Oriental Fruit Moth Pheromone (3M oriental fruit moth sprayable pheromone®) + TX, Peachtree Borer Pheromone (Isomate-P®) + TX, Tomato Pinworm Pheromone (3M Sprayable pheromone®) + TX, Entostat powder (extract from palm tree) (Exosex CM®) + TX, (E + TX,Z + TX,Z)- 3 + TX,8 + TX,1 1 Tetradecatrienyl acetate + TX, (Z + TX,Z + TX,E)-7 + TX,1 1 + TX,13- Hexadecatrienal + TX, (E + TX,Z)-7 + TX,9-Dodecadien-1 -yl acetate + TX, 2-Methyl-1 -butanol + TX, Calcium acetate + TX, Scenturion® + TX, Biolure® + TX, Check-Mate® + TX, Lavandulyl senecioate; Macrobials including: Aphelinus abdominalis + TX, Aphidius ervi (Aphelinus-System®) + TX, Acerophagus papaya + TX, Adalia bipunctata (Adalia-System®) + TX, Adalia bipunctata (Adaline®) + TX, Adalia bipunctata (Aphidalia®) + TX, Ageniaspis citricola + TX, Ageniaspis fuscicollis + TX, Amblyseius andersoni (Anderline® + TX, Andersoni-System®) + TX, Amblyseius californicus (Amblyline® + TX, Spical®) + TX, Amblyseius cucumeris (Thripex® + TX, Bugline cucumeris®) + TX, Amblyseius fallacis (Fallacis®) + TX, Amblyseius swirskii (Bugline swirskii® + TX, Swirskii-Mite®) + TX, Amblyseius womersleyi (WomerMite®) + TX, Amitus hesperidum + TX, Anagrus atomus + TX, Anagyrus fusciventris + TX, Anagyrus kamali + TX, Anagyrus loecki + TX, Anagyrus pseudococci (Citripar®) + TX, Anicetus benefices + TX, Anisopteromalus calandrae + TX, Anthocoris nemoralis (Anthocoris-System®) + TX, Aphelinus abdominalis (Apheline® + TX, Aphiline®) + TX, Aphelinus asychis + TX, Aphidius colemani (Aphipar®) + TX, Aphidius ervi (Ervipar®) + TX, Aphidius gifuensis + TX, Aphidius matricariae (Aphipar-M®) + TX, Aphidoletes aphidimyza (Aphidend®) + TX, Aphidoletes aphidimyza (Aphidoline®) + TX, Aphytis lingnanensis + TX, Aphytis melinus + TX, Aprostocetus hagenowii + TX, Atheta coriaria (Staphyline®) + TX, Bombus spp. + TX, Bombus terrestris (Natupol Beehive®) + TX, Bombus terrestris (Beeline® + TX, Tripol®) + TX, Cephalonomia stephanoderis +
TX, Chilocorus nigritus + TX, Chrysoperla carnea (Chrysoline®) + TX, Chrysoperla carnea
(Chrysopa®) + TX, Chrysoperla rufilabris + TX, Cirrospilus ingenuus + TX, Cirrospilus quadristriatus + TX, Citrostichus phyllocnistoides + TX, Closterocerus chamaeleon + TX, Closterocerus spp. + TX, Coccidoxenoides perminutus (Planopar®) + TX, Coccophagus cowperi + TX, Coccophagus lycimnia + TX, Cotesia fiavipes + TX, Cotesia plutellae + TX, Cryptolaemus montrouzieri (Cryptobug® + TX, Cryptoline®) + TX, Cybocephalus nipponicus + TX, Dacnusa sibirica + TX, Dacnusa sibirica
(Minusa®) + TX, Diglyphus isaea (Diminex®) + TX, Delphastus catalinae (Delphastus®) + TX, Delphastus pusillus + TX, Diachasmimorpha krausii + TX, Diachasmimorpha longicaudata + TX, Diaparsis jucunda + TX, Diaphorencyrtus aligarhensis + TX, Diglyphus isaea + TX, Diglyphus isaea (Miglyphus® + TX, Digline®) + TX, Dacnusa sibirica (DacDigline® + TX, Minex®) + TX, Diversinervus spp. + TX, Encarsia citrina + TX, Encarsia formosa (Encarsia max® + TX, Encarline® + TX, En- Strip®) + TX, Eretmocerus eremicus (Enermix®) + TX, Encarsia guadeloupae + TX, Encarsia haitiensis + TX, Episyrphus balteatus (Syrphidend®) + TX, Eretmoceris siphonini + TX, Eretmocerus californicus + TX, Eretmocerus eremicus (Ercal® + TX, Eretline e®) + TX, Eretmocerus eremicus (Bemimix®) + TX, Eretmocerus hayati + TX, Eretmocerus mundus (Bemipar® + TX, Eretline m®) +
TX, Eretmocerus siphonini + TX, Exochomus quadripustulatus + TX, Feltiella acarisuga (Spidend®) + TX, Feltiella acarisuga (Feltiline®) + TX, Fopius arisanus + TX, Fopius ceratitivorus + TX,
Formononetin (Wirless Beehome®) + TX, Franklinothrips vespiformis (Vespop®) + TX, Galendromus occidentalis + TX, Goniozus legneri + TX, Flabrobracon hebetor + TX, Harmonia axyridis
(HarmoBeetle®) + TX, Heterorhabditis spp. (Lawn Patrol®) + TX, Heterorhabditis bacteriophora (NemaShield HB® + TX, Nemaseek® + TX, Terranem-Nam® + TX, Terranem® + TX, Larvanem® + TX, B-Green® + TX, NemAttack ® + TX, Nematop®) + TX, Heterorhabditis megidis (Nemasys H® + TX, BioNem H® + TX, Exhibitline hm® + TX, Larvanem-M®) + TX, Hippodamia convergens + TX, Hypoaspis aculeifer (Aculeifer-System® + TX, Entomite-A®) + TX, Hypoaspis miles (Hypoline m® + TX, Entomite-M®) + TX, Lbalia leucospoides + TX, Lecanoideus floccissimus + TX, Lemophagus errabundus + TX, Leptomastidea abnormis + TX, Leptomastix dactylopii (Leptopar®) + TX,
Leptomastix epona + TX, Lindorus lophanthae + TX, Lipolexis oregmae + TX, Lucilia caesar
(Natufly®) + TX, Lysiphlebus testaceipes + TX, Macrolophus caliginosus (Mirical-N® + TX, Macroline c® + TX, Mirical®) + TX, Mesoseiulus longipes + TX, Metaphycus flavus + TX, Metaphycus lounsburyi + TX, Micromus angulatus (Milacewing®) + TX, Microterys flavus + TX, Muscidifurax raptorellus and Spalangia cameroni (Biopar®) + TX, Neodryinus typhlocybae + TX, Neoseiulus californicus + TX, Neoseiulus cucumeris (THRYPEX®) + TX, Neoseiulus fallacis + TX, Nesideocoris tenuis
(NesidioBug® + TX, Nesibug®) + TX, Ophyra aenescens (Biofly®) + TX, Orius insidiosus (Thripor-I®
+ TX, Oriline i®) + TX, Orius laevigatus (Thripor-L® + TX, Oriline I®) + TX, Orius majusculus (Oriline m®) + TX, Orius strigicollis (Thripor-S®) + TX, Pauesia juniperorum + TX, Pediobius foveolatus + TX, Phasmarhabditis hermaphrodita (Nemaslug®) + TX, Phymastichus coffea + TX, Phytoseiulus macropilus + TX, Phytoseiulus persimilis (Spidex® + TX, Phytoline p®) + TX, Podisus maculiventris (Podisus®) + TX, Pseudacteon curvatus + TX, Pseudacteon obtusus + TX, Pseudacteon tricuspis + TX, Pseudaphycus maculipennis + TX, Pseudleptomastix mexicana + TX, Psyllaephagus pilosus +
TX, Psyttalia concolor (complex) + TX, Quadrastichus spp. + TX, Rhyzobius lophanthae + TX, Rodolia cardinalis + TX, Rumina decollate + TX, Semielacher petiolatus + TX, Sitobion avenae (Ervibank®) + TX, Steinernema carpocapsae (Nematac C® + TX, Millenium® + TX, BioNem C® + TX, NemAttack®
+ TX, Nemastar® + TX, Capsanem®) + TX, Steinernema feltiae (NemaShield® + TX, Nemasys F® + TX, BioNem F® + TX, Steinernema-System® + TX, NemAttack® + TX, Nemaplus® + TX, Exhibitline sf® + TX, Scia-rid® + TX, Entonem®) + TX, Steinernema kraussei (Nemasys L® + TX, BioNem L® + TX, Exhibitline srb®) + TX, Steinernema riobrave (BioVector® + TX, BioVektor®) + TX, Steinernema scapterisci (Nematac S®) + TX, Steinernema spp. + TX, Steinernematid spp. (Guardian Nematodes®) + TX, Stethorus punctillum (Stethorus®) + TX, Tamarixia radiate + TX, Tetrastichus setifer + TX, Thhpobius semiluteus + TX, Torymus sinensis + TX, Trichogramma brassicae (Tricholine b®) + TX, Trichogramma brassicae (Tricho-Strip®) + TX, Trichogramma evanescens + TX, Trichogramma minutum + TX, Trichogramma ostriniae + TX, Trichogramma platneri + TX, Trichogramma pretiosum + TX, Xanthopimpla stemmator, and
other biologicals including: abscisic acid + TX, bioSea® + TX, Chondrostereum purpureum (Chontrol Paste®) + TX, Colletotrichum gloeosporioides (Collego®) + TX, Copper Octanoate (Cueva®) + TX, Delta traps (Trapline d®) + TX, Erwinia amylovora (Harpin) (ProAct® + TX, Ni-HIBIT Gold CST®) +
TX, Ferri-phosphate (Ferramol®) + TX, Funnel traps (Trapline y®) + TX, Gallex® + TX, Grower's Secret® + TX, Homo-brassonolide + TX, Iron Phosphate (Lilly Miller Worry Free Ferramol Slug & Snail Bait®) + TX, MCP hail trap (Trapline f®) + TX, Microctonus hyperodae + TX, Mycoleptodiscus terrestris (Des-X®) + TX, BioGain® + TX, Aminomite® + TX, Zenox® + TX, Pheromone trap (Thripline ams®) + TX, potassium bicarbonate (MilStop®) + TX, potassium salts of fatty acids (Sanova®) + TX, potassium silicate solution (Sil-Matrix®) + TX, potassium iodide + potassiumthiocyanate (Enzicur®) + TX, SuffOil-X® + TX, Spider venom + TX, Nosema locustae (Semaspore Organic Grasshopper Control®) + TX, Sticky traps (Trapline YF® + TX, Rebell Amarillo®) + TX and Traps (Takitrapline y + b®) + TX.
The references in brackets behind the active ingredients, e.g. [3878-19-1] refer to the Chemical Abstracts Registry number. The above described mixing partners are known. Where the active ingredients are included in "The Pesticide Manual" [The Pesticide Manual - A World Compendium; Thirteenth Edition; Editor: C. D. S. TomLin; The British Crop Protection Council], they are described therein under the entry number given in round brackets hereinabove for the particular compound; for example, the compound "abamectin" is described under entry number (1). Where "[CCN]" is added hereinabove to the particular compound, the compound in question is included in the "Compendium of Pesticide Common Names", which is accessible on the internet [A. Wood; Compendium of Pesticide Common Names. Copyright © 1995-2004]; for example, the compound "acetoprole" is described under the internet address http://www.alanwood.net/pesticides/acetoprole.html.
Most of the active ingredients described above are referred to hereinabove by a so-called "common name", the relevant "ISO common name" or another "common name" being used in individual cases. If the designation is not a "common name", the nature of the designation used instead is given in round brackets for the particular compound; in that case, the lUPAC name, the lUPAC/Chemical Abstracts name, a "chemical name", a "traditional name", a "compound name" or a "develoment code" is used or, if neither one of those designations nor a "common name" is used, an "alternative name" is employed.“CAS Reg. No” means the Chemical Abstracts Registry Number.
The active ingredient mixture of the compounds of formula I selected selected from the compounds defined in the Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27 and with active ingredients described above comprises a compound selected from one compound defined in the Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27 and an active ingredient as described above preferably in a mixing ratio of from 100:1 to 1 :6000, especially from 50:1 to 1 :50, more especially in a ratio of from 20:1 to 1 :20, even more especially from 10:1 to 1 :10, very especially from 5:1 and 1 :5, special preference being given to a ratio of from 2:1 to 1 :2, and a ratio of from 4:1 to 2:1 being likewise preferred, above all in a ratio of 1 :1 , or 5:1 , or 5:2, or 5:3, or 5:4, or 4:1 , or 4:2, or 4:3, or 3:1 , or 3:2, or 2:1 , or 1 :5, or 2:5, or 3:5, or 4:5, or 1 :4, or 2:4, or 3:4, or 1 :3, or 2:3, or 1 :2, or 1 :600, or 1 :300, or 1 :150, or 1 :35, or 2:35, or 4:35, or 1 :75, or 2:75, or 4:75, or 1 :6000, or 1 :3000, or 1 : 1500, or 1 :350, or 2:350, or 4:350, or 1 :750, or 2:750, or 4:750. Those mixing ratios are by weight.
The mixtures as described above can be used in a method for controlling pests, which comprises applying a composition comprising a mixture as described above to the pests or their environment, with the exception of a method for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body.
The mixtures comprising a compound of formula I selected from the compounds defined in the Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27 and one or more active ingredients as described above can be applied, for example, in a single“ready-mix” form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compounds of formula I and the active ingredients as described above is not essential for working the present invention.
The compositions according to the invention can also comprise further solid or liquid auxiliaries, such as stabilizers, for example unepoxidized or epoxidized vegetable oils (for example epoxidized coconut oil, rapeseed oil or soya oil), antifoams, for example silicone oil, preservatives, viscosity regulators, binders and/or tackifiers, fertilizers or other active ingredients for achieving specific effects, for example bactericides, fungicides, nematocides, plant activators, molluscicides or herbicides.
The compositions according to the invention are prepared in a manner known per se, in the absence of auxiliaries for example by grinding, screening and/or compressing a solid active ingredient and in the presence of at least one auxiliary for example by intimately mixing and/or grinding the active ingredient with the auxiliary (auxiliaries). These processes for the preparation of the compositions and the use of the compounds I for the preparation of these compositions are also a subject of the invention.
The application methods for the compositions, that is the methods of controlling pests of the abovementioned type, such as spraying, atomizing, dusting, brushing on, dressing, scattering or pouring - which are to be selected to suit the intended aims of the prevailing circumstances - and the use of the compositions for controlling pests of the abovementioned type are other subjects of the invention. Typical rates of concentration are between 0.1 and 1000 ppm, preferably between 0.1 and 500 ppm, of active ingredient. The rate of application per hectare is generally 1 to 2000 g of active ingredient per hectare, in particular 10 to 1000 g/ha, preferably 10 to 600 g/ha.
A preferred method of application in the field of crop protection is application to the foliage of the plants (foliar application), it being possible to select frequency and rate of application to match the danger of infestation with the pest in question. Alternatively, the active ingredient can reach the plants via the root system (systemic action), by drenching the locus of the plants with a liquid composition or by incorporating the active ingredient in solid form into the locus of the plants, for example into the soil, for example in the form of granules (soil application). In the case of paddy rice crops, such granules can be metered into the flooded paddy-field.
The compounds of formula I of the invention and compositions thereof are also be suitable for the protection of plant propagation material, for example seeds, such as fruit, tubers or kernels, or nursery plants, against pests of the abovementioned type. The propagation material can be treated with the compound prior to planting, for example seed can be treated prior to sowing. Alternatively, the compound can be applied to seed kernels (coating), either by soaking the kernels in a liquid composition or by applying a layer of a solid composition. It is also possible to apply the compositions when the propagation material is planted to the site of application, for example into the seed furrow during drilling. These treatment methods for plant propagation material and the plant propagation material thus treated are further subjects of the invention. Typical treatment rates would depend on the plant and pest/fungi to be controlled and are generally between 1 to 200 grams per 100 kg of seeds, preferably between 5 to 150 grams per 100 kg of seeds, such as between 10 to 100 grams per 100 kg of seeds.
The term seed embraces seeds and plant propagules of all kinds including but not limited to true seeds, seed pieces, suckers, corns, bulbs, fruit, tubers, grains, rhizomes, cuttings, cut shoots and the like and means in a preferred embodiment true seeds.
The present invention also comprises seeds coated or treated with or containing a compound of formula I. The term "coated or treated with and/or containing" generally signifies that the active ingredient is for the most part on the surface of the seed at the time of application, although a greater or lesser part of the ingredient may penetrate into the seed material, depending on the method of application. When the said seed product is (re)planted, it may absorb the active ingredient. In an embodiment, the present invention makes available a plant propagation material adhered thereto with a compound of formula I. Further, it is hereby made available, a composition comprising a plant propagation material treated with a compound of formula I. Seed treatment comprises all suitable seed treatment techniques known in the art, such as seed dressing, seed coating, seed dusting, seed soaking and seed pelleting. The seed treatment application of the compound formula I can be carried out by any known methods, such as spraying or by dusting the seeds before sowing or during the sowing/planting of the seeds.
In each aspect and embodiment of the invention, "consisting essentially" and inflections thereof are a preferred embodiment of "comprising" and its inflections, and "consisting of and inflections thereof are a preferred embodiment of "consisting essentially of and its inflections.
The disclosure in the present application makes available each and every combination of
embodiments disclosed herein.
It should be noted that the disclosure herein in respect of a compound of formula I applies equally in respect of a compound of each of formulae I*, I’a, l-A, I’-A, and Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27. Further the preferred enantiomer of formula I’a or I’-A applies also to compounds of Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27 and Table P. Also, made available herein is an agrochemically acceptable salt, stereoisomer, enantiomer, tautomer and/or N-oxide of the compound of formula formulae I*, I’a, l-A, I’-A, and Tables A-1 to A-27, B-1 to B-27, C-1 to C-27, D-1 to D-27 and E-1 to E-27 and Table P.
The compounds of the invention can be distinguished from other similar compounds by virtue of greater efficacy at low application rates and/or different pest control, which can be verified by the person skilled in the art using the experimental procedures, using lower concentrations if necessary, for example 10 ppm, 5 ppm, 2 ppm, 1 ppm or 0.2 ppm; or lower application rates, such as 300, 200 or 100, mg of Al per m2. The greater efficacy can be observed by an increased safety profile (against non-target organisms above and below ground (such as fish, birds and bees), improved physicochemical properties, or increased biodegradability).
Biological Examples:
The Examples which follow serve to illustrate the invention. Certain compounds of the invention can be distinguished from known compounds by virtue of greater efficacy at low application rates, which can be verified by the person skilled in the art using the experimental procedures outlined in the Examples, using lower application rates if necessary, for example 50 ppm, 24 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm, 0.8 ppm or 0.2 ppm.
Example B1 : Diabrotica balteata (Corn root worm)
Maize sprouts placed onto an agar layer in 24-well microtiter plates were treated with aqueous test solutions prepared from 10Ό00 ppm DMSO stock solutions by spraying. After drying, the plates were infested with L2 larvae (6 to 10 per well). The samples were assessed for mortality and growth inhibition in comparison to untreated samples 4 days after infestation.
The following compounds gave an effect of at least 80% control in at least one of the two categories (mortality or growth inhibition) at an application rate of 200 ppm:
P3, P4, P6, P7, P8, P9, P10, P1 1 , P13, P15, P19, P21 , P22, P23, P24, P25, P26, P28, P29, P30, P33, P34, P35, P37
Example B2: Euschistus herns (Neotropical Brown Stink Bug)
Soybean leaves on agar in 24-well microtiter plates were sprayed with aqueous test solutions prepared from 10Ό00 ppm DMSO stock solutions. After drying the leaves were infested with N2 nymphs. The samples were assessed for mortality and growth inhibition in comparison to untreated samples 5 days after infestation.
The following compounds gave an effect of at least 80% control in at least one of the two categories (mortality or growth inhibition) at an application rate of 200 ppm:
P1 , P3, P5, P24, P28, P33, P35, P37.
Example B3: Bemisia tabaci (Cotton white fly): Feedinq/contact activity
Cotton leaf discs were placed on agar in 24-well microtiter plates and sprayed with aqueous test solutions prepared from 10Ό00 ppm DMSO stock solutions. After drying the leaf discs were infested with adult white flies. The samples were checked for mortality 6 days after incubation.
The following compounds resulted in at least 80% mortality at an application rate of 200 ppm:
P35
Example B4: Chilo suppressalis (Striped rice stemborer)
24-well microtiter plates with artificial diet were treated with aqueous test solutions prepared from 10Ό00 ppm DMSO stock solutions by pipetting. After drying, the plates were infested with L2 larvae (6-8 per well). The samples were assessed for mortality, anti-feeding effect, and growth inhibition in comparison to untreated samples 6 days after infestation. Control of Chilo suppressalis by a test sample is given when at least one of the categories mortality, anti-feedant effect, and growth inhibition is higher than the untreated sample.
The following compounds resulted in at least 80% control in at least one of the three categories (mortality, anti-feeding or growth inhibition) at an application rate of 200 ppm:
P1 , P2, P3, P4, P5, P6, P7, P8, P9, P10, P11 , P12, P13, P14, P15, P16, P18, P19, P20, P21 , P22, P23, P24, P25, P26, P27, P28, P29, P30, P31 , P32, P33, P34, P35, P37, P38.
Example B5: Plutella xylostella (Diamond back moth)
24-well microtiter plates with artificial diet were treated with aqueous test solutions prepared from 10Ό00 ppm DMSO stock solutions by pipetting. After drying, Plutella eggs were pipetted through a plastic stencil onto a gel blotting paper and the plate was closed with it. The samples were assessed for mortality and growth inhibition in comparison to untreated samples 8 days after infestation.
The following compounds gave an effect of at least 80% control in at least one of the two categories (mortality or growth inhibition) at an application rate of 200 ppm:
P1 , P2, P3, P4, P5, P6, P7, P8, P9, P10, P11 , P12, P13, P14, P15, P16, P17, P18, P19, P20, P21 , P22, P23, P24, P25, P26, P27, P28, P29, P30, P31 , P32, P33, P34, P35, P36, P37, P38.
Example B6: Mvzus persicae (Green peach aphid): Intrinsic activity
Test compounds prepared from 10Ό00 ppm DMSO stock solutions were applied by pipette into 24- well microtiter plates and mixed with sucrose solution. The plates were closed with a stretched Parafilm. A plastic stencil with 24 holes was placed onto the plate and infested pea seedlings were placed directly on the Parafilm. The infested plate was closed with a gel blotting paper and another plastic stencil and then turned upside down. The samples were assessed for mortality 5 days after infestation.
The following compounds resulted in at least 80% mortality at a test rate of 12 ppm:
P3, P22, P23, P26, P27, P28, P35
Example B7: Spodoptera littoralis (Egyptian cotton leaf worm)
Cotton leaf discs were placed onto agar in 24-well microtiter plates and sprayed with aqueous test solutions prepared from 10Ό00 ppm DMSO stock solutions. After drying the leaf discs were infested with five L1 larvae. The samples were assessed for mortality, anti-feeding effect, and growth inhibition in comparison to untreated samples 3 days after infestation. Control of Spodoptera littoralis by a test sample is given when at least one of the categories mortality, anti-feedant effect, and growth inhibition is higher than the untreated sample.
The following compounds resulted in at least 80% control in at least one of the three categories (mortality, anti-feeding or growth inhibition) at an application rate of 200 ppm:
P1 , P2, P3, P4, P5, P6, P7, P8, P9, P10, P11 , P12, P13, P15, P17, P18, P19, P20, P21 , P22, P23, P24, P25, P26, P27, P28, P29, P30, P31 , P32, P33, P34, P35, P36, P37, P38.
Example B8: Spodoptera littoralis (Egyptian cotton leaf worm)
Test compounds were applied by pipette from 10Ό00 ppm DMSO stock solutions into 24-well plates and mixed with agar. Lettuce seeds were placed onto the agar and the multi well plate was closed by another plate which contained also agar. After 7 days the compound was absorbed by the roots and the lettuce grew into the lid plate. The lettuce leaves were then cut off into the lid plate. Spodoptera eggs were pipetted through a plastic stencil onto a humid gel blotting paper and the lid plate was closed with it. The samples were assessed for mortality, anti-feedant effect and growth inhibition in comparison to untreated samples 6 days after infestation.
The following compounds gave an effect of at least 80% control in at least one of the three categories (mortality, anti-feeding, or growth inhibition) at a test rate of 12.5 ppm: P22, P23, P24, P34, P35, P37
Example B9: Mvzus persicae (Green Peach Aphid)
Test compounds prepared from 10'OOO ppm DMSO stock solutions were applied by a liquid handling robot into 96-well microtiter plates and mixed with a sucrose solution. Parafilm was stretched over the 96-well microtiter plate and a plastic stencil with 96 holes was placed onto the plate. Aphids were sieved into the wells directly onto the Parafilm. The infested plates were closed with a gel blotting card and a second plastic stencil and then turned upside down. The samples were assessed for mortality 5 days after infestation.
The following compounds resulted in at least 80% mortality at an application rate of 50 ppm:
P22, P23, P26, P28
Example B10: Plutella xylostella (Diamondback Moth)
96-well microtiter plates containing artificial diet were treated with aqueous test solutions, prepared from 10Ό00 ppm DMSO stock solutions, by a liquid handling robot. After drying, eggs (~30 per well) were infested onto a netted lid which was suspended above the diet. The eggs hatch and L1 larvae move down to the diet. The samples were assessed for mortality 9 days after infestation.
The following compounds gave an effect of at least 80% mortality at an application rate of 500 ppm: P12, P13, P14, P15, P16, P17, P18, P19, P20, P21 , P22, P23, P24, P25, P26, P27, P28, P29, P30, P31 , P34
Example B11 : Tetranvchus urticae (Two-spotted spider mite): Feedinq/contact activity
Bean leaf discs on agar in 24-well microtiter plates were sprayed with aqueous test solutions prepared from 10Ό00 ppm DMSO stock solutions. After drying the leaf discs were infested with a mite population of mixed ages. The samples were assessed for mortality on mixed population (mobile stages) 8 days after infestation.
The following compounds resulted in at least 80% mortality at an application rate of 200 ppm:
P16

Claims (13)

1. A compound of the formula I
wherein
Ri is H, Ci-C6alkyl, Ci-C6cyanoalkyl, aminocarbonylCi-Cealkyl, hydroxycarbonylCi-Cealkyl, Ci- Cenitroalkyl, trimethylsilaneCi-C6alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6haloalkeny, C2-C6alkynyl, C2-C6haloalkynyl, C3-C4cycloalkylCi-C2alkyl-, C3-C4cycloalkylCi-C2alkyl- wherein the C3-C4cycloalkyl group is substituted with 1 or 2 halogen atoms, oxetan-3-yl-CH2-, benzyl or benzyl substituted with halogen or Ci-C6haloalkyl;
R2 is selected from phenyl, pyridine, pyrimidine, pyrazine, pyridazine, and phenyl, pyridine, pyrimidine, pyrazine and pyridazine, each of which is substituted with one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon C=X is attached, and each substituent is independently selected from: Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3haloalkylthio, Ci-C3alkoxy, Ci- C3haloalkoxy, halogen, SFs, CN, CONH2, and C(S)NH2; R3 is Ci-C3alkyl or Ci-C3haloalkyl;
A2 is CR4b or N;
R4b is hydrogen, or halogen;
R4a is cyano, or Ci-C3haloalkoxy;
R5a and Rsb are, independently of each other, selected from hydrogen, halogen, CN, Ci-C3alkyl, Ci- C3haloalkyl, C3-C4cycloalkyl, Ci-C3alkoxy, and Ci-C3haloalkoxy; or agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of the compounds of formula I.
2. The compound according to claim 1 wherein R3 is methyl.
3. The compound according to either claim 1 or claim 2 wherein Ri is hydrogen, methyl, ethyl, n- propyl, isobutyl, cyclopropylmethyl or HCHºCCH2-.
4. The compound according to any one of claims 1 to 3 wherein R2 is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, or the phenyl, pyridine, pyrimidine, pyrazine and pyridazine, each of which is substituted with one to three substituents, provided the substituent(s) are not on either carbon adjacent to the carbon C=X is attached, and each substituent is independently selected from: Ci- Cshaloalkyl, Ci-C3haloalkylthio, Ci-C3alkoxy, Ci-C3haloalkoxy, and halogen.
6. The compound according to any one of claims 1 to 5, wherein R4a is cyano, or Ci- C3fluoroalkoxy.
7. The compound according to any one of claims 1 to 6, wherein A2 is N.
8. The compound according to any one of claims 1 to 7, wherein A2 is CH.
9. The compound according to any one of claims 1 to 8, wherein Rsa and Rsb, independent of each other, are selected from hydrogen, bromo, chloro, methyl, and methoxy.
10 A composition comprising a compound as defined in any one of claims 1 to 9, one or more auxiliaries and diluent, and optionally one more other active ingredient.
1 1 . A method
(i) of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound as defined as defined in any one of claims 1 to 9 or a composition as defined claim 10; or
(ii) for the protection of plant propagation material from the attack by insects, acarines, nematodes or molluscs, which comprises treating the propagation material or the site, where the propagation material is planted, with an effective amount of a compound as defined in any one of claims 1 to 9 or a composition as defined claim 10; or
(iii) of controlling parasites in or on an animal in need thereof comprising administering an effective amount of a compound as defined in any one of claims 1 to 9 or a composition as defined claim 10.
12. A plant propagation material, such as a seed, comprising, or treated with or adhered thereto, a compound as defined in any one of claims 1 to 9 or a composition as defined claim 10.
13. A compound of formulae llaa to Mae
Mad Cl Mae
wherein Ri is as defined in either claim 1 or 3, and R4 is the cyclic group containing A2 and the substituent R4a in formula I, wherein A2 and R4a are as defined in any one of claims 1 , 6, 7 and 8.
AU2020272472A 2019-04-11 2020-04-07 Pesticidally active diazine-amide compounds Abandoned AU2020272472A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19168715.1 2019-04-11
EP19168715 2019-04-11
EP19196236.4 2019-09-09
EP19196236 2019-09-09
EP20152751.2 2020-01-20
EP20152751 2020-01-20
PCT/EP2020/059924 WO2020208036A1 (en) 2019-04-11 2020-04-07 Pesticidally active diazine-amide compounds

Publications (1)

Publication Number Publication Date
AU2020272472A1 true AU2020272472A1 (en) 2021-10-28

Family

ID=70057155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020272472A Abandoned AU2020272472A1 (en) 2019-04-11 2020-04-07 Pesticidally active diazine-amide compounds

Country Status (17)

Country Link
US (1) US20220169629A1 (en)
EP (1) EP3953343A1 (en)
JP (1) JP2022528181A (en)
KR (1) KR20210152508A (en)
CN (1) CN113677672A (en)
AU (1) AU2020272472A1 (en)
CA (1) CA3131861A1 (en)
CL (1) CL2021002572A1 (en)
CO (1) CO2021013350A2 (en)
IL (1) IL286564A (en)
JO (1) JOP20210273A1 (en)
MA (1) MA55587A (en)
MX (1) MX2021012290A (en)
PE (1) PE20220172A1 (en)
TW (1) TW202104206A (en)
UY (1) UY38651A (en)
WO (1) WO2020208036A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128650A (en) * 2019-10-11 2021-08-01 德商拜耳動物保健有限公司 Novel heteroaryl-substituted pyrazine derivatives as pesticides
MX2022007670A (en) 2019-12-18 2022-07-19 Intervet Int Bv Anthelmintic compounds comprising a quinoline structure.
WO2021122906A1 (en) 2019-12-18 2021-06-24 Intervet International B.V. Anthelmintic compounds comprising azaindoles structure
WO2021170881A1 (en) * 2020-02-27 2021-09-02 Syngenta Crop Protection Ag Pesticidally active diazine-bisamide compounds
AU2021395477A1 (en) 2020-12-11 2023-06-22 Intervet International B.V. Anthelmintic compounds comprising a thienopyridine structure
CN112924599A (en) * 2021-02-01 2021-06-08 江西省林业科学院 Method for extracting and detecting bromofenoxanil residue in rice field environment
BR112023022763A2 (en) 2021-05-06 2024-01-02 Bayer Ag CANCELLED IMMIDAZOLES REPLACED BY ALKYLAMIDE AND THEIR USE AS INSECTICIDES
EP4140986A1 (en) 2021-08-23 2023-03-01 Basf Se Pyrazine compounds for the control of invertebrate pests
WO2023025602A1 (en) 2021-08-23 2023-03-02 Basf Se Pyrazine compounds for the control of invertebrate pests
AU2022335669A1 (en) 2021-08-25 2024-02-01 Bayer Aktiengesellschaft Novel pyrazinyl-triazole compounds as pesticides
WO2023072849A1 (en) 2021-10-27 2023-05-04 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds
WO2023104714A1 (en) 2021-12-10 2023-06-15 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8600161A (en) 1985-01-18 1986-09-23 Plant Genetic Systems Nv CHEMICAL GENE, HYBRID, INTERMEDIATE PLASMIDIO VECTORS, PROCESS TO CONTROL INSECTS IN AGRICULTURE OR HORTICULTURE, INSECTICIDE COMPOSITION, PROCESS TO TRANSFORM PLANT CELLS TO EXPRESS A PLANTINIDE TOXIN, PRODUCED BY CULTURES, UNITED BY BACILLA
CA1340685C (en) 1988-07-29 1999-07-27 Frederick Meins Dna sequences encoding polypeptides having beta-1,3-glucanase activity
US5169629A (en) 1988-11-01 1992-12-08 Mycogen Corporation Process of controlling lepidopteran pests, using bacillus thuringiensis isolate denoted b.t ps81gg
NZ231804A (en) 1988-12-19 1993-03-26 Ciba Geigy Ag Insecticidal toxin from leiurus quinquestriatus hebraeus
EP0392225B1 (en) 1989-03-24 2003-05-28 Syngenta Participations AG Disease-resistant transgenic plants
GB8910624D0 (en) 1989-05-09 1989-06-21 Ici Plc Bacterial strains
CA2015951A1 (en) 1989-05-18 1990-11-18 Mycogen Corporation Novel bacillus thuringiensis isolates active against lepidopteran pests, and genes encoding novel lepidopteran-active toxins
EP0427529B1 (en) 1989-11-07 1995-04-19 Pioneer Hi-Bred International, Inc. Larvicidal lectins and plant insect resistance based thereon
US5639949A (en) 1990-08-20 1997-06-17 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
UA48104C2 (en) 1991-10-04 2002-08-15 Новартіс Аг Dna fragment including sequence that codes an insecticide protein with optimization for corn, dna fragment providing directed preferable for the stem core expression of the structural gene of the plant related to it, dna fragment providing specific for the pollen expression of related to it structural gene in the plant, recombinant dna molecule, method for obtaining a coding sequence of the insecticide protein optimized for corn, method of corn plants protection at least against one pest insect
US5530195A (en) 1994-06-10 1996-06-25 Ciba-Geigy Corporation Bacillus thuringiensis gene encoding a toxin active against insects
US5631072A (en) 1995-03-10 1997-05-20 Avondale Incorporated Method and means for increasing efficacy and wash durability of insecticide treated fabric
BR9913745B1 (en) 1998-09-15 2011-05-31 pyridine ketones, herbicidal composition and plant growth inhibitor, its use, method for controlling unwanted plant growth, as well as method for inhibiting plant growth.
JP2004506432A (en) 2000-08-25 2004-03-04 シンジェンタ・パティシペーションズ・アクチェンゲゼルシャフト Novel insecticidal toxin derived from Bacillus thuringiensis insecticidal crystal protein
DE10121003A1 (en) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
WO2003000906A2 (en) 2001-06-22 2003-01-03 Syngenta Participations Ag Plant disease resistance genes
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
ATE302546T1 (en) 2001-10-25 2005-09-15 Siamdutch Mosquito Netting Com TREATMENT OF TISSUES WITH AN INSECTICIDE
AR037856A1 (en) 2001-12-17 2004-12-09 Syngenta Participations Ag CORN EVENT
US20050132500A1 (en) 2003-12-22 2005-06-23 Basf Aktiengesellschaft Composition for impregnation of fibers, fabrics and nettings imparting a protective activity against pests
DE102004023894A1 (en) 2004-05-12 2005-12-08 Basf Ag Process for the treatment of flexible substrates
DE102005020889A1 (en) 2005-05-04 2006-11-09 Fritz Blanke Gmbh & Co.Kg Antimicrobial finishing of textiles, particularly fabrics, by treatment first with bath containing silver particles and then with bath containing aqueous binder
KR20080018934A (en) 2005-06-03 2008-02-28 바스프 악티엔게젤샤프트 Composition for the impregnation of fibers, fabrics and nettings imparting a protective activity against pests
PT1984555T (en) 2006-02-03 2016-08-18 Basf Se Process for treating textile substrates
WO2008151984A1 (en) 2007-06-12 2008-12-18 Basf Se Aqueous formulation and process for the impregnation of non-living-materials imparting a protective activity against pests
KR20130065663A (en) 2010-05-06 2013-06-19 바이엘 크롭사이언스 아게 Process for the preparation of dithiine tetracarboxydiimides
KR101564806B1 (en) 2010-05-13 2015-10-30 암젠 인크 Nitrogen heterocyclic compounds useful as pde10 inhibitors
CN103313989B (en) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 Three ring PI3K inhibitor compound and usings method
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
WO2013092943A1 (en) * 2011-12-23 2013-06-27 Basf Se Isothiazoline compounds for combating invertebrate pests
TW201348231A (en) 2012-02-29 2013-12-01 Amgen Inc Heterobicyclic compounds
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
PT2871180T (en) 2012-07-04 2018-05-08 Agro Kanesho Co Ltd 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient
UA118182C2 (en) 2012-12-19 2018-12-10 Байєр Кропсайєнс Акцієнгезелльшафт Difluoromethyl-nicotinic-indanyl carboxamides as fungicides
RU2701370C2 (en) 2014-04-11 2019-09-26 Зингента Партисипейшнс Аг Fungicidal derivatives of n'-[2-methyl-6 [2-alkoxyethoxy]-3-pyridyl]-n-alkylformamidine for use in agriculture
SI3230281T1 (en) * 2014-12-09 2021-08-31 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
ES2935981T3 (en) 2015-03-27 2023-03-13 Syngenta Participations Ag Intermediates for the preparation of microbicidal heterobicyclic derivatives
MX2017012709A (en) 2015-04-02 2017-11-23 Bayer Cropscience Ag Novel 5-substituted imidazole derivatives.
EP3307707B1 (en) 2015-06-15 2020-10-07 Bayer CropScience Aktiengesellschaft Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
AR105640A1 (en) 2015-08-12 2017-10-25 Syngenta Participations Ag MICROBICIDE HETEROBICYCLIC DERIVATIVES
BR112018002890A2 (en) 2015-08-14 2020-03-10 Bayer Cropscience Aktiengesellschaft TRIAZOL DERIVATIVES, THEIR INTERMEDIATES AND USE AS FUNGICIDES
MX2018004038A (en) 2015-10-02 2019-07-18 Syngenta Participations Ag Microbiocidal oxadiazole derivatives.
WO2017055469A1 (en) 2015-10-02 2017-04-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10640497B2 (en) 2015-12-02 2020-05-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
UY37062A (en) 2016-01-08 2017-08-31 Syngenta Participations Ag DERIVATIVES OF ARYL OXADIAZOL FUNGICIDAS
PT3426032T (en) 2016-03-10 2020-09-04 Syngenta Participations Ag Microbiocidal quinoline (thio)carboxamide derivatives
TWI696615B (en) 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 Heteroaryl-1,2,4-triazole and heteroaryl-tetrazole compounds
AR108745A1 (en) 2016-06-21 2018-09-19 Syngenta Participations Ag MICROBIOCIDES OXADIAZOL DERIVATIVES
ES2862453T3 (en) 2016-10-06 2021-10-07 Syngenta Participations Ag Microbiocide oxadiazole derivatives
WO2018153707A1 (en) 2017-02-22 2018-08-30 Basf Se Crystalline forms of a strobilurin type compound for combating phytopathogenic fungi
UY37623A (en) 2017-03-03 2018-09-28 Syngenta Participations Ag DERIVATIVES OF OXADIAZOL THIOPHEN FUNGICIDES
KR102395784B1 (en) 2017-03-27 2022-05-10 삼성전자주식회사 Organometallic compound and organic light emitting device including the same
EP3618629A1 (en) 2017-05-02 2020-03-11 Basf Se Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
US11154058B2 (en) 2017-06-14 2021-10-26 Syngenta Participations Ag Fungicidal compositions
EP3720846A1 (en) 2017-12-04 2020-10-14 Syngenta Participations AG Microbiocidal phenylamidine derivatives

Also Published As

Publication number Publication date
CA3131861A1 (en) 2020-10-15
KR20210152508A (en) 2021-12-15
JOP20210273A1 (en) 2023-01-30
UY38651A (en) 2020-11-30
MX2021012290A (en) 2021-11-12
MA55587A (en) 2022-02-16
IL286564A (en) 2021-12-01
PE20220172A1 (en) 2022-01-28
WO2020208036A1 (en) 2020-10-15
CL2021002572A1 (en) 2022-04-29
EP3953343A1 (en) 2022-02-16
JP2022528181A (en) 2022-06-08
US20220169629A1 (en) 2022-06-02
CN113677672A (en) 2021-11-19
TW202104206A (en) 2021-02-01
CO2021013350A2 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
EP3867237B1 (en) Pesticidally active azole-amide compounds
WO2021037614A1 (en) Pesticidally active pyrazine-amide compounds
WO2020094363A1 (en) Pesticidally active azole-amide compounds
US20210298306A1 (en) Pesticidally active azole-amide compounds
AU2020272472A1 (en) Pesticidally active diazine-amide compounds
WO2020193341A1 (en) N-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-2-cyclopropyl-6-(trifluoromethyl)pyridine-4-carboxamide derivatives and related compounds as insecticides
AU2020255265A1 (en) Pesticidally active diazine-amide compounds
EP3947358A1 (en) Pesticidally active diazine-amide compounds
WO2020169445A1 (en) Pesticidally active azole-amide compounds
EP4051673A1 (en) Pesticidally active fused bicyclic heteroaromatic compounds
EP3941915A1 (en) Pesticidally active azole amide compounds
WO2021122645A1 (en) Pesticidally active azole-amide compounds
EP4069688A1 (en) Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2022053567A1 (en) Pesticidally active heterocyclic derivatives with sulfur containing substituents
US20230120895A1 (en) Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021224409A1 (en) Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022101265A1 (en) Pesticidally active fused bicyclic heteroaromatic compounds
WO2022258481A1 (en) Pesticidally active diazine-amide compounds
WO2021175822A1 (en) Pesticidally amidine-substituted benzoic acid amide compounds
AU2022318251A1 (en) Pesticidally active fused bicyclic heteroaromatic compounds
WO2021213929A1 (en) Pesticidally active substituted 1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives with sulfur containing substituents
WO2021144354A1 (en) Pesticidally-active bicyclic heteroaromatic compounds

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period